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SUMMARY.
This project was initiated to study some of the mechanisms by which retinoic 
acid inhibits the experimental lung colonization of mice by murine melanoma cells. 
Using the metastatic cell line B16F1M2, this was investigated in three ways.
When B16F1M2 cells treated with lO'^M retinoic acid are injected via the 
tail vein into syngeneic mice, the number of lung colonies produced is reduced when 
compared to those established from control cells. In vitro, retinoic acid has an 
inhibitory effect on B16F1M2 cell growth and the morphology of the cells is affected 
with a shifting to a more "normal" form. The first stage of the project was to examine 
the effect of retinoic acid on the adhesion of these cells to basement membrane 
components, intact extracellular matrix and to other cells (both homotypic and 
heterotypic).
It was found that retinoic acid pretreatment inhibited the adhesion of the 
cells to laminin/nidogen and type IV collagen in a time-dependent and 
concentration-dependent manner, while adhesion to fibronectin remained unaffected. 
The adhesion of the cells to intact subendothelial extracellular matrix was also 
inhibited. The ability of the cells to spread on the substrates was also affected by 
pretreatment with retinoic acid, with cells remaining rounded on laminin/nidogen and 
type TV collagen. The density of the cultures also affected cell adhesion, with 
low-density cultures exhibiting reduced adhesion when compared to almost confluent 
cultures.
Reports have suggested that some of the effects of retinoic acid are 
reversible once the molecule is removed from the system. This was found to be the 
case for adhesion to laminin/nidogen and type IV collagen, although removal of the 
retinoid did not allow cells to return to control levels within the two days of the 
experiment. Addition of the retinoid after two days did reduce the degree of adhesion.
Cell-cell adhesion was also investigated. B16F1M2 homotypic adhesion was 
inhibited by retinoic acid treatment. If both the monolayer and the seeding cell 
suspension were exposed to retinoic acid, an inhibition in adhesion was also observed. 
Cell aggregate formation was similarly affected with cells treated with 10‘^M retinoic
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acid forming aggregates which were more readily dispersed and, indeed, these were 
also smaller than those formed by control cells. Heterotypic adhesion to endothelial 
cells was inhibited and this was accompanied by a change in cell morphology with 
adherent retinoic acid-treated cells remaining rounded on the endothelial monolayer.
The second part of the project was to investigate the ability of the cells to 
degrade the extracellular matrix. Subendothelial extracellular matrix was prepared 
and labelled with either [^H] proline which labelled collagen or newly synthesised 
collagens present or which labelled the sulphated glycosaminoglycans.
Retinoic acid was found to have an inhibitory effect on the release of products 
labelled with ^ S ,  but a variable effect on the release of ^H-labelled products. This is 
in disagreement with many other reports.
One specific enzyme, plasminogen activator, was investigated more closely. 
B16F1M2 cells grown in the presence of lO'^M retinoic acid were found to exhibit 
increased activity of this enzyme, both intracellularly and extracellularly.
The third part was to examine the changes, both qualitative and quantitative, 
in cell surface glycosaminoglycans induced by retinoic acid. In the initial separation 
the glycosaminoglycans from retinoic acid-treated cells eluted as two peaks when the 
first separation was carried out as compared to one for the control cells. Enzymatic 
digestion and further chromatography - both DEAE cellulose and gel filtration - 
revealed little or no difference in the profiles obtained from both sets of cells. 
Quantitatively, there was a decrease in sulphated glycosaminoglycan production in 
cells grown in the presence of retinoic acid. Both the heparan sulphates and the 
chondroitin sulphates were demonstrated to have a reduced degree of sulphation 
following exposure to retinoic acid.
INTRODUCTION
1:1. GENERAL INTRODUCTION.
l.The Metastatic Process.
Metastasis from a primary malignant tumour is a complex multistep process. 
Once the initial transforming event has occurred, the neoplastic cells proliferate 
forming the primary tumour mass. Cells detach from the tumour and invade the 
surrounding interstitial connective tissue matrix, infiltrating the intercellular spaces. 
The cells then cross the basement membrane and enter the circulation via the blood or 
lymph'systems. Evidence suggests that much of the invasive activity of the cells is 
due to the activation and secretion of a variety of degradative enzymes by both 
tumour cells and those of the host. These enzymes are capable of degrading the 
various barriers crossed by the cell before reaching the circulation (Liotta et al, 1983). 
The tumour cells are also capable of active migration which may be controlled by the 
secretion of autocrine or paracrine factors, stimulating the second messenger 
signalling systems (Liotta et al, 1989a). Once invasion has occurred, the cells may 
grow at the initial site of penetration, or alternatively, they may be released as either 
single cells or as small aggregates of cells into the circulation.
The survival of tumour cells in the circulation is an important step in the 
continuation of the metastatic process. However, the presence of viable neoplastic 
cells in the blood or lymph does not give a positive indication of eventual metastatic 
development (Weiss, 1985). Circulating tumour cells are subjected to trauma and 
this is responsible for the death of the majority of them (Weiss, 1987). While 
circulating, it is possible for the cells to interact with host cells such as platelets, 
lymphocytes and monocytes and many of these interactions are thought to be 
cytotoxic to the tumour cells (Fidler et al, 1978). Those cells which survive the 
trauma of recirculation and any cytotoxic interactions, and remain viable, may be able 
to arrest in the microvasculature at a distant site forming, potentially, a metastatic 
colony.
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Detachment of cells from the primary tumour, the heterotypic or 
homotypic clumping of cells, and the cellular adhesion to the microvascular 
endothelium or exposed basement membrane at the site of metastatic formation, are 
all dependent upon cell surface moieties on both tumour and host cells. It is probable 
that variations in the expression and regulation of cell and substrate adhesion 
molecules play an important role in the success of the metastatic process (Juliano, 
1987).
Once the tumour cells have arrested within the target organ, they must 
extravasate in order to form secondary growths. This requires penetration of the 
vascular basement membrane, followed by dissolution of the extravascular connective 
tissue stroma, thus allowing the cell to pass through it. To form a metastatic lesion, 
the cell must proliferate and grow, establishing a secondary tumour which can, itself, 
generate the metastatic sequence thus possibly initiating further secondary growths 
(Weiss, 1985).
The ability of tumour cells to spread is very complex and depends on an 
interplay between host and tumour cell properties. The forces of selection, when 
applied to a heterogeneous starting population of cells are thought to allow the 
emergence of pre-existing populations suggesting that, on the whole, metastasis is a 
selective process (Hart & Fidler, 1980; Poste & Fidler, 1980).
The first step in the metastatic process is the detachment of cells from the 
primary tumour, which may be brought about by the loss of intercellular junctions, 
alterations in the chemical composition and physical properties of the cell coat, and 
loosening of interactions between the cell and the substrate (Schirrmacher, 1985). 
The site of release of the tumour cell is an important factor, as if cell detachment 
occurs prior to contact between the tumour and blood vessels, the tumour cell will 
probably enter the lymphatic system which, in the instance of melanoma, may occur 
by active locomotion (Weiss & Ward, 1983). If contact with blood vessels has been 
made prior to detachment, then venous dissemination will be the preferred initial 
route (Weiss & Ward, 1983). Entry to the blood system requires invasion and results 
in exposure of the tumour cells to the vessel lumen.
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Cells detach from the primary tumour by a combination of factors, 
including mechanical agitation generated by body movements and trauma (Weiss, 
1980), however, the flow of blood is not considered to be a major mechanism of 
detachment Cells can also enter the circulation by shedding into vascular clefts 
which are lined by tumour cells, as opposed to vascular endothelium, thus this 
mechanism of entry does not require prior invasion and is a common feature of 
sarcomas (Willis, 1952).
Necrosis is a common feature of solid tumours and may play a role in cell 
detachment Work on tumour necrosis in breast cancer has demonstrated a positive 
correlation between necrosis and treatment failure (Fisher et al, 1978), confirming 
earlier work which indicated that there was a higher incidence of tumour cells in the 
blood where there was necrosis of the primary tumour as compared to those tumours 
where little or no necrosis was found (Malmgren, 1968).
The heterogeneity of the cells within the tumour must also be a 
consideration, as a tumour originated from a single transformed cell will have a cell 
population which is both phenotypically and genotypically heterogeneous (Fialkow, 
1979). Tumours can be heterogenous in several different ways as can be seen in 
tumours of the same histological type but, coming from different individuals and 
tumour progression within one patient, ie from tumourigenic non-invasive via 
invasive, non-metastatic to invasive and metastatic subpopulations (Schirrmacher,
1985). Heterogeneity can also occur within a single tumour at any one time as 
revealed histologically, while malignant tumours have been shown to be heterogenous 
with respect to metastatic capacity (Fidler, 1973a; Poste et al, 1982). The 
heterogeneity of the tumour cell population also has an effect on its stability, as has 
been demonstrated in clonal lines of B16 melanoma of both high and low metastatic 
potential, with the highly metastatic cells often being less stable (Poste et al, 1981). 
Cells of the highly metastatic KV-2237 fibrosarcoma have been shown to be 
composed of subclones exhibiting a wide range of metastatic phenotypes, whereas a 
clone which had low metastatic potential was found to retain this phenotype. 
However, several groups have shown that individual subpopulations, and their
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subsequent clones are heterogeneous in their stability (Chambers et al, 1981; Neri & 
Nicolson, 1981; Miller et al, 1983). Changes in the tumour subpopulations can be 
sudden or gradual and this can result in phenotypes which are either more or less 
malignant (Heppner & Miller, 1983), also changes can occur after passage either in 
vivo or in vitro. Clonal analysis of B16 melanoma metastases, produced 
experimentally by intravenous injection, revealed that they were unicellular in origin 
(Talmadge et al, 1982; Poste et al, 1982). During the early stages of clonal growth, 
most lesions contain cells with no distinguishable metastatic phenotypes, however the 
progressive stage is accompanied by the emergence of cells which have altered 
metastatic properties (Poste et al, 1982; Talmadge et al, 1984).
Heterogeneity may result from genetic errors arising in either the classical 
genetic mechanisms, or from the production of cellular variants as in normal tissue 
differentiation. Genetic errors may include mutations in structural genes, mutations 
in regulatory genes, or major genomic changes due to numerical or structural 
alterations to the chromosomes (Schirrmacher, 1985). Oncogenes may affect gene 
regulation by varying their number and insertion sites, however recent work suggests 
that many of the modified properties of metastatic populations are not necessarily 
acquired or regulated independently, but may be controlled through the modification 
in expression of a small number of key genes (Greenberg et al, 1989). These genes 
are normally essential for the regulation of diverse cellular functions including 
proliferation, differentiation, cell-cell communication and motility (Bishop, 1987; 
Sager, 1989).
In addition to genetic factors, microenvironmental factors may also be 
involved in tumour heterogeneity, and it is possible that the tumour microenvironment 
may activate genetic programs within the tumour cell subpopulation causing 
phenotypic changes similar to those in normal tissue differentiation (Schirrmacher, 
1980; Altevogt et al 1982). For this to occur, the influence of the host must be not 
only selective but also inductive, and if this is the case then multiple phenotypes can
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be expressed by one common genotype. Microenvironmental soluble factors as well 
as cell-matrix contact or cell-cell contact-mediated signals may have a regulatory role 
on tumour cell phenotypes and expression of heterogeneity (Reid, 1982).
Heterogeneity is also seen in normal tissues, and tumour cells may give 
rise to variants through a process resembling normal tissue differentiation (Pierce, 
1974). Differentiation and dedifferentiation can be illustrated using clones of the 
B16 mouse melanoma cell line with pigment production being used as a marker of 
differentiation. Using time-lapse photography, differentiation appeared unrelated to 
cell division and could be reversed in a proportion of cells, but dedifferentiation was 
associated with cell proliferation, with pigmented clones being small and most of the 
nonpigmented clones being large (Bennett, 1983). This suggests that the functions 
which are associated with differentiation can switch on and off.
An extension of this may be that metastatic capability can be modulated 
by cell shape in the B16 melanoma cell line (Raz & Ben-Ze’ev, 1983). Normal cells 
attach and spread on a solid surface until the surface is completely covered by a sheet 
of cells which then stop proliferating - anchorage dependent growth (Stoker et al, 
1968). Proliferation of nontransformed cells will occur when hormonal growth 
factors are available, but such factors are ineffective if the cells are grown as 
suspension cultures (Otsuka & Maskowitz, 1975). Anchorage-dependent growth 
may then be cell-contact and cell-shape dependent (Maroudas, 1975), with the loss of 
anchorage dependent growth control being one of the major manifestations of 
tumorigenicity (Vasiliev, 1985).
In an analysis of the rate of DNA synthesis as a function of cell spreading 
on a substrate, cell variants of B16 melanoma and UV-2237 fibrosarcoma tumour cell 
lines displaying low, intermediate and high metastatic potentials, displayed no direct 
correlation between the metastatic phenotype and the changes in DNA synthesis in 
response to changes in cell shape (Raz & Ben-Ze’ev, 1982). However, if the 
difference between the control of cell shape is studied, growth of cells in a spherical 
configuration induces a marked increase in their metastatic capability and these cells 
will attach and spread more quickly when resuspended and set up in culture. The
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alterations in the metastatic capabilities can be reversed by allowing the cells to grow 
as a monolayer for 24-48h (Raz & Ben-Ze’ev, 1983), and this suggests a central role 
for changes in cell shape in the modulation of metastatic capability. In vivo, 
metastases are not necessarily caused by cells with the highest metastatic potential, 
but by cells which have a metastatic phenotype (Poste, 1983). Additionally, signals 
from the microenvironment can regulate the expression of various genetic programs, 
which in turn may activate, or repress, various cellular activities which may affect the 
metastatic potential (Schirrmacher, 1980), and the reversible modulation of the 
metastatic capability of changes in cell shape is compatible with this.
The shape of cells in vitro is determined by the interaction of the cell with 
the extracellular matrix and/or with neighbouring cells (Edelman, 1985). These 
points of cellular interaction with the environment are characterised by the specific 
organisation of cytoskeletal elements in characteristic molecularly defined structures. 
Specific integral membrane proteins mediate these interactions between the 
cytoskeleton, the extracellular matrix and neighbouring cells. Such interactions may 
have a role in determining pattern formation and tissue morphogenesis (Obrink,
1986).
Tumour cells have well developed cytoskeletal networks (Raz & Geiger, 
1982; Vasiliev, 1985; Ben-Ze’ev, 1985), and the organisation of these may have an 
effect on the active directional mobility of metastatic cells as well as their ability to 
deform (Raz & Ben-Ze’ev, 1987). Analysis of the organisation of these networks 
revealed significant differences between cells of low and high metastatic potentials. 
The differences were found mainly in the actin-containing networks, with highly 
metastatic variants having distorted actin bundles (Raz & Geiger, 1982; Zvibel & 
Raz, 1985). Further work revealed that the organisation of actin is a primary 
manifestation of a stable cellular phenotype and as such is important in metastasis 
(Raz & Ben-Ze’ev, 1987).
When invasion occurs, the migrating cells are confronted with the 
extracellular matrix which is a dense latticework of collagen and elastin, embedded in 
a viscoelastic ground substance composed of proteoglycans and glycoproteins. It is a
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supporting scaffold which isolates tissue compartments, mediates cell attachment and 
influences the tissue architecture (Kleinman et al, 1981; Wicha et al, 1980). The 
matrix acts as a selective macromolecular filter and plays a role in mitogenesis and 
differentiation. Altered interactions between tumour cells and the matrix may have 
an effect on tumour cell proliferation and invasion (Liotta et al, 1983).
In vertebrate organisms, tissue compartments are bordered by basement 
membrane and intersitial stroma (Hay, 1982). The basement membrane is composed 
of type IV collagen, which forms the structural framework, glycoproteins, such as 
laminin and entactin/nidogen, and heparan sulphate proteoglycans (Timpl et al, 1981; 
Vracko, 1974; Kefalides et al, 1979). In most tissues, the parenchymal cells secrete 
and assemble the basement membrane. The epithelial basement membrane 
undergoes widespread changes during the transition from benign tumour to invasive 
carcinoma (Siegal et al, 1981; Barsky et al, 1983). Benign pathological disorders 
with epithelial disorganisation or proliferation are usually characterised by a 
continuous basement membrane which separates the epithelium from the stroma. By 
comparison, invasive carcinomas consistently exhibit a defective basement membrane 
adjacent to the invading tumour cells in the stroma, and it is also defective around 
tumour cells in lymph nodes and metastatic deposits (Burtin et al, 1982). In some 
regions of well-differentiated carcinomas, the production of basement membrane by 
differentiated structures can be identified; however it is often abnormal in that it is 
either discontinuous or focally reduplicated. Electron microscopy has revealed focal 
defects in the continuity of the lamina densa of carcinomas in situ (Liotta, 1986). 
Such defects in the basement membrane may be the earliest stages of the tumour 
progression process, as in zones of microinvasion, the basement membrane is 
fragmented or absent (Burtin et al, 1982). This may be due to decreased synthesis, or 
to the abnormal assembly of the secreted components, or alternatively, the loss of 
basement membrane may be due to increased breakdown by host-derived proteases 
(Liotta, 1986). Normal epithelial cells are thought to require a basement membrane 
for anchorage and growth (Hay, 1982; Kleinman et al, 1981; Wicha et al, 1980), and 
it may be that invasive tumour cells lack such a requirement.
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When tumour cells detach from the primary tumour they must interact 
with host basement membranes at many stages in the metastatic cascade. During 
intravasation or extravasation, the tumour cells must penetrate the subendothelial 
basement membrane and the ability of tumour cells to cross the vascular basement 
membrane is the rate-limiting step in the exit of tumour cells from the circulation to 
initiate metastatic colonies (Liotta et al, 1987). The majority of newly released 
tumour cells arrest in the first capillary bed they encounter (Liotta et al, 1979), with 
the mechanism of arrest due to impaction, or embolization of the tumour cell clump, 
or the direct adherence of the tumour cell to the endothelial surface (Fidler et al, 1978; 
Fidler & Hart, 1982). The presence of the arrested tumour cell causes the underlying 
endothelium to actively retract, exposing the subendothelial basement membrane. 
The kinetics of tumour cell adhesion to endothelial cell monolayers varies among 
tumour subpopulations, and it often correlates with the invasive abilities of the cells 
as observed in vivo (Kramer & Nicolson, 1981; Varani et al, 1980; Varani et al, 
1985). Analysis of the adhesive characteristics of cloned cell lines derived from a 
rhabdomyosarcoma revealed that the majority of clones which had low lung 
colonizing ability showed low attachment rates to endothelial cells, while all of the 
highly colonizing clones had high attachment rates (Korach et al, 1986).
In general, the subendothelial matrix provides a better adhesive substrate 
for most tumour cells as compared to endothelial cell surfaces (Kramer et al, 1980). 
However, differences in metastatic potential are not usually reflected by different 
adhesion rates (Vlodavsky et al, 1983; Nicolson et al, 1981), although correlations 
between the metastatic potential of various tumour cells and their adhesion to 
particular extracellular matrix components have been reported (Nicolson, 1988; 
McCarthy et al, 1985). Once tumour cells attach to the basement membrane, the 
retracted endothelial cells extend over the tumour cell surface covering the cell. 
After a time, local dissolution of the basement membrane occurs immediately below 
the tumour cell, followed by protrusion of tumour cell pseudopodia through the area 
of dissolution (Wallace et al, 1978). Following this, the tumour cell fully 
extravasates to form a metastatic colony. At the site where the colonies are initiated,
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the extravasated tumour cells must migrate through the perivascular interstitial stroma 
before tumour colony growth can occur in the organ parenchyma (Wallace et al,
1978).
2.The Retinoids.
Retinoids are a group of vitamin A metabolites and synthetic analogues 
which have been shown to suppress carcinogenesis and promote the differentiation of 
several types of tumour cells (Lotan, 1980; Sherman, 1986; Lippman et al, 1987). 
Neoplastic cell types classified as epithelial, mesenchymal and cells derived from the 
neural ectoderm and primitive ectoderm have all been shown to respond to treatment 
with retinoids.
The parent substance trans - vitamin A alcohol, or trans retinol, and its 
naturally occurring oxidation products trans - retinal (vitamin A aldehyde) and trans - 
retinoic acid (vitamin A acid) have a common structure consisting of a cyclic end 
group, a polyene chain and a polar end group.
R
CYCLIC END POLYENE POLAR END
GROUP CHAIN GROUP
from Spom & Roberts,1984.
Each region of the retinoid molecule can be chemically modified in many ways, 
resulting in an almost unlimited number of compounds, eg for retinoic acid.
CH
CH
CH
OHCH
from Spom & Roberts, 1984.
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Synthetic vitamin A analogues may share some, or all of the biological 
activities of the naturally occurring compounds. Some analogues are both less toxic 
and more potent than the naturally occurring retinoids while others are inactive, 
indicating that there are certain specific structural requirements for activity (Spom et 
al, 1976).
Although it has been shown that retinoic acid may play a role in cellular 
differentiation, the possible mode of action could not be investigated until a suitable 
model was developed. This utilised cells in cultures derived from embryonal 
carcinoma cells of testicular origin (Strickland & Mahdavi, 1978). These cells, 
especially the F9 clonal cells, show very little spontaneous differentiation into the two 
extraembryonic cell types, parietal and visceral endoderm. But the addition of small 
amounts of retinoic acid (lO '^m ol/L) induces their differentiation into an early 
embryonic cell type (Strickland & Mahdavi, 1978; Strickland et al, 1980). The 
synthesis of some proteins has been shown to be influenced specifically by the 
addition of retinoic acid to embryonal carcinoma cells or other cells in culture, eg 
cytoskeletal proteins and glycoproteins such as collagen (Strickland et al, 1980; 
Forest et al, 1982), fibronectin (Grover et al, 1982) and laminin (Strickland et al, 
1980; Grover et al, 1982; Carlin et al, 1983), enzymes such as glycosyltransferase 
(Lotan, 1985) and plasminogen activator (Strickland et al, 1980), and 
glycosaminoglycans (King & Tabiowo, 1981).
Retinoic acid appears to affect gene transcription, and specific gene 
sequences influenced by retinoic acid have been cloned (Wang et al, 1985). The 
suggestion that retinoids have an effect on the formation of mRNA is supported by the 
fact that retinol affects the terminal differentiation of cultured keratinocytes by 
differential expression of specific keratin mRNAs (Fuchs & Green, 1981). 
Additionally, cloning of cDNA specifying retinol-responsive human keratins (Eeckert 
& Green, 1984), and co-ordinative control of keratin gene expression in human 
keratinocytes (Gilfix & Eeckert, 1985) has also been reported.
Most of the effects of retinoids on gene expression have been determined 
after exposing the cells to the retinoids for several hours, and as most of the gene 
products are cytoskeletal proteins, suggests that the appearance of these gene products 
represent a late event in retinoid action (Chytil, 1986). However, animal studies have 
shown that retinoic acid simultaneously activates, and inhibits gene expression 
(Omori & Chytil, 1983), and that this occurs within one hour of administration. 
Furthermore, chromatin structure is also influenced, and this may account for the 
large number of genes affected.
Many normal and malignant tissues contain both the cellular retinoic 
acid-binding protein (CRABP) and the cellular retinol-binding protein (CRBP) 
(Chytil, 1986). These proteins appear to transport their non-covalently bound ligands, 
either extracellularly or intracellularly, to sites of action or metabolism. Both sets of 
proteins are characterised by a sediment coefficient of apparent value 2S 
corresponding to a molecular weight of 14.6kDa, and by a high binding specificity 
and affinity for their respective ligands. As well as binding all-trans retinoic acid, 
CRABPs can also bind 13-cis-retinoic acid (Chytil & Ong, 1984), the acid form of 
etretinate (Chytil & Ong, 1976) and some arotinoids (Sherman et al, 1983). There has 
been shown to be a correlation between the ability of these proteins to bind retinoic 
acid derivatives and the biological activity of these derivatives (Chytil & Ong, 1976; 
Jetten & Jetten, 1979; Trown et al, 1980). Furthermore, the availability of the free 
carboxyl group at the C15 position appears to be a necessary condition for the 
binding to CRABP to occur (Trown et al, 1980; Sani & Hill, 1974; Lotan et al, 1980).
In humans, two CRABPs have been isolated and characterised - CRABP-I 
and CRABP-II (Astrom et al, 1991) - and been shown to be highly homologous to the 
murine, avian and rat forms. CRABP-II was demonstrated to be highly selectively and 
markedly induced after topical retinoid treatment to the skin, which suggests that it 
might function to regulate the cutaneous actions of retinoic acid (Astrom et al,1991).
Two families of nuclear retinoic acid receptors have, to date, been 
identified - retinoic acid receptors (RARs)(Petkovich et al, 1987; Giguere et al, 1988; 
Krust et al, 1989) and retinoid X receptors (RXRs)(Mangelsdorf et al, 1990). Both
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consist of three receptor types - «< P , and # - and belong to the superfamily of steroid 
hormone receptors. RAR is the prominent receptor mRNA expressed in both murine 
and human skin (Krust et al, 1989; Elder et al, 1991; Zelent et al, 1990), while RXR 
has been seen predominantly in the skin, liver and digestive tract epithelia of the adult 
mouse (Mangelsdorf et al, 1992). RARs bind with high affinity to both all-trans 
retinoic acid and its stereoisomer 9-cis retinoic acid, however, although RXRs bind to 
both compounds, binding with high affinity only occurs with 9-cis retinoic acid 
(Allenby et al, 1993). Both sets of receptors are ligand-inducible trans-regulators 
which control transcription initiated from the promotors of retinoic acid target genes 
by interacting with specific DNA sequences termed retinoic acid response elements 
(RAREs), which are generally located upstream from the sites of transcriptional 
initiation (Glass et al, 1991; Leid et al, 1992).
Although the mechanisms by which retinoids exert their effects are 
unknown, it is thought that changes in the growth potential in responsive cells most 
likely results from a block or retardation of the progression of the cells through the 
cell cycle or from enhanced differentiation or maturation of the cells (Sachs, 1978; 
Sachs, 1980). Other effects of retinoids which have been observed include inhibition 
of cell growth in monolayer cultures, inhibition of anchorage-independent growth in 
semi-solid medium which is generally thought to correlate with tumourigenicity 
(Kahn & Shin, 1979; Cifore & Fidler, 1980), and the promotion of terminal 
differentiation of certain fully neoplastic embryonal carcinoma and promyelocytic 
leukaemia cells to non-neoplastic differentiated cell types. Many of the effects of 
retinoids on the growth of transformed cells are reversible, and thus probably 
represent the suppression of certain aspects of the transformed phenotype. However, 
their effects on the neoplastic embryonal carcinoma and promyelocytic leukaemia 
cells represents a stable alteration of the transformed phenotype to a non-neoplastic 
phenotype (Roberts & Spom, 1984).
The response of melanoma cells to retinoic acid has been well 
documented. Unlike other cell types where irreversible terminal differentiation is 
induced, melanoma cells treated with retinoic acid respond with a reversible
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inhibition of growth (Lotan et al, 1981), which is accompanied by an increase in 
melanogenesis (Edward et al, 1988). When protein synthesis was investigated it was 
found that retinoic acid treatment of Cloudman S91 murine melanoma cells brought 
about only minor quantitative changes in the proteins expressed (Lotan et al, 1982). 
This is in marked contrast to murine embryonal carcinoma cells in which retinoic 
acid-induced differentiation was accompanied by qualitative changes in protein 
synthesis (Strickland et al, 1980).
A variety of melanoma cells, both human and murine, have been treated 
with retinoic acid, and in every case where growth inhibition was observed, it was 
dependent on the concentration of retinoic acid and independent of cell density (Lotan 
et al, 1978; Meyskens & Fuller, 1980; Maniglia & Sartorelli, 1981), with 48-72h 
treatment required before a decrease in cell growth rate could be detected. 
Additionally, both anchorage-dependent and anchorage-independent growth of these 
cells was affected by continuous exposure to retinoic acid. It may be that retinoic acid 
affects the cells in the phase of growth and slows their entry into S phase (Lotan et 
al, 1981; Lotan et al, 1982). Retinoic acid was not found to be cytotoxic to the cells as 
demonstrated by the restoration of the growth rate to control levels 48-72h after 
removal of the retinoic acid (Lotan et al, 1978).
Melanoma cell lines from various origins, and even subclones derived 
from the B16 murine melanoma respond in a heterogeneous manner to retinoic acid, 
with the murine melanoma cell line Cloudman S91 being the most responsive (Lotan 
et al, 1978; Lotan & Nicolson, 1979; Meyskens & Fuller, 1980; Hoal et al, 1982). 
However, the most variable response was found in clones of B16 melanoma where the 
parental clone was inhibited by 40%, whereas several of the cloned derivatives 
showed no inhibition at all (Lotan & Nicolson, 1979). As yet the basis for this 
variability is not understood.
Retinoic acid can stimulate melanogenesis as measured by tyrosinase 
activity and melanin production in some murine and human melanoma cell lines 
(Lotan & Lotan, 1980; Lotan & Lotan, 1981; Meyskens & Fuller, 1980). In direct 
contrast to this, melanogenesis is inhibited by exposure to retinoids in some human
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melanoma cell lines (Hoal et al, 1982). The induction of melanogenesis by retinoic 
acid is not accompanied by an increase in cAMP levels, unlike melanogenesis 
induced byC<-MSH (Lotan & Lotan, 1980; Lotan & Lotan, 1981). Retinoic acid 
inhibition of cell growth was not a result of increased melanogenesis, as inhibition of 
tyrosinase activity had no effect on growth inhibition (Lotan & Lotan, 1981).
Specific changes in cell surface glycoproteins can also be induced by 
retinoic acid (Lotan, 1980; Lotan et al, 1983; Lotan et al, 1984). It is possible that 
some of these alterations in cell membrane components are related to the 
antiproliferative action of retinoic acid, with support for this coming from the finding 
that retinoic acid augments sialyltransferase activity. Additionally, retinoic acid has 
been shown to affect the cell surface glycosaminoglycans, thus it is possible that there 
is a correlation between these changes, the effects retinoic acid exerts on the 
adhesion of tumour cells, and the inhibition of the formation of lung tumours.
The process of invasion can also be affected by retinoids. In a system 
utilising a reconstituted basement membrane, invasion by human melanoma cells was 
inhibited by retinoid treatment in a time-dependent manner (Wood et al, 1990). Cells 
treated with retinoic acid were also shown to secrete lower levels of collagenolytic 
activity and tissue-type plasminogen activator activity. B-actin levels and the 
expression of mRNA for various oncogenes were also decreased (Wood et al, 1990). 
From this it was concluded that the inhibitory effect of retinoic acid was caused by 
the suppression of type IV collagenase and plasminogen activator activity, which may 
have been triggered through a complex series of oncogene trans-acting factors which 
induce effects on the cytoskeleton, and ultimately have an effect on cell motility.
1:2. THE EXTRACELLULAR MATRIX.
A three-step theory of invasion has been proposed to explain the 
biochemical events in the metastatic process (Liotta et al, 1977). The first step is the 
attachment of tumour cells to the extracellular matrix, and in the case of epithelial 
tumours such as melanoma, the first matrix encountered is the basement membrane. 
The interaction of cells with macromolecular components of the extracellular matrix
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plays a critical role in the regulation of cell morphology, growth and differentiation 
and in morphogenetic processes during development (Edelman, 1984; Yamada et al, 
1985; Yamada, 1983). Alterations in these cell-matrix interactions have been 
implicated in the pathogenesis of cancer (Poste & Fidler, 1980; Nicolson, 1984; 
Liotta, 1986).
The existence of cell-matrix interactions was suspected for some time, 
but validation was only begun when the biochemical interactions of the process of 
invasion were investigated. The most significant development was the identification 
of glycoproteins capable of promoting cell adhesion and spreading in vitro, and which 
seemed to play a role in the organisation of the extracellular matrix. The first major 
glycoprotein identified was fibronectin (Yamada et al, 1985), followed by laminin, 
vitronectin and a variety of tissue-specific nectins (Enestein & Furcht, 1984; Hynes 
& Yamada, 1982). The adhesion-promoting glycoproteins are often found as part of 
the insoluble extracellular matrix material, with laminin being confined mainly to the 
basal lamina of the basement membrane and fibronectin and vitronectin being found 
in a soluble form in blood plasma and other tissue fluids (Yamada et al, 1985). These 
proteins are large complex molecules, each of which has a variety of functional 
activities, but share a common functional pattern comprising a series of 
proteinase-stable functional domains, displaying binding activities for other 
macromolecules linked by proteinase-sensitive interdomain regions (Juliano, 1987).
1 .Laminin.
Laminin is a glycoprotein originally isolated from the EHS sarcoma 
(Timpl et al, 1979), with a molecular weight of 90kDa and an unique cross-shaped 
structure composed of three short arms and one long arm which was revealed by 
rotary shadowing (Engel et al, 1981). It is composed of three large polypeptide chains 
designated Bj, B2  and A which are linked to each other by disulphide bonds (Cooper 
et al, 1981). The short arms of the molecule are 37nm in length and consist of two
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globular domains connected by rod-like elements, while the long arm appears as a 
77nm rod terminating in a complex globular domain (Engel et al, 1981), which 
appears to consist of three smaller globules (Paulsson et al, 1985).
Proteolytic fragmentation and immunological techniques have revealed 
that the three short arms of the molecule are formed from individual N-terminal 
segments of the Bj,B2  and A chains respectively. The three chains are then aligned 
in parallel through the rod of the long arm, where the Bj and B2  chains terminate 
with an internal disulphide bridge. The globular end of the long arm is formed from 
the C-terminal segment of the A chain (Timpl, 1989). The globular end domains of 
the short arms exhibit type IV collagen binding ability (Laurie et al, 1986), as does the 
globular domain of the long arm (Charonis et al, 1986b). However, this ability to 
bind to type IV collagen has been shown to occur only when the laminin is in the 
form of a complex with nidogen/entactin, another basement membrane component 
(Aumailley et al, 1989). Heparan sulphate and heparin have also been shown to bind 
to laminin (Sakashita et al, 1980), with at least two different binding sites having been 
identified. A major binding site has been mapped at the end of the long arm, with 
some weaker binding activity located in the short arm structures. Cell binding 
activity has also been identified, with cell binding domains being located on the short 
arms of the molecule (Graf et al, 1987; Kleinman et al, 1989).
The cell adhesion receptor, located on the rod shaped intersection of the 
short arms, has been shown to play a role in metastasis (Barsky et al, 1984). Using 
animal models, tumour cells selected for their ability to attach via laminin will 
produce increased numbers of metastases after i.v. injection (Terranova et al, 1982). 
The intact laminin molecule attached to the tumour cell surface will stimulate 
hematogenous metastasis (Barsky et al, 1984; Varani et al, 1983), but cells treated 
with the receptor-binding fragment of laminin will be inhibited in the formation of 
lung colonies after i.v. injection (Barsky et al, 1984). The deduction from this is that 
the laminin receptor can play a role in hematogenous metastasis through at least two 
mechanisms. If the receptor is occupied, the cell can use the laminin as an 
attachment bridge through the globular end domains, however, if the receptor is
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unoccupied, the cell can bind directly to the host laminin. Both mechanisms can be 
blocked by the fragment of laminin capable of binding to the receptor but which lacks 
the globular end domains (Liotta, 1986).
Retinoic acid has been shown to modulate the attachment of cells to 
laminin. Mouse fibroblasts treated with retinoic acid were shown to have increased 
attachment to laminin-coated dishes (Kato & DeLuca, 1987). In contrast to this, B16 
melanoma cells treated with retinoic acid were found to exhibit decreased attachment 
to laminin-coated dishes (Edward et al, 1989). This highlights the diverse effects 
retinoic acid can have on the same process.
2.Type IV Collagen.
The highly insoluble nature of basement membranes, and the fact that 
they possess a stability against mechanical forces, has been correlated with the 
presence of large amounts of collagenous protein, which was shown to be different 
from the interstitial or fibre-forming collagens (Kefalides, 1973). Type IV collagen 
is specific for basement membranes and can account for as much as 60% of the total 
matrix protein (Kefalides et al, 1979; Timpl & Dziadek, 1986). It has a triple helical 
structure composed of two genetically distinct chains, and studies have revealed that 
its most likely structural composition is that of a heterotrimer [o<.l(IV)2 ] «<2 (IV) 
(Trueb et al, 1982; Mayne & Zettergren, 1980). The typical collagenous Gly-X-Y 
repeats of the triple helical region are frequently interrupted by several 
non-collagenous sequences (Oberbaumer et al, 1985; Pihlajaniemi et al, 1985), and it 
is these interruptions which give flexibility to the molecule, but also makes it more 
susceptible to proteolytic attack (Timpl & Dziadek, 1986). This is important in the 
subsequent degradation of the basement membrane by tumour cells, as the ability to 
produce enzymes capable of breaking down type IV collagen can be related to the 
breakdown of the structural support unit of the membrane, and as such, expose the 
other components of the membrane to proteolytic attack.
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Early work revealed the shape of the type IV collagen molecule to be that 
of a long hockey stick (Timpl et al, 1982). Although the molecules may occur singly, 
more frequently they are combined by association of their C-terminal globules or less 
frequently four molecules can combine to form tetramers by joining at their 
N-teminals (Leblonde & Inoue, 1989). A third mode of association has also been 
observed where two or three collagen molecules join along part of their length 
(Yurchenco & Furthmayr, 1984), producing a lateral association and giving the 
molecule some rigidity. In addition to this a fourth mode has been identified in vitro 
in which the globular end of free monomers bind to sites at intervals of about lOOnm 
along other collagen molecules (Tsilbary & Charonis, 1986).
Type IV collagen can interact with laminin and the other major 
component of the basement membrane, heparan sulphate proteoglycan. Laminin has 
a higher affinity for native type IV collagen than for denatured type IV collagen or 
other collagen types but it is a weak affinity. Pepsin digestion of the native type IV 
collagen, which removes the globular domain NCI and about lOOnm of the helix, 
inhibited laminin binding, indicating that the binding site is in the NCI domain or 
close to it (Rao et al, 1985). Conversely, it has been reported that isolated NCI 
domain did not bind to laminin but pepsin treated material did (Charonis et al, 1986a).
3.1nterstitial Collagens.
Interstitial collagens are fibre-forming collagens which have, in principle, 
the same molecular structure, the majority of which consists of a continuous triple 
helical domain. They can interact directly with cells via specific receptors at the cell 
surface (Mollenhauer & Von der Mark, 1983), or the interaction can be mediated by 
other extracellular matrix components, with fibronectin having a particularly high 
affinity for denatured collagens. The collagen binding region has been identified 
(Kleinman et al, 1976) as a region which overlaps with the cleavage site of vertebrate 
collagenase with the integrity of this collagenase-sensitive region being required for 
fibronectin binding (Kleinman et al, 1981).
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4. Proteoglycans.
Proteoglycans are proteins which have one or more glycosaminoglycan 
chains covalently attached to them. They have been implicated in the control of 
certain biological processes such as adhesion (Rapraeger et al, 1985), migration 
(Klebe et al, 1984) and cell proliferation (Martin et al, 1984; Uhlrich et al, 1986). 
Alterations in proteoglycan metabolism in tumour cells or in the adjacent host cells 
may contribute to the altered adhesiveness and abnormal assembly of the extracellular 
matrix (Iozzo, 1988). Additionally, malignant cells can secrete factors which are 
able to modulate the proteoglycan metabolism of the host (Iozzo & Muller-Gauser, 
1985).
Heparan sulphate proteoglycans have been isolated and characterised 
from several basement membranes (Hassell et al, 1980; Dziadek et al, 1985; Hassell 
et al, 1985) and this has, initially, provided conflicting results on their size and 
composition. Studies on heparan sulphate proteoglycan isolated from the EHS 
sarcoma have indicated the existence of at least two forms of the molecule, which 
differ in size and heparan sulphate content, and thus in their buoyant density 
(Fujiwara et al, 1984; Hassell et al, 1985; Kato et al, 1987). The low density form 
has been examined using biosynthetic studies, and found to have a uniform protein 
core precursor of about 400 kDa (Ledbetter et al, 1985) and antibodies to the protein 
core have shown a widespread occurrence in cultured cells and tissues, but limited to 
their basement membranes (Dziadek et al, 1985; Fenger et al, 1984).
The protein core probably plays a crucial role in the integration of low 
density heparan sulphate proteoglycan into basement membranes, as it cannot be 
dissociated by high salt concentrations which would interfere with ionic interactions. 
This strong binding may include self assembly of the molecule to oligomers 
(Yurchenco et al, 1987), additionally, association to dimers and to more complex 
stellate clusters occurs by binding between terminal domains of the core protein 
which are most distal to the heparan sulphate attachment region. Proteolytic removal 
of these domains abolishes self assembly (Timpl, 1989).
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Heparan sulphate chains have been shown to bind weakly to laminin and 
the NCI domain of type IV collagen (Fujiwara et al, 1984), but this binding was non 
specific, as dextran sulphate and to some extent chondroitin sulphate could displace it 
from its ligands, with the binding properties varying according to the sulphate content 
of the glycosaminoglycan (Pejler et al, 1987). Some heparan sulphate proteoglycans 
may also be involved in the control of serine proteinase activity, which may be 
important in the maintenance and remodelling of basement membranes (Pejler et al, 
1987), and also in the invasion of tumour cells through the basement membrane by 
proteolytic degradation.
Evidence that heparan sulphate proteoglycans promote cell adhesion 
when incorporated into basement membranes is not extensive. However reports have 
indicated that heparin, and sulphated glycosaminoglycans in general, can support the 
attachment and spreading of a wide variety of cell types including neural crest 
(Erickson & Turley, 1983) and neuronal cells (Stamatoglou & Keller, 1983) with the 
effect, in some cases, being caused by the sulphate group (Erickson & Turley, 1983; 
Turley, 1980). Also, highly metastatic cells release a heparinase, and this may 
possibly alter basement membrane architecture or the adhesive properties which 
affect cell attachment to it (Nicolson, 1982).
5.Fibronectin.
Fibronectin is a dimeric glycoprotein composed of two similar 240kDa 
disulphide bonded subunits and occurs in two forms - the soluble form which is found 
in high concentrations in plasma, other body fluids and the conditioned medium of 
cultured cells, and the insoluble form, in which high molecular weight 
disulphide-bonded multimers are organised into an extracellular fibrillar matrix 
(Mosher, 1980; Mosher, 1984; Hynes, 1981; Hedman & Varani 1989). The 
insoluble form provides a substrate for cell migration during embryogenesis and 
wound healing (Thiery et al, 1989), and is capable of promoting the attachment, 
spreading and migration of a variety of cell types including tumour cells (Ruoslahti, 
1988b; Ruoslahti & Pierschbacker, 1987). The molecule contains two distinct
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cell-binding domains, one located in the centre of the molecule and the other in a 
region which is alternatively spliced from precursor mRNA termed the type in 
connecting segment (DICS) (Yamada, 1988).
1:3. CELL ADHESION.
1. The Integrins
Cell attachment to fibronectin is mediated, in part, by the interaction of 
the Arg-Gly-Asp-Ser (RGDS) sequence with a specific cell surface fibronectin 
receptor which is a member of the noncovalent heterodimer integrin receptor
group (Pytela et al, 1985; Hynes, 1987; Ruoslahti, 1988). The integrins form a 
family of related matrix receptors (Buck & Horwitz, 1987) which are membrane 
glycoproteins consisting of two subunits - o L  and j s  - both of which have a large 
extracellular domain, a transmembrane domain and a short cytoplasmic domain 
(Ruoslahti & Giancotti, 1989). The ©(.and^subunits are non-covalently bound to one 
another and the association is promoted by divalent cations (Ginsberg et al, 1988).
The integrins are divided into at least five subfamilies, each being defined 
by a common f t  subunit (Hynes, 1987), with the specificity for ligand binding being 
determined by the particular combination of«4 and ^ subunits. The best characterised 
integrins are those belonging to the subfamily, which includes receptors for 
laminin, fibronectin and collagen; to the ^  subfamily found on leukocytes which 
includes receptors mediating cell-cell interactions; and the ^ 3  subfamily, which 
includes the platelet glycoprotein 1 lb /1 1 1 a complex and the vitronectin receptor 
which also binds fibrinogen, thrombospondin and von Willebrand’s factor (Cheresh & 
Spiro, 1987; Lawler etal, 1988).
In vitro and in vivo comparisons of control and malignant cells have 
suggested that changes in integrin expression may be part of malignant 
transformation, but no uniform pattern of change has been demonstrated. Rodent 
cells transformed with Rous sarcoma virus (Plantefaber & Hynes, 1989), basal cell 
and squamous cell carcinomas (Peltonen et al, 1989), exhibit a reduction in the 
expression of integrins from the P . y  subfamily. In contrast to this, chemically
39
transformed, tumourigenic human osteosarcoma cells display an increase in p j  
integrins when compared to nontumourigenic osteosarcoma cells (Dedhar & Sauliner, 
1990), while other transformed cells show an alteration in the distribution of integrins 
but no changes in their expression (Akiyama et al, 1990).
Despite the lack of evidence outlined above, functional studies suggest 
that integrins are important in the metastatic process. Synthetic peptides containing 
the RGD sequence which block the binding of many integrins to their extracellular 
matrix ligands (Pierschbacher & Ruoslahti, 1984; Yamada & Kennedy, 1984), inhibit 
the movement of human melanoma cells through an amniotic basement membrane in 
an experimental model of invasion (Gehlsen et al, 1988). Such peptides also reduced 
the number of metastatic deposits found in the lungs of mice following i.v. injection 
of B16F10 metastatic melanoma cells (Humphries et al, 1988; Saiki et al, 1988). 
Consistent with these findings is the observation that antibodies against the ^ 3  
subfamily prevent the establishment of tumours when human melanoma cells are 
implanted into nude mice (Boukerche et al, 1989). Studies have shown that 
melanoma cells, both in tissues and in culture, express a wide variety of integrins in a 
relatively heterogeneous pattern, but in tissue sections the expression of they^j 
subfamily was restricted to only the tumorigenic cells (Albelda et al, 1990).
However, perhaps the most consistent adhesion marker for metastatic 
potential is the expression of the °*v ^ 3  integrin which recognizes several ligands 
including vitronectin, fibrinogen and thrombospondin. Melanoma cells that do not 
express this integrin have been demonstrated to be less invasive, in vivo, than those 
cells which do express*8^ P 3  (Felding-Habermann et al, 1992). The expression o f ° y ^  
has also been shown to affect the expression and secretion of type IV collagenase 
(Seftor et al, 1992). These findings would suggest that the integrins expressed by 
melanoma cells are relevant to their invasive phenotype.
2.Cell-Cell Adhesion.
One of the earliest and most important, adhesive events in invasion is the 
adhesion of tumour cells to the vascular endothelium. Although many tumour cells 
become trapped in the first vascular bed they encounter, passive cell trapping is not 
sufficient to promote tumour metastasis (Hart & Fidler, 1980; Hart, 1982; Tarin, 
1985; Nicolson, 1988). In many cases tumour cells will lodge in the first organ 
encountered, but metastatic colonies will only be found in organs downstream of the 
site of first arrest. From this it has been speculated that a specific cellular adhesive 
interaction may initiate the formation of metastatic deposits at a particular secondary 
site (Green &  Harvey, 1964; Zetler, 1990). In vitro work has revealed that, in many 
cases, metastatic tumour cells adhere selectively to capillary endothelial cells derived 
from their preferred secondary site (Alby & Auerbach, 1986; Auerbach et al, 1987). 
This has been confirmed by using melanoma cells which preferentially metastasise to 
the lung, and lymphoma cells which preferentially metastasise to the liver (Roos et al, 
1984; Nicolson, 1988).
Most of the information on adhesion of tumour cells to endothelial cells 
has come from studies on lymphocytes which home to specific endothelial cells in 
lymph nodes or Peyers patches (Stoolman, 1989), and a set of cell adhesion molecules 
on endothelial cells that interact with a set of adhesive receptors on the lymphocyte 
cell surface have been identified (Yednock & Rosen, 1989), and named vascular 
addressins. Antibodies to these receptors can inhibit experimental metastasis of 
certain lymphoid tumours (Sher et al, 1988), which implies that they may be 
important in the metastatic cascade.
A cell membrane proteoglycan, CD44, has also been identified and 
implicated in various cell processes. One of its major functions would appear to be in 
the regulation of lymphocyte adhesion to cells from endothelial venules during 
lymphocyte migration (Gallatin et al, 1987; Jalkanen et al, 1986). This process has 
many similarities to the metastatic spread of solid tumours (Sher et al, 1988). CD44 
has also been shown to be the principal cell surface receptor for hyaluronate (Aruffo
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et al, 1990; Miyake et al, 1990), a glycosaminoglycan that plays a major role in 
diverse cellular processes which include cell-cell adhesion, embryonic development, 
cell migration and angiogenesis (Toole, 1981; Westet al, 1985).
3. Retinoids and Cell Adhesion.
The effect of retinoids on the ability of cells to attach varies depending on 
the type of cell under investigation. They can enhance the attachment of 3T3 cells to 
both laminin and type IV collagen, but if this cell line is virally transformed, 
attachment is unaffected (Kato & De Luca, 1987). 3T3 cells have been shown to 
adhere poorly to the two substrates, but the transformed cells adhere readily. This is 
supported by the finding that laminin receptor expression is increased in highly 
metastatic cells (Liotta et al, 1986b).
Retinoic acid has also been shown to have an effect on cell-cell adhesion. 
The adhesion of a human epithelial cell line to plastic is reduced by treatment with 
retinoic acid, as is the ability of these cells to form clusters (Shapiro & Poon, 1979). 
BHK21/C13 cell-cell adhesion has also been shown to be reduced by retinoids, but 
cell-substrate adhesion is increased (Kamei, 1983). This illustrates the diverse effects 
retinoids can have on the same process.
The synthesis of extracellular matrix molecules which may be involved in 
cell adhesion can also be affected by retinoids. Glycosaminoglycan synthesis can be 
increased in some cell types while being decreased in others, suggesting that the 
action of these compounds may be cell specific. Certain tumour cell lines have been 
shown to express heparan sulphates with a reduced degree of sulphation following 
treatment with retinoids (Robinson et al,1984). This would suggest that one possible 
function of retinoids is to alter the surface molecules involved in cell adhesion.
1:3. DEGRADATION OF THE EXTRACELLULAR MATRIX.
When invading tumour cells attach themselves to the basement 
membrane, they must degrade it before further dissemination can occur. The 
presence of proteolytic enzymes in the process of matrix degradation associated with
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tumour invasion has been well documented (Nicolson, 1982; Liotta et al, 1983; 
Saksela, 1985), and reports indicate an increase in the proteinase activity in malignant 
tumour tissue as compared to that in normal tissues. Indeed, a direct correlation 
between metastatic potential and the production of certain proteinases has been 
established for some tumour cell lines - sublines of the B16 murine melanoma have 
been shown to have an increased production of type IV collagenase (Liotta et al, 
1980; Liotta et al, 1979), and an endoglycosidase capable of degrading heparan 
sulphate (Nakajima et al, 1983), which correlate with increased metastatic potential. 
The origin of the proteinases has been traced to both the tumour cells and the host 
cells (Bauer et al, 1979), thus it would appear that the degradation of the extracellular 
matrix in tumour invasion is a highly complicated process, involving the abnormal 
expression of proteinase genes in cells of the tumour and the host (Tryggvason et al, 
1987).
Proteinases are enzymes which are capable of hydrolysing peptide bonds 
as either exopeptidases or endopeptidases. They can be divided into four main 
classes depending on criteria such as their catalytic site, optimum pH, cation 
requirements and susceptibility to inhibitors. The proteinases most often associated 
with the malignant phenotype are the serine proteinases such as plasminogen 
activator, the cysteine or thiol proteinases which include the cathepsins, and the 
metalloproteinases.
1.Plasminogen Activators.
These are a group of serine proteolytic enzymes which specifically 
convert plasminogen to the active enzyme plasmin (Saksela, 1985; Dano et al, 1985). 
The inactive proenzyme plasminogen is abundant in the vasculature, in most body 
fluids and in the basal layers of the epidermis (Isseroff & Rifkin, 1983), while the 
active enzyme, plasmin, is the primary effector enzyme in thrombolysis as it 
effectively cleaves fibrin. Plasmin, however, can also participate in the extravascular
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breakdown of extracellular matrix and basement membrane glycoproteins, and it may 
also be involved in the activation of procollagenase to collagenase, which is a 
requirement for collagen degradation in the matrix (Salo et al, 1982).
Two different types of plasminogen activator are produced - tissue type 
plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) 
(Nielsen et al, 1983; Golds et al, 1983). They differ from each other with respect to 
tissue distribution, and in catalytic, molecular and immunological properties. 
Additionally, it has been established that they are independent gene products (Rajput 
et al, 1985). Both types are secreted as single chain polypeptides (Saksela, 1985; 
Dano et al, 1985), but in this form u-PA has little or no enzyme activity (Eaton et al, 
1984; Kasai et al, 1985). Activation occurs by the cleavage of peptide bonds which 
results in the formation of a two chain structure, and this process can be mediated in 
the extracellular space by plasmin (Dano et al, 1985). This may be an important 
regulatory step in the process, however, it is not known if specific enzymes for the 
initial proenzyme activation exist on the cell surface. Initial activation of 
plasminogen may occur through the interaction of single chain u-PA and plasminogen 
when the macromolecules are present on the cell surface or in the matrix (Miles & 
Plow, 1985; Miles and Plow 1987; Hajjar et al, 1986). These interactions may lead 
to alterations in plasminogen configuration, which favours the formation of a complex 
with the single chain form, and eventually to the generation of catalytic amounts of 
plasmin capable of converting the single chain u-PA to the active two chain form. 
Unlike u-PA, single chain t-PA is active and readily activates plasminogen in the 
presence of fibrin.
Using immunological methods, u-PA has been identified in fibroblast-like 
cells in vivo (Skriver et al, 1984; Kristensen et al, 1985), whereas t-PA has been 
localised to the vascular endothelium of many tissues (Kristensen et al, 1985). 
Cultured cells produce mainly u-PA (Saksela, 1985; Dano et al, 1980; Vetterlein et al,
1979), but there are examples of cell lines which produce only t-PA (Strassburger et 
al, 1983; Paranjpe et al, 1980) or both u-PA and t-PA (Levin & Loskutoff, 1982; 
Vetterlein et al, 1980). Plasminogen activators have also been found in cells of
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neoplastic origin, with u-PA being found in the conditioned media of cells derived 
from endometrial carcinomas (Swanberg & Astedd, 1979), and a number of cell lines 
of neoplastic origin have been reported to produce u-PA (Strickland et al, 1983; 
Azzarone et al, 1983; Dano et al, 1985). t-PA is also produced by a number of 
neoplastic cells, the most notable being a number of melanoma cell lines (Rifkin et al, 
1974; Orenstein et al, 1983; Strickland et al, 1983).
2.Plasminogen Activator Inhibitors.
Secreted plasminogen activator activity is effectively controlled by 
specific inhibitors produced by a number of cell types and, indeed, two proteinase 
inhibitors specific for plasminogen activators have been identified and purified. 
Plasminogen activator inhibitor type-1 (PAI-1) has been shown to be released by 
endothelial cells, some neoplastic cell lines including those derived from melanoma 
(Andreasen et al, 1986; Emeis et al, 1983; Levin, 1983; Loskutoff et al, 1983), and it 
is also present in thrombocytes and blood plasma (Erickson et al, 1985; Wiman et al,
1984). Plasminogen activator inhibitor type-2 (PAI-2) was initially purified from 
placental extracts, but has been found to be released by cultured 
monocytes-macrophages (Astedt et al, 1985; Chapman & Stone, 1985; Saksela et al,
1985). Although both inhibitors belong to the serine proteinase inhibitor family - the 
serpins - they differ in immunological reactivity and in some physiological 
characteristics (Hekman & Luskutoff, 1985; Ny et al, 1986; Pannekoek et al, 1986). 
A third plasminogen activator inhibitor has been identified as the proteinase nexin 1 
(PN1) which has been isolated from fibroblasts, but is also produced by other cultured 
cell types (Baker et al, 1980). However, unlike PAI-1 and PAI-2, PN1 also inhibits 
plasmin, thrombin and other trypsin-like serine proteinases (Scott et al, 1985).
3.Metalloproteinases.
Metalloproteinases are a family of enzymes which usually act at a neutral 
pH, have tightly bound Zn^+, require Ca^+ for activity and cleave internal as opposed 
to terminal peptide bonds (Khokha & Denhardt, 1989). They include interstitial
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collagenases, type IV collagenase (gelatinase) and a stromelysin (proteoglycanase, 
collagenase-activating proteinase, transin), and are typically secreted as proenzymes 
which require activation. Both intracellular and membrane-bound metalloproteinases 
have been described (Bond & Beynon, 1985; Chen & Chen, 1987; Harris et al, 1984). 
a/ Interstitial Collagenases.
The interstitial collagens are highly resistant to attack by proteinases, but 
they can be degraded by highly specific metalloproteinases which have been isolated 
from a variety of cells and tissues. Interstitial collagenases have been purified from a 
number of sources including rabbit synovial fibroblasts (Werb & Reynolds, 1975), 
rabbit V2-carcinoma (Woolley & Grafton, 1980) and human skin (Stricklin et al, 
1978). They require Ca^+ and Zn^+ as cofactors for maximum activity, and are 
secreted as proenzymes which must be activated. Activation can be achieved by a 
variety of proteinases such as trypsin, chymotrypsin, plasmin, cathepsin B, kallikrein 
and mast cell proteinases (Paranjpe et al, 1980; O’Grady et al, 1981; Werb et al, 1977; 
Woolley, 1984; Nagase et al, 1982; Eckhout & Vaes, 1977). Additionally, some 
endogenous neutral proteinases (Horwitz et al, 1976) and serine proteinases 
(Woessner, 1977) may be able to activate latent collagenases, either directly or after 
they themselves have been activated (Eckhout & Vaes, 1977). Procollagenase 
secreted by human skin fibroblasts can also be autoactivated without any detectable 
change in molecular weight (Stricklin et al, 1977)- the endogenous activator isolated 
from the medium of cultured human skin and rat uterus activates collagenase without 
any measurable change in the molecular weight of the zymogen (Tyree et al, 1981). 
Activation can also be initiated chemically, especially by organic mercurials and 
chaotropic agents, again without any apparent change in molecular weight, and this 
may occur by the formation of alternative disulphide bridges in the molecule 
(Goldberg et al, 1986).
The activated interstitial collagenases cleave the native triple-helical 
molecules at a single site, with both soluble and fibrillar collagen molecules being 
cleaved. Types I, II and HI collagen are degraded in a similar fashion, although the 
cleavage of type II collagen is slower than that of other types (Woolley & Grafton,
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1980; Cawston et al, 1981). The enzymes cut the polypeptide chains at a Gly-Leu or 
Gly-Ile sequence depending on the type of chain (Woolley, 1984; Woolley et al, 
1978). The triple helix has also been reported to be unstable at this sequence and as 
such it makes the molecules, particularly type in collagen, susceptible to the action of 
trypsin and thermolysin (Gross et al, 1980). When the molecule has been cleaved, the 
degradation fragments, which are thermally labile, are denatured and can be further 
degraded by collagenase itself or by other proteinases (Woolley, 1984).
In 1965, ultrastructural evidence was provided for the breakdown of 
collagen fibres by tumour cells (Birbeck & Wheatley, 1965), and this was supported 
by reports of increased collagenolytic activity in breast carcinoma cells (Keiditsch & 
Strauch, 1976), as well as in a number of tumour tissues, and in cultured tumour cells 
(Woolley & Grafton, 1980; Hashimoto et al, 1972; Bauer et al, 1979; Biswas, 1982). 
However, a direct correlation between the secretion of interstitial collagenases and the 
metastatic potential of tumour cells has not been established. The collagenases may 
often be secreted by host tissue cells (Biswas & Dayer, 1979), and it is likely that the 
specific activities of the different tumour collagenases, as well as their diffusibility 
within tissues can vary greatly and can, in turn, affect the invasive potentials of 
different tumours.
b / Type IV Collagenase.
Type IV collagen is specifically degraded by a metalloproteinase-type 
collagenase (Liotta et al, 1979; Salo et al, 1982), and is resistant to attack by 
interstitial collagenases (Babel & Glanville, 1984). Type IV collagenase has been 
found in malignant tumour tissue (Liotta et al, 1979; Salo et al, 1982), cultured 
tumour cells (Salo et al, 1985) and also in proliferating human fibroblasts (Salo et al,
1985). The enzyme has been purified and identified as a glycoprotein with a 
molecular weight of 60-70kDa (Salo et al, 1982; Salo et al, 1985; Garbisa et al,
1986). Serine and sulphydryl proteinase inhibitors do not inhibit type IV collagenase 
whereas metal chelators do, which confirms that the enzyme is a metalloproteinase. 
However, it can be activated, in vitro, by pretreatment with plasmin, trypsin or 
organomercurials and in this respect it resembles the interstitial collagenases. It
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cleaves the native type IV collagen molecule at a single site in the helical domain 
(Fessler et al, 1984), and in this way the enzyme may be able to decompose the 
collagen network of basement membranes and as such solubilize the structure.
The association of type IV collagenase and neoplasia has been confirmed 
by the demonstration that type IV collagenolytic activity is secreted by tumour tissue 
and numerous tumour cells in culture (Salo et al, 1982; Eisenbach et al, 1985; Starkey 
et al, 1984). Enzyme activity detected in the culture media of variants of the B16 
murine melanoma has been shown to correlate with the metastatic potential of the 
cells (Poste and Fidler, 1980). In contrast, type IV collagenase activity has been 
detected in several other tumour cell lines, but no correlation determined between 
enzymatic activity and metastatic potential (Starkey et al, 1984). The reason for the 
discrepancy in the observations of enzyme activity are not clear, but changes in the 
cellular phenotypic properties may be responsible.
Work with melanoma cells has demonstrated that the secretion of type IV 
collagenase was enhanced by laminin but was unaffected by fibronectin 
(Turpeenniemi-Hujanen et al, 1986), and this agreed with in vivo work which 
demonstrated that laminin can potentiate the metastatic capacity of tumour cells 
(Terranova et al, 1982; Barsky et al, 1984). Laminin binds to a specific cell surface 
protein which does not bind fibronectin or any of the collagens, and it was found that 
fragments of laminin which contain the receptor-binding domain, but none of the 
other matrix attachment domains, had a much greater effect on type IV collagenase 
production than the whole molecule (Turpeenniemi-Hujanen et al, 1986). 
Monoclonal antibodies to the laminin receptor completely blocked the effects of 
laminin on type IV collagenase, and although the possibility that laminin may affect 
type IV collagenase production through channels other than the laminin receptor 
cannot be excluded, the evidence would suggest this to be the case. This would link 
the adherence of a tumour cell to laminin in the basement membrane with the 
production of a degradative enzyme in the process of invasion, 
c/ Stromelysin.
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Unlike the collagenases, stromelysin is not specific for any one 
component of the extracellular matrix. It can degrade a broad spectrum of substrates 
including proteoglycans, nonhelical regions of collagen, elastin, fibronectin and 
laminin (Chin et al, 1985; Khokha & Denhardt, 1989). It is secreted as a proenzyme 
which can be activated by trypsin or mercurials (Chin et al, 1985), and the molecule 
itself has been shown to resemble the interstitial collagenases in that there is a 
significant homology in the amino acid sequences of both molecules (Tryggvason et 
al, 1987). Production of stromelysin can be induced in fibroblasts by the same agents 
capable of inducing collagenase production, which suggests that secretion of 
stromelysin may be associated with malignant transformation (Chin et al, 1985).
4.Metalloproteinase Inhibition.
Metalloproteinases must be tightly regulated at the enzyme level because 
of the potential to degrade collagens at a neutral pH. As stated, these enzymes are 
secreted in latent forms which can be activated either by factors inducing 
conformational changes, by limited proteolysis, or by a catalytic process involving 
another metalloproteinase (Harris et al, 1984; Murphy & Reynolds, 1985; Peppin & 
Weiss, 1986; Okada et al, 1988). An important control is exerted on the 
metalloproteinases by inhibitors of enzyme activity (Tryggvason et al, 1987; 
Cawston, 1986), which have been identified in serum and several body tissues 
including skin, bone, tendon and uterus from various animal species. 
^Macroglobulin accounts for much of the anti-metalloproteinase activity in serum 
where it mainly acts against proteinases that enter the blood stream. Smaller cationic 
proteins are another class of tissue inhibitors which prevent events such as 
tumour-induced vascular proliferation, bone resorption and new vessel growth into 
cartilage (Harris et al, 1984; Cawston, 1986). However, perhaps the most important 
inhibitors are the highly effective tissue inhibitors of metalloproteinases (TIMPs) 
found in many body fluids.
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TIMP, also called collagenase inhibitor, is not active against the serine, 
cysteine or aspartic proteinases (Murphy & Reynolds, 1985; Cawston, 1986; Welgus 
et al, 1985), but it can inhibit the matrix metalloproteinases. It regulates the 
breakdown of collagen and basement membrane components in a number of 
situations (Jeffrey, 1986) by forming a 1:1 complex with the target metalloproteinase 
which is effectively irreversible, with small changes in the ratio having a dramatic 
effect on enzyme activity (Welgus et al, 1985; Harris et al, 1984).
There is strong correlative, as well as direct, evidence implicating TEMP 
in controlling the invasive potential and metastatic proficiency of cells, with an 
inverse correlation between the levels of TIMP production of various intracranial 
tumours (Halaka et al, 1983), and a series of metastatic variants derived from 
NIH7T1/2 cells (Hicks et al, 1984). In contrast to this, human cirrhotic livers possess 
high levels of metalloproteinase inhibitors and are able to resist invasion by 
metastasizing cancers (Barsky & Gopalakrishna, 1988). Purified TIMP was able to 
partially inhibit the invasion of human amnion by M5076 cells (Thorgeirsson et al, 
1982), and it was shown that recombinant human TEMP blocked invasion of the 
amnion at a step after adhesion. Frequent intraperitoneal infusions of TEMP 
produced a significant inhibition of colonization of the mouse lung by subcutaneously 
injected B16F10 melanoma cells. This effect was specific for invasion since TEMP 
treatment did not alter the growth rate of the primary tumour, or the size of the 
metastatic nodules that formed in the lung.
5.Endoglycosidases.
The proteoglycan heparan sulphate is a major constituent of basement 
membranes and, as such, its degradation is important in the process of metastatic 
invasion. Heparan sulphate-degrading activity has been identified in metastatic 
melanoma sublines and, indeed, this activity correlates with their lung colonizing 
potentials (Nakajima et al, 1983). The melanoma heparan sulphate degrading 
enzyme is an endo-f-D-glucuronidase (heparanase) that cleaves heparan sulphate at 
specific intrachain sites (Nakajima et al, 1984). If melanoma cells are treated with
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heparanase inhibitors, the number of experimental lung metastases produced is 
decreased, which indicates that heparanase plays an important role in melanoma 
metastasis (Irimura et al, 1986).
Endoglycosidase activity is not unique to metastatic tumour cells, and it 
has been found in a variety of normal tissues and cells including liver (Hook et al, 
1984), skin fibroblasts (Klein et al, 1976) and inflammatory macrophages (Naparstek 
et al, 1984; Savion et al, 1984). In some cases these normal cell enzymes have been 
shown to be different from tumour enzymes - a platelet derived endo-f 
-D-glucuronidase which is different from melanoma heparanase in that the normal 
cell enzyme is capable of degrading both heparan sulphate and heparin, whereas 
heparin is a potent inhibitor of melanoma heparanase (Oosta et al, 1982; Nakajima et 
al, 1984).
There have been several reports indicating that plasminogen activator can 
have an effect on the action of heparanase (Bar-Ner et al, 1986). Using several 
normal and malignant cell types, it has been shown that degradation of heparan 
sulphate proteoglycans in the subendothelial extracellular matrix is accelerated by a 
proteolytic activity which is thought to make the heparan sulphate side chains more 
accessible to the action of heparanase (Bar-Ner et al, 1985). Plasmin has been shown 
to digest various extracellular matrix components such as fibronectin, laminin and 
proteoglycans (Liotta et al, 1981; Jones & De Clerck, 1980). Thus it is possible that 
the effects observed are due to plasmin-mediated degradation of various matrix 
constituents, not necessarily heparan sulphate proteoglycan, and this would allow a 
better interaction between the heparanase and the extracellular matrix heparan 
sulphate. Another possibility is that a limited degradation of the heparan sulphate 
proteoglycan core protein could occur which would lead to the release of soluble high 
molecular weight fragments with heparan sulphate side chains which would be more 
readily cleaved by the heparanase than those still bound to the extracellular matrix.
6. Effect of Retinoids on Matrix Degradation.
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Retinoids have been shown to have an inhibitory effect on tumour cell 
invasion. Indeed, retinoic acid has been demonstrated to inhibit invasion by human 
melanoma cells and rat mammary adenocarcinoma cells through a basement 
membrane in an in vitro assay system, with the inhibition of invasion being correlated 
to a decrease in type IV collagenolytic activity (Hendrix et al, 1990; Nakajima et al, 
1989). Retinoic acid inhibition of invasion was found to be dose and time dependent, 
but the inhibitory effect was found to be reversible on removal of the retinoid from 
the assay system (Hendrix et al, 1990). In this system, the presence of the retinoic 
acid in the basement membrane model had no effect on invasion, but pretreatment of 
cells suppressed invasion which would suggest that an effect of retinoic acid on the 
cells, rather than on the matrix, is responsible for alterations in cell invasion (Hendrix 
et al, 1990). This is in contrast to a study examining the effect of retinoic acid on the 
invasion of virally transformed rat cells through a chick chorioallantoic membrane 
(Fazely et al, 1985). Although invasion was inhibited, it was dependent upon 
pretreatment of the chorioallantoic membrane with retinoid and on the continuous 
presence of retinoid during the assay. Thus, the inhibitory effect was attributed to the 
ability of retinoic acid to enhance the differentiation of the chorioallantois rather than 
the tumour cells (Fazely et al, 1985).
The ability of retinoids to inhibit invasion of melanoma cells and rat 
mammary adenocarcinoma cells through a basement membrane system has been 
correlated to a decrease in type IV collagenolytic activity (Hendrix et al, 1990; 
Nakajima et al, 1989). In contrast to this, reports have also indicated that retinoids 
have no effect on type IV collagenase activity (Oikarinen & Salo, 1986). This 
illustrates, again, the diverse effects retinoids can have on the same processes in 
different cells.
Retinoic acid has also been shown to have an effect on t-PA production 
by human melanoma cells (Hendrix et al, 1990). A decrease in t-PA was observed 
when human melanoma cells were exposed to retinoic acid. Various reports have 
shown that tumour cell invasion through a basement membrane matrix is dependent 
upon a proteolytic cascade in which plasminogen activators have important roles, one
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of which being the activation of procollagenase type IV (Tryggvason et al, 1987; 
Saksela & Rifkin, 1988). Thus, inhibition of invasion by retinoids may be due to 
reduced levels of plasminogen activators rather than directly on type IV 
collagenolytic activity.
In human skin fibroblasts, retinoids have been shown to have an 
inhibitory effect on type I collagenase activity (Bauer et al, 1983). However, there is 
little evidence in the literature to suggest that retinoids have any effect on other 
degradative enzymes such as the heparanases.
1:5. PROTEOGLYCANS.
Proteoglycans are complex macromolecules which contain a protein core 
to which one or more glycosaminoglycan (GAG) chains are covalently bound. They 
are present in all mammalian tissue, are most prominent in connective tissues, and 
occupy highly strategic positions such as on the cell surface, the basal lamina and the 
extracellular matrix where most of the cell-cell interaction events take place. They are 
dynamic macromolecules which can influence fundamental biological processes 
including cell proliferation, cell recognition and cytodifferentiation, with most of 
these effects being due to the polyanionic nature of proteoglycans, their expanded 
configuration in tissues and their ability to interact with a variety of extracellular 
matrix components. Experimental evidence suggests that in pathological processes in 
which tissue remodelling occurs such as atherosclerosis, inflammation and tumour 
invasion, there are concurrent alterations in proteoglycans.
Glycosaminoglycans are unbranched chains with characteristic repeating 
disaccharide units which contain hexosamine, either D-glucosamine or 
D-galactosamine, and uronic acid - either D-glucuronic acid or L-iduronic acid - with 
the exception of keratan sulphate, in which a galactose residue replaces uronic acid. 
There are four main types of glycosaminoglycan - heparin/heparan sulphate, 
chondroitin sulphate/dermatan sulphate, keratan sulphate and hyaluronic acid. With 
the exception of hyaluronic acid, all glycosaminoglycans are O-sulphated to varying 
degrees, with heparin and heparan sulphate also having N-sulphated groups. Although
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other macromolecules such as some basement membrane glycoproteins contain 
sulphate, the density of the sulphate groups in these compounds is generally much 
less than that of the glycosaminoglycans, in which the maximum is from three to four 
sulphate groups per disaccharide as found in some of the repeating units of heparin. 
Because of their sulphate and carboxyl groups, the glycosaminoglycans have an 
unusually high charge density, and this contributes significantly to their biological 
properties and governs some of their interactions with other molecules (Hook et al, 
1984; Lindahl & Hook, 1978).
The glycosaminoglycan portions of chondroitin sulphate, dermatan 
sulphate, heparan sulphate and heparin proteoglycans contain additional sugars at 
their reducing end which include one xylose and two galactose molecules covalently 
linked to the hydroxyl group of serine on the protein core (Lindahl & Roden, 1966; 
Lindahl & Roden, 1972).
l.The Glycosaminoglycans. 
a/ Hyaluronic Acid.
This is the largest glycosaminoglycan with molecular weights ranging 
from lOOkDa to lOOOkDa. It is made up of repeating disaccharide units of 
N-acetylglucosamine and D-glucuronic acid but, unlike the other glycosaminoglycans 
it is not covalently linked to a protein core (Mason et al, 1982) and is nonsulphated. It 
is found in nearly all connective tissues and in some instances, such as umbilical cord, 
synovial fluid and vitreous humour, it is the principal glycosaminoglycan. Although it 
is abundant in embryonic tissue, it is later replaced by other glycosaminoglycans; thus 
it may represent the earliest evolutionary form of these macromolecules (Toole, 
1973;Toole, 1981). A primary role of hyaluronic acid is to retain water, and it is an 
effective lubricant for the synovial and mesothelial surfaces as well as being a 
resilient buffer against mechanical stress.
During wound repair, and in normal development, hyaluronic acid is 
produced in large quantities. In both of these processes a major reassembly of cellular 
and extracellular elements occurs, and it has been shown that the enzymatic removal
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of hyaluronic acid coincides with the cessation of cell migration (Toole, 1981). 
However, in cartilage of various kinds, hyaluronic acid represents only a minor 
proportion of the total uronic acid present (Muir, 1980), but it plays an essential role 
in the aggregation of proteoglycans and is mostly present as a component of 
proteoglycan aggregates rather than in the free state.
Hyaluronic acid is also the primary constituent of the pericellular coat 
surrounding a variety of cells (Goldberg & Toole, 1984; McBride & Bard, 1979; 
Underhill & Toole, 1982), and its interaction with the cell surface can influence 
proteoglycan synthesis and secretion (Handley & Lowther, 1976; Solursh et al, 1980; 
Wiebkin & Muir, 1973). Even at relatively low concentrations, hyaluronic acid can 
have a profound influence on its environment by, for example, affecting the 
movement of macromolecules across tissues (Ogston & Preston, 1966). In 
physiological solution, hyaluronic acid is polyanionic and assumes a stiff, randomly 
kinked coil structure which occupies large solution domains. Individual molecules can 
entangle through specific associative interactions to form networks which can, 
perhaps, contribute to the properties of the matrix (Wight et al, 1991). 
b/ Chondroitin Sulphate.
Chondroitin sulphate consists of repeating units of D-glucuronic acid and 
N-acetylgalactosamine. Two common isomers can be distinguished containing a 
sulphate group either on the fourth or sixth carbon of the galactosamine residue - 
chondroitin-4-sulphate and chondroitin-6 -sulphate. The size of the chondroitin 
sulphate chain varies greatly, with an average of about 40 repeating disaccharide units 
for the cartilage proteoglycan, which corresponds to a molecular weight of about 2 0  
kDa, also the number of sulphate ester groups varies with an average of 0.8 per 
disaccharide. The chondroitin sulphates are found in a variety of tissues, but most 
often in cartilage and intervertebral discs where it can reach a concentration of up to 
1 0 % of the total wet weight. 
c l  Dermatan Sulphate.
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Dermatan sulphate may be considered as an isomer of chondroitin 
sulphate in which a variable proportion of D-glucuronic acid has been reconverted to 
L-iduronic acid. However, formation of L-iduronic acid is generally incomplete, 
therefore dermatan sulphate chains are hybrid molecules, with several alternating 
sequences, each containing one to several disaccharide units of either type (Fransson 
& Havsmark, 1970; Fransson & Malmstrom, 1971). The formation of L-iduronic acid 
occurs by C5 epimerization of the D-glucuronic acid already incorporated into the 
growing polymer (Malmstrom et al, 1975), and the proportion of disaccharide units 
containing L-iduronic acid varies widely from a few percent to over 90%. The 
average amount of sulphate per disaccharide is usually higher than for chondroitin 
sulphate, mainly because of an additional ester sulphate group at the two position of 
the L-iduronic acid. Dermatan sulphate is widely distributed among tissues and occurs 
in relatively high concentrations in fibrous connective tissues such as skin, tendon and 
blood vessels.
d/ Heparin and Heparan Sulphate.
These are structurally related glycosaminoglycans with repeating 
disaccharide units of D-glucosamine and either L-iduronic acid or D-glucuronic acid, 
with a unique feature of both polysaccharides being the presence of N-sulphated
groups on the glucosamine residues. However, there are significant structural and
functional differences between the two. In heparan sulphate, D-glucuronic acid is the 
predominant uronic acid and about half of the glucosamine residues are N-sulphated 
with an average of one or less sulphate groups per disaccharide. It also contains block 
structures of N-acetylated or N-sulphated disaccharides which results in the
production of fragments of various sizes after nitrous acid treatment - nitrous acid
removes the N-substitution and cleaves the exposed bond thus producing fragments. 
In contrast, heparin contains a relatively high proportion of L-iduronic and N- 
sulphated glucosamine residues, thus nitrous acid generates small fragments which 
are' predominantly disaccharides. Additionally, most iduronic acid and glucosamine
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residues are sulphated at the C2 and C6  positions respectively, thus heparin is the 
most charged glycosaminoglycan with as many as three or four sulphate and one 
carboxyl group per disaccharide.
Heparan sulphate is produced by a variety of cells, and is generally 
present in the form of a high molecular weight proteoglycan on cell surfaces, 
basement membranes and/or in the extracellular matrix (Rapraeger & Bemfield,
1983). The intracellular forms of heparan sulphate are generally small chains which 
are either free or linked to short peptides, and they represent the degradation products 
of a larger precursor proteoglycan (Iozzo, 1984). In contrast, heparin is limited mainly 
to mast cells and, intracellularly, it tends to occur as a high molecular weight 
proteoglycan (Robinson et al, 1978), which is stored in mast cell granules from which 
it is released in response to specific signals. 
e/.Keratan Sulphate.
This is the only glycosaminoglycan that contains a hexose (D-galactose) 
instead of uronic acid in the repeating disaccharide unit. It usually has a relatively low 
molecular weight with the sulphate groups on the C6  positions of the D-galactose and 
D-glucosamine residues being present in roughly equal amounts (Bhavanandan & 
Meyer, 1968). It has limited distribution among tissues, but is present in cornea and 
tissues of skeletal origin including cartilage and intervertebral discs. However, it 
differs from other glycosaminoglycans in the linkage region to the protein core which 
lacks the xylose-serine linkage. Comeal keratan sulphate is bound to the protein core 
via a N-glycosidic linkage between N-acetylglucosamine and asparagine (Baker et al, 
1975; Nilsson et al, 1983). Skeletal keratan sulphate is linked to the core protein via 
an O-glycosidic linkage between N-acetylgalactosamine and the hydroxyl groups of 
serine or threonine residues (Bray et al, 1967; Seno & Toda, 1970).
2.Cell-Associated Proteoglycans.
Proteoglycans associated with the cell surface may be integral or 
peripheral plasma membrane components and, in both cases, the glycosaminoglycan 
chains can be deeply embedded in the extracellular matrix or free to interact with
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proteins in the extracellular fluid. The core protein has a hydrophobic segment which 
is intercalated into the lipid bilayer of the membrane, while the extracellular protein 
core and attached GAG chains can interact with other molecules in the matrix.
Many heparan sulphate proteoglycans serve as multivalent matrix 
receptors (Hook et al, 1984; Rapraeger et al, 1986). Syndecan, a cell surface 
proteoglycan, contains both heparan sulphate and chondroitin sulphate GAG chains 
(Rapraeger et al, 1985), and it has been found to bind to several extracellular matrix 
components via its heparan sulphate chains - it binds, with high affinity, to interstitial 
collagens (Koda et al, 1985), fibronectin (Saunders & Bemfield, 1988), 
thrombospondin (Sun et al, 1989) and basic fibroblast growth factor (Bemfield & 
Saunders, 1990). Other heparan sulphate-containing proteoglycans such as 
fibroglycan and glypican are also capable of binding matrix macromolecules. 
Additionally, proteoglycans can also align with actin bundles, with the suggestion that 
the cytoplasmic portion interacts with the cytoskeleton (Fransson, 1987). Thus, the 
proteoglycan could link the extracellular matrix to the cytoskeleton and both stabilise 
cell morphology and organise the matrix. An alternative peripheral association could 
be via a membrane receptor (Hook et al, 1984). Both of these receptors could 
participate in the endocytosis of extracellular proteoglycans. At the surface of 
chondrocytes another form of peripheral association has been described - the large 
cartilage proteoglycan binds via the N-terminal globular domain of the core protein to 
chains of hyaluronate, which are actively synthesised on the intracellular side of the 
plasma membrane (Sommarin & Heinegard, 1986).
Much evidence points towards a role for heparan sulphate proteoglycans 
in the control of cell growth. Many growth factors have a strong affinity for 
heparin-like molecules (Thomas & Gimenez-Gallego, 1986), also cell surface heparan 
sulphate proteoglycans may sequester growth factors and thereby regulate their 
effect. Heparin-like chains have direct antiproliferative effects and can also interfere 
with nuclear activities (Hook et al, 1984; Gallagher et al, 1986). It is possible that 
both growth factors and heparan sulphate fragments have nuclear sites of action 
(Ishihara et al, 1987) - in a hepatocyte cell line which exhibits contact inhibition in
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confluent monolayers, changes in the amount and structure of the nuclear pool of 
heparan sulphate are observed when growing cells reach confluence. If entry of 
heparan sulphate into the nucleus of these cells is prevented, then contact inhibition is 
lost (Ishihara et al, 1987).
3.Extracellular Matrix Proteoglycans.
Heparan sulphate and chondroitin sulphate proteoglycans are integral 
components of the extracellular matrix of basement membranes and indeed all 
basement membranes contain heparan sulphate proteoglycan (Dziadek et al, 1985; 
Hassell et al, 1985; Paulsson, 1987; Paulsson et al, 1987). Basement membrane 
heparan sulphate proteoglycan can be subdivided into three groups which differ from 
each other in respect of their density, size of their heparan sulphate side chains and 
size of the protein core, although some of them do share immunological properties. 
The smallest high-density, low-molecular weight form has four heparan sulphate side 
chains, which each have a molecular weight of about 3kDa, and a very small protein 
core (Paulsson et al, 1987).
The large, low-buoyant density form has a large core protein which, by 
rotary shadowing, has been shown to be made up of six globular domains (Paulsson, 
1987; Paulsson et al, 1987), with the three heparan sulphate side chains 
asymmetrically located at one end of the protein core (Ledbetter et al, 1987; Paulsson 
et al, 1987).
A third population of basement membrane-derived heparan sulphate 
proteoglycan has a relatively higher buoyant density and is of intermediate size. They 
have a shorter protein core than the low-buoyant density, high-molecular weight 
proteoglycans, but have identical glycosaminoglycan side chains, and are derived 
from the high-molecular weight, low-buoyant density heparan sulphate proteoglycan 
(Ledbetter et al, 1985).
The most widely studied basement membrane proteoglycan is the large 
heparan sulphate proteoglycan isolated from the Engelbreth-Holm-Swarm (EHS) 
tumour. Structural information about this macromolecule has come from the
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sequencing of cDNA from two large nonoverlapping cDNA clones (Noonan et al,
1988). One of the clones contains two cysteine-rich domains and two domains which 
lack cysteine. The latter are homologous to each other and may represent two globular 
domains of the molecule. The cysteine-rich domains display homology to the 
cysteine-rich domains of the B1 and B2 chains of laminin (Sasaki et al, 1987;Sasaki 
& Yamada, 1987). The second cDNA clone consists of eight internally homologous 
repeats, each of which have two cysteines capable of forming a disulphide bond. 
These repeats show homology with neural-cell adhesion molecule (N-CAM), a 
member of the immunoglobulin gene superfamily. This heparan sulphate 
proteoglycan can interact with itself and with other basement membrane 
macromolecules, including type IV collagen and laminin. Laminin also binds type IV 
collagen, and this shared property with this heparan sulphate proteoglycan may be a 
functional reflection of the structural homologies (Laurie et al, 1986). Antibody 
studies suggest that the core proteins of these proteoglycans are anchored in or at the 
surface of the lamina densa via specific interactions that may contribute to the 
architecture of the basement membrane (Schittny et al, 1988).
Some of the potential functions of heparan sulphate proteoglycans have 
been examined by studying their GAG chains. Heparan sulphate isolated from several 
different basement membranes has been shown to have more extensive O-sulphation 
than N-sulphation (Pejler et al, 1987; Gallagher & Lyon, 1989).
Basic fibroblast growth factor (bFGF) binds to heparan sulphate 
glycosaminoglycan chains of basement membrane heparan sulphate proteoglycan, and 
is released by heparinase, an enzyme which degrades heparan sulphate (Folkman et 
al, 1988), additionally proteinases such as plasmin, can release bFGF still complexed 
with the heparan sulphate chains. In this form, bFGF retains its biological activities, 
but is protected from inactivation by other proteinases (Rifkin & Moscatelli, 1989; 
Klagsbrun, 1990). Thus heparan sulphate proteoglycans can sequester and/or 
concentrate particular growth factors important in the regulation of a variety of 
cellular processes (Roberts et al, 1988).
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Heparan sulphate chains can also act directly with certain cell types, 
influencing their growth properties. Heparan sulphate from the proteoglycan 
synthesised by vascular endothelial cells can inhibit vascular smooth muscle cell 
proliferation (Castellot et al, 1981; Marcum et al, 1987). Heparan sulphate 
proteoglycans synthesised by pulmonary endothelial cells also exhibit growth 
inhibitory effects on smooth muscle cells (Benitz et al, 1990). Thus, heparan sulphate 
proteoglycans in endothelial basement membranes may regulate smooth muscle cell 
growth during development and vascular remodelling and/or cell proliferation, cell 
migration and matrix production in response to vascular damage (Wight, 1989).
Many basement membranes also contain chondroitin sulphate 
proteoglycans. A chondroitin sulphate proteoglycan with a protein core of about 
150kDa and approximately 20 chondroitin sulphate chains has been isolated from 
Reichert’s membrane (McCarthy et al, 1989). Immunolocalization of this 
proteoglycan with specific antibodies has stained basement membranes of nerve 
fibres, blood vessels, dermal-epidermal junctions, striated muscles, kidney tubules 
and glomerular mesangium, but not glomerular basement membrane (McCarthy et al,
1989).
4.Proteoglycans and Cell Adhesion.
Proteoglycans have also been shown to play a role in cell adhesion. 
Extracellular matrices and most of their individual components, when insolubilized 
on a surface, enhance cell attachment. Many of their cell attachment-promoting 
activities are related to the tripeptide recognition sequence RGD which is the cell 
recognition site of a variety of extracellular matrix components. These 
RGD-containing proteins and their cell surface receptors (integrins) constitute the 
primary mechanism whereby many cells attach to extracellular matrices (Ruoslahti & 
Pierschbacher, 1987). However, in general, proteoglycans do not promote cell 
attachment in the same way as the RGD containing proteins. The proteoglycans at the 
cell surface which reinforce cell attachment are probably of the heparan sulphate 
variety (Lark & Culp, 1984; Cole et al, 1985; Izzard et al, 1986; Wightman et al,
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1986; Woods et al, 1986; Farach et al, 1987; Saunders & Bemfield, 1988), because 
the attachment of cells to various glycosaminoglycan-binding substances can be 
prevented by treating the cells with an enzyme which specifically degrades heparan 
sulphate (Ruoslahti, 1988a). Chondroitin sulphate/dermatan sulphate proteoglycans 
existing in solution or bound to extracellular matrix have the opposite effect on cell 
adhesion.
Chondroitin sulphate proteoglycans such as the large cartilage 
proteoglycan, serglycin, and the decorin-related small dermatan sulphate 
proteoglycans are able to inhibit attachment of cells to insoluble fibronectin or type I 
collagen (Knox & Wells, 1979; Ts’ao & Eisenstein, 1981; Brennan et al, 1983; 
Schmidt et al, 1987). Certain malignant cells express increased amounts of 
chondroitin sulphate proteoglycans (Iozzo, 1985b), which suggests that the decreased 
adhesiveness of such cells could be, at least, partly due to the inhibitory effect of 
these proteoglycans. The cell attachment-inhibiting effect may also underlie the 
ability of certain proteoglycans to inhibit cell migration (Funderburg & Markwald, 
1986; Perris & Johansson, 1987), which requires cell attachment (Ruoslahti & 
Pierschbacher, 1987), and is accompanied by changes in proteoglycan synthesis 
(Kinsella & Wight, 1986). The interaction of cell surface proteoglycans with 
immobilised extracellular matrix molecules facilitates the organisation of actin in 
stress fibres and the formation of adhesion plaques in the attaching cells (Izzard et al, 
1986; Woods et al, 1986), all of which have profound effects on the cells.
5.Proteoglycans and Neoplasia.
Several studies have reported changes in the amounts and types of 
glycosaminoglycans and proteoglycans associated with neoplasms. High levels of 
hyaluronic acid have been found in the blood and urine of patients with 
nephroblastoma, and tumour tissue or cells derived from such tumours synthesise high 
levels of this glycosaminoglycan (Morse & Nussbaum, 1967; Hopwood & Dorfman, 
1987). Surgical removal of the affected kidney results in the blood levels of 
hyaluronic acid returning to normal levels (Powars et al, 1972). This work would
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suggest that Wilm’s tumours synthesise and release large amounts of hyaluronic acid 
in vivo. Support for such transformation-related changes comes from the findings that 
cells infected with oncogenic viruses (Hopwood & Dorfman, 1977), or cells isolated 
from breast carcinoma (Angello et al, 1982a), hyperplastic mammary nodules 
(Angello et al, 1982b) and human gliomas (Glimelius et al, 1978) also show a marked 
increase in the synthesis of hyaluronic acid.
A variety of epithelial and mesenchymal neoplasms express abnormal 
levels of chondroitin sulphate, and attempts have been made to establish a 
relationship between this glycosaminoglycan and tumour cell properties (Iozzo, 1984; 
Iozzo, 1985). Chondroitin sulphate is generally found in only trace amounts in most 
adult and normal non-cartilaginous tissue (Iozzo, 1985), but is present in elevated 
concentrations in tumours of the breast (Takeuchi et al, 1982), lung (Iozzo et al, 
1981), liver (Kojima et al, 1975), colon (Iozzo et al, 1982; Iozzo & Wight, 1982) and 
prostate (De Klerk et al, 1984). The elevated amounts of both sulphated and 
unsulphated glycosaminoglycans may contribute either directly or indirectly to the 
growth of the cancer cells. The findings suggest that the loss of control over cell 
proliferation, at least in some transformed cells, may be associated with changes in 
hyaluronic acid and chondroitin sulphate.
Much evidence links alterations in heparan sulphate proteoglycan to the 
neoplastic phenotype. One of the most consistent qualitative abnormalities in heparan 
sulphate structure that has been proposed to be directly related to the transformed 
phenotype is a reduced degree of sulphation in the heparan sulphate chains (Underhill 
& Keller, 1975). Over production of heparan sulphate can also be linked with 
neoplasia as seen in patients with multiple myeloma (Khoory et al, 1980; Palmer et al,
1984).
6 .Retinoids and Proteoglycans.
The literature suggests that the effects of retinoids on glycosaminoglycan 
synthesis are inconsistent, however several general points can be made. Retinoids 
have been reported to decrease glycosaminoglycan synthesis in comeal fibroblasts
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(Dahl & Axelsson, 1980), primitive mesenchyme (Pennypacker et al, 1978) and 
chondrocytes (Shapiro & Poon, 1976), whereas an increase in synthesis was observed 
in cells derived from the dermis and the epidermis (Shapiro & Poon, 1976; King & 
Tabiowo, 1981) and in mouse fibroblasts (Jetten et al, 1979), suggesting that the 
effect on glycosaminoglycan production is cell type specific. If the production of 
these macromolecules is measured in the culture medium, the cell matrix and inside 
the cell, a differential effect may be observed. It has been shown that retinoid 
treatment of cultured dermal cells results in an increase in glycosaminoglycan levels 
in the cellular and matrix components, however a reduction was observed in the 
medium fraction. In contrast, the glycosaminoglycan levels were increased in all three 
fractions in epidermal cells (Shapiro & Poon, 1976; Shapiro & Poon, 1979). The 
different glycosaminoglycan types can also be independently affected by retinoid 
treatment. For example, if rat chondrocytes are treated with retinoic acid, there is a 
dose dependent increase in heparan sulphate levels, a decrease in chondroitin 
4-sulphate, but the amount of chondroitin 6 -sulphate remains the same (Shapiro & 
Poon, 1976).
The sulphation of the molecules may also be affected by retinoids. This is 
the case in intestinal cells in which retinoic acid treatment changes the ratio of 
N-sulphate to O-sulphate in heparan sulphate without a significant change in the total 
sulphate incorporation. Changes in the levels of glycosaminoglycans can be detected 
within 4-8h of treatment and the direction of the changes in the glycosaminoglycan 
synthesis may vary with the time of treatment (Maniglia & Sartorelli, 1981). These 
changes occur before any changes in cell growth and adhesion are seen (King & 
Tabiowo, 1981).
1:6 Experimental Plan.
The reported ability of retinoids to inhibit the growth of some tumour 
cells would suggest that they may be useful agents in the prevention of metastatic 
spread. By using retinoic acid within the murine melanoma cell system B16F1M2 it is 
possible that an insight into the mode of action of the retinoid and the mechanisms of 
metastatic spread may be achieved.
One of the first steps in the metastatic cascade is the adhesion of the 
neoplastic cells to the extracellular matrix which, in the case of melanoma cells, is the 
basement membrane. Thus initial experiments were designed to investigate B16F1M2 
cell adhesion after pretreatment with retinoic acid to various extracellular matrix 
components and eventually to an intact subendothelial extracellular matrix. Time and 
dose dependency were investigated as was the effect of cell density. Alterations in 
cell morphology both on the different substrates and on plastic after retinoic 
acid-pretreatment were also considered.
In vivo, the melanoma cells do not exist in isolation, thus cell-cell 
interactions of both a homotypic and heterotypic nature were examined. The effects of 
retinoic acid on these processes would perhaps give an indication of the strength of 
the interactions as well as adhesive events leading to degradation of any underlying 
extracellular matrix.
Degradation of the basement membrane must occur to allow the cells 
access to the circulation. Thus the production of degradative enzymes by the 
melanoma cells or the host cells will be of importance in the metastatic cascade. The 
degradation of intact subendothelial extracellular matrix was examined by monitoring 
the release of radio-labelled fragments from the matrix. Also, the ability of B16F1M2 
cells to produce specifically collagenases, endoglycosidases and plasminogen 
activators was investigated and any effects retinoic acid may have on this production 
determined.
The bulk of the project was centred around the adhesion of B16F1M2 
cells to extracellular matrix or other cells, thus the molecules by which such adhesion 
occurs are also of importance. To this end the production of cell surface
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glycosaminoglycans by the melanoma cells was determined both in the presence and 
absence of retinoic acid. It is possible that any changes detected in the synthesis of 
cell surface glycosaminoglycans may be related to alterations demonstrated in the 
adhesion patterns of the cells. Both a qualitative and a quantative analysis of 
glycosaminoglycans was performed.
As stated above, tumour cells in the primary tumour do not exist in 
isolation within the host. It is probable that they produce a factor or factors which can 
influence the surrounding host cell population. To this end the effect of 
B16FlM2-conditioned medium (both with and without retinoic acid) on fibroblasts 
suspended within collagen gels was examined. The factors produced by the tumour 
cells are thought to stimulate host fibroblasts to modify the extracellular matrix such 
that cellular migration is aided. Stimulation of the host fibroblasts to increase the 
amount of hyaluronic acid present in the tumour environment is of importance in the 
movement of cells during tumour cell invasion.
MATERIALS AND METHODS.
2:1. .Cell Lines,
B16F1M2 murine melanoma cells were derived from the poorly 
metastatic B16F1 cell line by injecting 5 x 1 0 ^ cells in 0.2ml of 0.15M NaCl into the 
tail vein of syngeneic C57BL mice and isolating the lung colonies three weeks later. 
Cells from the lung colonies were cultured and passaged through the lungs once more 
to yield a highly metastatic cell line. The cells were checked for metastatic capacity 
by re-injecting into mice and comparing the number of lung colonies produced with 
those observed with control cells (B16F1). These were the only melanoma cells used 
in the project and as such the findings related only to this particular derivative of the 
parent cell line.
Cells were maintained in Eagle’s minimal essential medium (MEM) 
supplemented with 10% foetal calf serum, 2mM L-glutamine, 100 units/ml penicillin 
and lOOjig/ml streptomycin (growth medium) at 37°C in a humidified atmosphere of 
5% CO2  in air. Cells were seeded at a density of 1.4 x 10^ cells per 75cm^ flask and 
cultured for 4 days with a medium change on day 3.
Calf pulmonary arterial endothelial cells (CPAE) were maintained in 
Dulbecco’s minimal essential medium with lOOOmg/L glucose (DMEM) 
supplemented with 10% foetal calf serum, 2mM L-glutamine, 100 units/ml penicillin 
and lOOjpg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2  in air. 
The cells were seeded at a density of 3.2 x 10^ cells per 75cm^ flask, and cultured 
until confluent (10-14 days) with a medium change every 3 days.
All tissue culture media, sera, supplements and plastics were obtained 
from Life Technologies, Paisley, Scotland.
All cell lines used in this project were tested for the presence of 
mycoplasma using the method of Chen (Chen, 1977). The method is as follows:-
Cells were seeded at the usual seeding densities on cover slips and 
incubated until 20% - 50% confluent, at which time the medium was then removed 
and the monolayer rinsed with BSS. A 1:1 solution of BSS:acetic methanol was added 
and the rinse discarded, followed by pure acetic methanol which was again discarded.
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Fresh acetic methanol was added and the cultures allowed to stand for 10 min after 
which the acetic methanol was removed and discarded. A stock solution of Hoechst 
33258 stain (Sigma) (ljil in 20ml BSS) was added, and the cells allowed to stand at 
room temperature for 10 min. The stain was then removed and the monolayer rinsed 
with distilled water. The cover slip was mounted and examined by epifluorescence.
2:2. Retinoic Acid.
All-trans retinoic acid (retinoic acid) (Sigma) was dissolved in ethyl 
alcohol under subdued light to give a stock solution of 10"^M. Serial dilutions were 
made from this to give a concentration range of 1 0 " -  10"^M. These stock 
solutions were then diluted 1 : 1 0 0 0  into culture medium, while control cultures 
received ethyl alcohol to a final concentration of 0.1%. Stock solutions were stored in 
the dark at -20°C and fresh solutions prepared every three months.
2:3. Determination of Relative Melanin Content (Lotan & Lotan, 1980)
B16F1M2 cells were grown in the presence and absence of retinoic acid. 
Once confluent, the monolayers were removed by scraping and counted. The cell 
pellet containing 5 x 10^ cells was placed in triplicate tubes then resuspended and 
lysed in 0.5ml distilled water and subjected to 2 cycles of freezing and thawing.
Perchloric acid (BDH) was added to a final concentration of 0.5M and the 
suspension kept on ice for 10 min, then centrifuged at 5000 x g for 5 min. The pellet 
was then extracted 2x with 0.5M perchloric acid followed by 2x with a cold mixture 
of ethyl alcohol/ether (both BDH) 3:1 v/v, and then a final extraction with ether. The 
pellets were air dried and 1ml of 0.85M KOH (BDH) added and the pellets dissolved 
by heating to 100°C for 10 min. The insoluble material was pelleted, the supernatant 
allowed to cool, and the absorbance measured at 400nm.
2:4. Adhesion Assays.
1. Preparation of Substrates.
(a) Fibronectin (Miekka et al, 1982).
Citrated human blood was centrifuged, the plasma collected and 0.78g/L 
benzadinium chloride (BDH) added to the plasma which was then centrifuged at
10,000 x g for 30min. 100ml of the supernatant was applied to a Sepharose-4B 
(Pharmacia) column (2.6 x 6 cm) equilibrated with 0.05M Tris (Boehringer 
Mannheim)/HCl pH 7.4 containing 0.005M benzadinium chloride and 0.02% w/v 
sodium azide (both BDH). The protein was eluted with equilibration buffer and the 
unbound proteins applied to a gelatin-Sepharose (Pharmacia) column (2.6 x 7cm) 
equilibrated in the above buffer. The column was washed with 0.1M NaCl, 0.05M 
6 -aminohexanoic acid, 0.003M sodium azide (All BDH), 0.05M Tris/HCl pH 7.4 and 
unspecifically bound proteins were eluted with 1M NaCl, 0.005M benzadinium 
chloride in equilibration buffer, followed by 50ml of 0.05M Tris/HCl pH7.4 
containing 0.001M EDTA. The fibronectin was eluted with 3M Urea (BDH), 0.001M 
EDTA, 0.05M Tris/HCl pH 7.4 and dialysed extensively against 0.15M NaCl, 0.05M 
Tris/HCl pH 7.4.
(b) Type I Collagen (Schor, 1980).
Rat tail tendon (lg) was dissolved in 0.5M acetic acid (250ml) (BDH) by 
stirring for 48h at 4°C, followed by centrifugation at 10,000 x g for 30 min. The 
pellet was discarded and an equal volume of 10% w/v NaCl was added to the 
supernatant. The collagen-rich salt-insoluble material was recovered by 
centrifugation (10,000 x g, 30 min) and resuspended in 0.25M acetic acid, then 
dialysed against several changes of 1 : 1 0 0 0  acetic acid before centrifugation (2 0 , 0 0 0  x 
g, 2h) to sterilise the solution. The collagen concentration was determined by freeze 
drying a set volume of the solution, then weighing it.
(c) Type IV Collagen (Kleinman et al, 1986).
EHS sarcoma tissue was removed from lathyritic mice and washed in 
3.4M NaCl, 0.05M Tris/HCl pH 7.4 containing 0.002M N-ethylmaleimide (Sigma) 
and 0.008M EDTA (protease inhibitors). The insoluble residue was homogenised in
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0.5M NaCl, 0.05M Tris/HCl, pH 7.4 containing protease inhibitors and then 
extracted twice overnight at 4°C. The residue was then extracted with 2M guanidine 
(Sigma) in 0.05M Tris/HCl, pH 7.4 containing protease inhibitors, followed by a 
further extraction with the same buffer containing 0.005M dithiothreitol (DTT) 
(Sigma) to solubilize the type IV collagen.
The extract was dialysed against 4M urea, 0.05M Tris/HCl, pH 7.4 
containing 0.25M NaCl and 0.005M DTT, then chromatographed on a 
DEAE-cellulose DE52 (Whatman) column (2.5 x 25cm) equilibrated in the same 
buffer. The unbound material was dialysed against 4M urea, 0.05M Tris/HCl pH 7.4 
containing 0.005M DTT and applied to a second DEAE-cellulose column equilibrated 
in the same buffer. The unbound material was retained and dialysed into 0.5M acetic 
acid prior to use.
(d) Laminin/Nidogen (Paulsson et al, 1987).
EHS tumour tissue was excised from mice and homogenised in 0.15M 
NaCl, 0.05M Tris/HCl pH 7.4 containing 0.0005M phenylmethylsulfonyl fluoride 
(PMSF) (Sigma) and 0.0005M N-ethylmaleimide as protease inhibitors. The 
homogenate was centrifuged (8000 x g, 2 0 min) and the supernatant discarded while 
the pellet was re-homogenized in the same buffer with the addition of 0.01M EDTA. 
After stirring for lh at 4°C, the extract was centrifuged (8000 x g, 20 min) and the 
supernatant stored at -20°C. Aliquots of the Tris/NaCl/EDTA extract were 
chromatographed on a Sepharose CL-6 B (Pharmacia) column (1 x 120cm) 
equilibrated in 0.15M NaCl, 0.05M Tris/HCl pH 7.4 containing 0.002M EDTA and 
protease inhibitors. The laminin/nidogen complex was collected in the void volume 
fraction and concentrated by filtration through an Amicon PM 10 filter unit (Amicon) 
to about lmg/ml, and stored at -20°C.
2. Protein Estimation (Bradford, 1976).
With the exception of type I collagen, the concentration of the substrates 
was determined as follows. A range of volumes of the protein of unknown 
concentration were adjusted to a volume of 0 .1 ml with the appropriate buffer and to
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this, 5ml of protein reagent was added. The tubes were mixed and the absorbance at 
595nm measured. The protein concentration was determined from a standard curve 
generated from set concentrations of bovine serum albumin (Sigma).
3. Preparation of Protein Solutions.
Protein solutions were diluted to the required concentrations with 
phosphate buffered saline (PBS) and 1.5ml aliquots used to coat 35mm tissue culture 
plastic petri dishes. The dishes were incubated at 37°C for lh, then washed twice 
with 1.5ml PBS. Any remaining protein absorption sites were blocked by a further 
incubation of 2h at room temperature with bovine serum albumin (BSA) (lOmg/ml).
4. Preparation of Cell Monolayers.
B16F1M2 or CPAE cells were seeded at 5 x 1 0 ^ and 8  x 1 0 ^ cells/35mm 
petri dish respectively, with care being taken to ensure that the cells were evenly 
distributed over the surface of the dish. Medium was changed every 3 days and the 
cells maintained until fully confluent (4 and 8  days respectively).
5. Preparation of Subendothelial Extracellular Matrix (Vlodavsky et al, 1983).
CPAE cells were seeded in 35mm petri dishes at a density of 4 x 10^ 
cells/dish in CPAE growth medium supplemented with 5% dextran (Sigma) and 
cultured until confluent (10-14 days), with a medium change every 3 days. Confluent 
cultures were washed once with PBS, then exposed to 0.5% Triton X-100 (Sigma) in 
PBS(v/v) and agitated gently. The cell layer was dissolved, and remaining nuclei and 
cytoskeletons removed by a brief exposure (2 min) to 0.025M NH4 OH (BDH) 
followed by four washes with PBS.
6 . Adhesion Assays.
(a) Cell-Substrate Adhesion.
B16F1M2 melanoma cells grown in the presence or absence of retinoic 
acid for 4 days, or 2 days for low density control cultures, were washed twice with 
PBS without Ca^+ and Mg^+, and detached by treatment with 0.05% trypsin in 
PBS/EDTA (0.02% EDTA in PBS without Ca^+ Mg^+). The cells were harvested in 
complete growth medium, centrifuged (400 x g, 5min), washed three times in 
serum-free medium and then resuspended in the same serum-free medium. Cells 
were added to the prepared 35mm petri dishes in 1.5ml of serum-free medium at a 
density of 2 x 10  ^cells/dish, and incubated at 37°C in a humidified atmosphere of 5% 
CC>2 in air for various times. Unattached cells were removed, and the dishes washed 
twice with 1.5ml PBS. The number of attached cells were determined using a 
Coulter Counter (Model Dn with coincidence correction) following detachment with 
trypsin/EDTA.
(b) Cell-Cell and Cell-Extracellular Matrix Adhesion.
B16F1M2 cells were grown in 75cm^ flasks in the presence or absence of 
retinoic acid (10'^M) for 4 days, or 2 days for low density controls. On day 3, or 
day 1 for low density controls, the medium was removed and replaced with growth 
medium containing ^ C r  (403mCi/mg Cr) (ICN Flow) (lOOpCi/flask). Following a 
24h incubation in the presence of ^ C r, the cells were processed as previously 
outlined. Adhesion was terminated by the removal of the medium containing 
unattached cells, followed by careful washing of the monolayer three times with PBS 
and finally the addition of 1.5ml, 0.1M NaOH (BDH) to solubilise the cells. 2 x
0.5ml samples were taken from each dish for counting using a gamma counter.
2:4. Glycosaminoglycan Analysis.
1. Qualitative Analysis.
B16F1M2 cells were seeded in 75cm^ flasks as follows:-
Control flasks at 1.9 x 1 0 ^ cells, retinoic acid treated cells at 2.7 x 1 0 ^ cells and 
low density controls at 1.9 x 1 0 ^ cells. 48h after initiation of the cultures, or at 
initiation in the case of the low density controls, retinoic acid-treated cells and low 
density controls were incubated with [^H] glucosamine (5jiCi/ml) (32 Ci/mmol) and 
subconfluent control cultures with [^C ] glucosamine (2 jiCi/ml) (58.7mCi/mmol) 
(both Amersham). The medium was then removed and the cell layer washed twice 
with 10ml PBS, without Ca^+ & Mg^+, then detached with trypsin/EDTA. Cells 
were harvested in MEM supplemented with 10% foetal calf serum, pelleted and 
washed twice with PBS, yielding three fractions - medium, trypsin releasable and 
cell-associated. All fractions were boiled for lOmin, then the medium fraction from 
the retinoic acid-treated cultures was mixed with the medium from the subconfluent 
control cultures, and the medium fraction from the low density control mixed with 
another subconfluent control medium fraction. The appropriate trypsin-releasable 
and cell-associated fractions were similarly combined. The fractions were 
concentrated by rotary evaporation and then dialysed against 0.05M Tris/HCl pH 7.6 
prior to incubation with Pronase (Sigma) (0.5mg/ml) for 24h at 50°C with a second 
addition of Pronase after 6 h incubation. The samples were boiled for lOmin to 
heat-inactivate the Pronase and then dialysed extensively against 0.05M NaCl, 0.01M 
Tris/HCl pH 7.6.
The glycosaminoglycans were separated using ion-exchange 
chromatography on DEAE cellulose columns (1 x 8 cm) equilibrated with 0.05M 
NaCl, 0.01M Tris/HCl pH 7.6 and eluted at room temperature with a linear gradient 
of NaCl (0.05M - 0.65M) in a total volume of 250ml and at a flow rate of 20ml/h. 
2.5ml fractions were collected and 0.3ml samples taken for scintillation counting. 
The peaks corresponding to the sulphated glycosaminoglycans were pooled, dialysed 
against distilled water, split into two equal portions and freeze dried. One half was 
treated with chondroitinase ABC (Sigma) (0.25units in 0.05M Tris/acetate buffer, pH
8.0 containing 0.15M NaCl and 0.1% (w/v) bovine serum albumin), while the other 
half was treated with nitrous acid for 90min at room temperature by the addition of 
1.8M acetic acid containing 0.25M sodium nitrite (BDH) followed by neutralisation
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with sodium carbonate (BDH) (Lindahl et al, 1973). All samples were then dialysed 
against 0.05M NaCl, 0.01M Tris/HCl pH 7.6 and rechromatographed on 
ion-exchange columns as described above.
2. Quantitative Analysis
B16F1M2 cells were seeded and incubated as outlined in section 4-1 
above, but all cultures were radiolabelled with [^H] glucosamine (32Ci/mmol) 
(5pCi/ml) and ^ S 0 4  (1154Ci/mmol) (20pCi/ml) (both Amersham). Similarly, the 
cells were harvested, digested with Pronase and the sulphated glycosaminoglycans 
isolated by DEAE ion-exchange chromatography as previously outlined. The pooled 
glycosaminoglycan fractions were concentrated by rotary evaporation, freeze dried, 
then dissolved in 0.25M NaCl. The samples were chromatographed on a Sephadex 
G-50 (Pharmacia) column (0.5 x 60cm), and the void volume peak pooled, dialysed, 
concentrated then digested with chondroitinase ABC as previously described. The 
digest was re-applied to the Sephadex G-50 column, with the chondroitinase ABC 
susceptible material being determined from the included peak. The void volume 
peak was further treated with nitrous acid and rechromatographed.
2:5. Degradative Assays.
1. Extracellular Matrix Degradation.
(a) Preparation of Radiolabelled Extracellular Matrix.
CPAE cells were seeded at a density of 4 x 10^ cells/35mm petri dish and 
maintained in CPAE growth medium containing 5 %  dextran. On day 3, ^ S 0 4  in 
sulphate-depleted growth medium or [^H]-proline (ICN flow) in proline-deficient 
medium (30pCi/ml) was added to the cultures with a second addition of radiolabel on 
day 7 without changing the medium. 5-7 days after reaching confluence (10-12 days 
after seeding), the matrix was prepared as previously described.
(b) Degradation Assay.
B16F1M2 cells previously treated with retinoic acid were suspended in 
serum-containing medium with the appropriate concentration of retinoic acid (1 0 ^ 
cells/35mm petri dish) and seeded onto the radiolabelled extracellular matrix. After 
2 h the cells had firmly attached to the matrix and unattached or floating cells were 
removed along with the medium. The cell monlayers were washed twice with
serum-free medium and 1ml of serum-free medium containing the appropriate 
concentration of retinoic acid added to the dishes. The dishes were further incubated 
for 48h, after which the medium was collected and centrifuged at 12,000 x g for 5min. 
lOOul samples of the supernatants were taken for total radioactivity measurements.
2.Glycosidase Assay (Niedbala et al, 1987).
Intracellular enzyme activity was determined by removing cells from the 
culture dishes by trypsinization, washing in growth medium containing 2 0 % (v/v) 
heat inactivated foetal calf serum, centrifuged at 500 x g for 10 min at 20°C and 
subsequently washed three times with cold PBS. The cell number was determined and 
the cell pellet homogenised in four volumes of 0.1% Triton X-100 with 30 strokes in a 
Dounce homogeniser at 4°C. The amount of glycosidase activity present in the 
cellular homogenates was determined at pH 4.3 using the commercially available 
p-nitrophenyl sugar derivative p-nitrophenyl-N-acetyl-^-D-glucosaminide (Sigma). 
The enzyme assay was carried out in the presence of 0.5ml citrate buffer ( 0.2M, pH 
4.3), 0.5ml 0.006M p-nitrophenyl-N-acetyl-^- D-glucosaminide and 0.02ml of the 
cellular homogenate. The reaction mixture was incubated for lh at 37°C and the 
reaction terminated by die addition of 2ml 0.4M glycine/NaOH buffer pH 10.5 
(BDH). The absorbance of the hydrolyzed p-nitrophenyl was measured at 420nm.
3.Type I Collagenase Assay.
(a)Acetylation of Collagen (Gisslow & McBride, 1975).
2mg/ml type I collagen (125ml) was brought to pH 8.9 by the addition of 
1M K2 HPO4 . The acetylating agent [1-^C] acetic anhydride (10.2mg, lOOpCi/mg) 
(Amersham) in 1.5ml benzene (BDH) was added dropwise over a period of 2 hours. 
The temperature of the reaction mixture was kept at 10°C and the pH maintained at
8.0 by the addition of 1M NaOH. The pH of the mixture was then adjusted to 4.0 with 
glacial acetic acid and the benzene removed. The acetylated collagen was dialyzed 
against distilled water at 4°C to remove [^C ] acetic acid, a by-product of the 
reaction. Dialysis was continued until no further was detected in the dialysate. 
The collagen was then freeze dried and stored at -20°C.
(b)Collagenase Assay (Bailly et al, 1990).
^C-labelled type I collagen was solubilized in 0.01% acetic acid by 
stirring overnight at 4°C, and was used as a substrate at a concentration of 140pg/ml. 
Collagenase activity was measured in the culture medium which was collected at each 
medium change and stored at -20°C until assayed. Medium containing serum was 
dialyzed against 3M KSCN (Sigma) to dissociate complexes between the enzyme and 
serum inhibitors, and then against 0.05M Tris, 0.15M NaCl, 0.002M CaCl2  pH 7.4 
(test buffer) before activation. Activation of latent collagenase was performed by 
incubating lOOpl medium with lOpg trypsin (Sigma) for 10 min at 37°C followed by 
the addition of a five fold excess of soybean trypsin inhibitor (Sigma). Activated 
medium was incubated for 16h at 25°C with 50pl of [^Cj-collagen. The enzymatic 
reaction was stopped by adding 0.002M EDTA and ethanol up to a final concentration 
of 18%(v/v). After 6 h at room temperature, the collagen precipitate was collected by 
centrifugation and the radioactivity of the supernatant determined.
4.Type IV Collagenase Assay (Eisenbach et al, 1985).
(a) Preparation of [^H] Proline-Labelled Type IV Collagen.
Solid EHS tumour was harvested after 3 weeks of growth, and the tissue 
minced, washed in PBS and incubated in lg/ml proline-free DMEM containing 20% 
dialyzed foetal calf serum, 75jig ascorbate (Sigma)/ml and 50pg
3-aminopropionitrile (Sigma)/ml. After 30 min [^H]proline was added to a final 
concentration of 5pCi/ml, and the organ culture incubated for 4-5h at 37°C. The 
tissue was washed, then homogenised at 4°C in ice-cold 0.5M acetic acid containing 
0.02M EDTA and 0.008M N-ethylmaleimide (lg/9ml) and extracted overnight at 
4°C. After centrifugation at 12,000 x g for 30 min, the supernatant was dialyzed 
against 0.05M acetic acid containing 10% NaCl, 0.02M EDTA and 0.008M 
N-ethylmaleimide. The precipitate was collected by centrifugation (12,000 x g, 30 
min), and re-dissolved in 0.5M acetic acid. Impurities were removed by a further 
centrifugation (15,000 x g, 30 min), and re-precipitated in 10% NaCl, 0.05M 
Tris/HCl, pH 7.4. The precipitate was dissolved in 0.5M acetic acid and freeze dried. 
Prior to use, the labelled collagen was dissolved in 0.5M acetic acid and dialyzed 
against 0.05M Tris/ECi, pH 7.6 containing 0.2M NaCl and 0.005M CaCl2  (reaction 
buffer).
(b)Preparation of Culture Medium for Testing.
Cell cultures in late log phase were rinsed with PBS and serum-free MEM 
containing L-glutamine and antibiotics added for the final 48-72h of the incubation. 
The medium was collected and the collagenase degradation activity enriched by 
precipitation in 25-50% ammonium sulphate (Sigma) - media proteins were directly 
precipitated by slowly adding ammonium sulphate to saturation at 25% at 4°C. The 
precipitate was collected by centrifugation (27,000 x g, 60 min), and solid ammonium 
sulphate was similarly added to the supernatant to achieve a final saturation of 50%. 
The 25%-50% ammonium sulphate precipitate was collected by centrifugation 
(27,000 x g, 60 min) dissolved in and dialyzed against reaction buffer.
78
(c)Preparation of Cell Extracts.
Cells in late log phase were collected in 0.1% PBS/EDTA, washed, 
counted and lysed in 0.5% Triton X-100 in water (2 x 10^ cells/ml) at 0°C. The 
lysates were centrifuged (5000 x g, 20 min) before being used.
3. Plasminogen Activator Assay.
(a) Preparation of cells.
B16F1M2 cells were seeded in a 24 well plate at a density of 10^ 
cells/well in complete growth medium containing the appropriate concentration of 
retinoic acid, and incubated at 37^C for 24h. The medium was then removed and 
replaced with serum-free medium containing 200pg/ml BSA and retinoic acid at the 
required concentration. The dishes were further incubated for 48h, after which the 
medium was removed and clarified by low speed centrifugation (400 x g). The cell 
monolayers were removed by scraping, concentrated, washed, counted and lysed in 
0.5% Triton X-100 in water.
(b) Preparation of Fibrin Plates (Eisenbach et al, 1985).
A fibrinogen solution (250pl) containing 27pg non-radioactive fibrinogen 
(Sigma) and O.ljiCi [ ^ 1] fibrinogen (ICN Flow) was added to each well of a 24 well 
plate and the plates air dried. Prior to the assay, conversion of fibrinogen to fibrin 
was achieved by incubating the plate at 37°C for 2h with 0.5ml MEM containing
0.5% foetal calf serum. Each well was then washed twice with 0.1M Tris/HCl pH 
8 . 1.
(c) Fibrin Plate Assay (Eisenbach et al, 1985).
Each well contained 300pl of reaction mixture consisting of 250pl 
Tris/HCl pH 8.1, 75jig BSA, 6 jig human plasminogen (Sigma) and 50pl of the test 
sample. Trypsin was included as a control for the maximum releasable counts. The 
reaction was initiated by incubating the plate at 37°C for the required time. 50pl 
aliquots were removed from each well and counted for soluble [ ^ ^ 1]-labelled fibrin 
degradation products.
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2:6 Effect of Retinoic Acid on Fibroblasts Within a Collagen Lattice.
1. Preparation of Collagen Gels.
Adult forearm fibroblasts were grown to confluence, trypsinized and 
counted. Aliquots containing 7.5 x 1 0 ^ cells were pelleted and resuspended in 1ml of 
serum (either foetal calf or newborn calf). 7ml of 3mg collagen/ml 1/1000 acetic acid 
was placed in an universal. The collagen solution was combined with 2ml 10 x MEM 
containing 1ml 0.34M NaOH, the pH adjusted to pH 7.2, and the serum/cell mixture 
added (all solutions were maintained at 4°C). The preparation was well mixed to 
ensure that the cells were evenly distributed and 3ml aliquots dispensed into 35mm 
petri dishes which were then incubated at 37°C. After the gels had solidified, 1.5ml of 
medium was added to each gel, followed by gentle detachment of the gels from the 
dishes. Contraction of the gel was measured on each subsequent day.
2. Preparation and Collection of Tumour-Conditioned Medium.
B16F1M2 cells were seeded at the usual density and incubated until 
almost confluent. The medium was then removed, the monolayers washed twice with 
serum-free MEM to remove any traces of serum and a set volume of serum-free MEM 
with or without lO'^M retinoic acid added to the flask. The cells were incubated for 
another two days after which the medium was removed, gently centrifuged (400 x g, 5 
min). The media were then placed in petri dishes on ice and irradiated for 2 hours 
with a U.V. source to eradicate any residual retinoic acid. Conditioned media were 
stored at -70°C until required.
2:7 Fibroblast Glycosaminoglycan Analysis.
Adult forearm fibroblasts were seeded in 25cm^ flasks and grown to near 
confluence ( 6  days). B16F1M2 murine melanoma-conditioned medium was prepared 
containing 10% foetal calf serum and with or without 10'^M retinoic acid and this 
was added to the near confluent fibroblast cultures along with [^H] glucosamine 
(5jiCi/ml) and the cultures incubated for 48h. Controls of 10% FCS containing 
medium +/- 10'^M retinoic acid, incubated for 2 days, irradiated then added to the
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fibroblasts were also included. After the incubation, the medium was collected and the 
monolayers washed with PBS. 2ml of trypsin/EDTA was added to each flask and the cells 
allowed to detach, then 5ml of complete medium was added and 2 x 0.5ml samples taken 
for cell counting. The cell suspension was added to the medium/wash and the flasks washed 
with 2 x 5ml PBS. Each sample was boiled, dialysed against distilled water followed by
0.05M Tris/HCl pH 7.6 then treated with Pronase. The fractions were boiled to inactivate 
the Pronase, dialysed against distilled water then 0.05 M NaCl, 0.01M Tris/HCl pH 7.6 
before being subjected to ion-exchange chromatography as previously described. Samples 
were taken for counting and the peaks pooled, rotary evaporated, dialysed against distilled 
water and the volume measured. 3 x 0.3ml samples were taken to determine the total 
amount of radioactivity in each peak.
The peaks corresponding to hyaluronic acid were treated with Streptomyces 
hyaluronidase (Sigma) and then rechromatographed on a gel filtration column as previously 
outlined. The sulphated GAG peaks were treated with chondroitinase ABC and similarly 
chromatographed. Each peak was again pooled, dialysed against distilled water and samples 
taken from each known volume to determine the total radioactivity in each peak.
The figures presented in the results section represent the average of triplicate samples 
taken from three separate cultures +/- S.D.. Standard deviations were calculated using the 
triplicate values obtained from the three separated experiments i.e. n = 9.
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RESULTS.
3:1. EFFECT OF RETINOIC ACID ON MELANOMA CELLS.
1.Dose Response of B16F1M2 Melanoma Cells to Retinoic Acid.
B16F1M2 cells were seeded onto 35mm petri dishes, exposed to a 
concentration range of retinoic acid (10"^M - 10'^M) and incubated for 4 days. The 
results are shown in Figure 1. Retinoic acid inhibited cell growth at all tested 
concentrations. A significant reduction in cell numbers was demonstrated at 
concentrations of 1 0 " and greater (p<0.01). At a concentration of 10'^M, the cell 
numbers were reduced to 71% of controls and 6 6 % of controls on exposure to 10"^M 
retinoic acid. At a retinoic acid concentration of 10'^M, the cell numbers were 
reduced to 31% of the controls, however this was probably due, in part, to the 
cytotoxic effects of the retinoid at this concentration - the cells looked vacuolated and 
enlarged - and as such 10‘^M was selected as the test concentration for all subsequent 
work.
2.B16F1M2 Growth Curves.
Figure 2 shows the growth profile of B16F1M2 cells in both the presence 
and absence of 10'^M retinoic acid. On day 1 there was no difference in the cell 
numbers, however by day 2  the number of cells present in the cultures treated with 
retinoic acid had been reduced by 16% when compared to control cultures. By the 
final day (day 4) the number of cells in the retinoic acid-treated dishes had been 
reduced by 36% as compared to control cells. This difference in cell numbers was 
found to be significant (p<0 .0 1 ).
The dishes were seeded at a density of 2.3 x 1 0 ^ cells/dish. The cell 
doubling time for the control cultures was approximately 33.25h, however when the 
cells were exposed to 10'^M retinoic acid, the cell doubling time was increased to 
approximately 42.75h.
Figure 1. Response of B16F1M2 Cells to 
Retinoic Acid.
1.4
1.2in
0.8
3  0.6
0.4
0.2
-10 -9 -3 -7
10 10 10
Retinoic Acid Concentration (M)
10
Figure 2. B16F1M2 Growth Curves +/- 10-6M 
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Figure 3. Effect of Retinoic Acid on B16F1M2 Cell Morphology.
a/ B16F1M2 Cells Grown in The Presence of 10'^M Retinoic Acid.
b/ B16F1M2 Cells Grown in The Absence of Retinoic Acid.

3.Effect of Retinoic Acid on B16F1M2 Cell Morphology.
B16F1M2 cells were incubated in the presence and absence of 1 0 “ 
retinoic acid. Cells treated with retinoic acid (fig. 3a) appeared to have a reduced 
tendency to form compact colonies. This supports the suggestion that retinoic acid 
treatment reduces the maximum cell density. Retinoic acid-treated cells also 
appeared less flattened and slightly more elongated than control cells (fig. 3b). In 
addition, exposure to retinoid caused the cells to exhibit more complex and extensive 
dendritic processes than those observed in control cells. When the cells were treated 
with trypsin for detachment, the retinoic acid-treated cells detached more readily than 
control cells which would suggest that retinoic acid has an effect on the adhesion 
processes of the cell.
4.Effect of Retinoic Acid on B16F1M2 Lung Colonization.
The lung colonizing ability of control and retinoic acid-pretreated cells is 
shown in Table 1. Subconfluent control cells formed many more pulmonary nodules 
than did the cells treated with 10“^ M retinoic acid. The difference in the number of 
lung colonies formed was found to be significant (p<0.01). The ability of low density 
control cells to form lung nodules was also investigated in an effort to eliminate any 
density-dependent affect being confused with the true effects of the retinoid 
treatment. The low density control cells formed fewer lung colonies than the 
subconfluent control cells but more than the retinoic acid-treated cells. Again the 
reduction in the number of lung colonies as compared to the subconfluent control 
cells was found to be significant (p<0.01). In subsequent experiments, control and 
retinoic acid treated cells were seeded such that, when harvested, the cell numbers 
were similar, thus eliminating any density effect.
5.Effect of Retinoic Acid on B16F1M2 Melanogenesis.
B16F1M2 cells were grown for 4 days in the presence of a range of 
retinoic acid concentrations (lO'^-lO'^M) and the total melanin content of the cells 
determined (fig.4). As can be seen, there was an increase in melanin content at all
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Table 1.Effect of Retinoic Acid and Cell Density 
on Lung-Colonizing Ability of B16F1M2 
Melanoma Cells.
No.Lung Nodules. Range (n=5).
Subconfluent Control 14.8+/-7.73* 7-24
R.A. Treated 0.4+/-0.89# 0-2
Low-Density 2.4 +/- 2.3# 0-6
* M ean +/- S.D.
#Significantly different from control, at p<0.01
Figure 4. Effect of Retinoic Acid on 
Melanogenesis.
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tested retinoic acid concentrations - as retinoic acid concentration increased, melanin 
content increased. The half maximal effect was achieved at a retinoic acid 
concentration of 10“^ M. On examination of the cultures, the increased melanin 
content could be observed - the cells appeared darker, with the cell pellets being 
brown\black as compared to the white of control cells, and the culture medium was 
also brown (results not shown). Previous studies have included tyrosinase activity in 
the measurement of melanogenesis, but in this instance no measure of this enzyme 
activity was made.
3:2.ADHESION TO BASEMENT MEMBRANE COMPONENTS.
l.Dose Dependency of Retinoic Acid on B16F1M2 Cell Attachment.
B16F1M2 cells were grown in the presence of various concentrations of 
retinoic acid (10'^-10"^M) for 4 days and their adhesion to 35mm petri dishes 
treated with 40pg in 1.5ml PBS or acetic acid of either fibronectin, laminin/nidogen, 
type I collagen or type IV collagen, investigated after 60 min incubation. The results 
are shown in figure 5. When the adhesion of cells to type I collagen was examined it 
was found that attachment to this substrate decreased as retinoic acid concentration 
increased. The half maximal effect was seen at a concentration of 10"^M retinoic 
acid. Indeed, the cells, even in the absence of retinoic acid did not readily adhere to 
type I collagen and were easily detached from this substrate.
The cells adhered much better to type IV collagen although, as with type I 
collagen, there was a decrease in attachment as the retinoic acid concentration 
increased.
When the effect of retinoic acid treatment on adhesion to fibronectin was 
examined, it was found that the cells adhered readily to this substrate at all test 
concentrations (fig.5b). There was no difference in the percentage of adherent control 
cells when compared to those cells pretreated with even the highest test concentration 
of retinoic acid (lO '^M ). However, adhesion to laminin/nidogen was concentration 
dependent - the number of adherent cells decreased as retinoic acid concentration 
increased (fig.5b). Half maximal adhesion occurred at a concentration of between
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Figure 5. Dose Dependent Adhesion of B16F1M2 to
Substrates, 
a/ Type I & IV Collagens.
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1 0 '^M and 10'^M. Unlike the pattern of adhesion observed with the collagens, a 
reduction in adhesion to laminin/nidogen was observed at even the lowest retinoic 
acid concentration tested (10" ^ M ). Indeed, at concentrations above lO'^M, adhesion 
to this substrate was reduced by approximately 60%.
2.Effect of Substrate Concentration on B16F1M2 Cell Adhesion.
(a) Fibronectin.
Melanoma cell line B16F1M2 readily attached to petri dishes coated with 
very low concentrations of fibronectin. Indeed, half maximum attachment was 
obtained following treatment of the dishes with 1.3pg protein in 1.5ml PBS (fig.6 ). 
Retinoic acid pretreatment did not increase this value and there was no significant 
increase in attachment at concentrations above lOpg protein in 1.5ml PBS (fig.6 ).
(b)Laminin/Nidogen.
B16F1M2 cells adhered to laminin/nidogen but not as readily as to 
fibronectin. Control cells adhered to this substrate in a concentration-dependent 
manner (fig.7). Very few cells attached to the lower substrate concentrations (<40pg 
protein in 1.5ml PBS). When the cells were pretreated with retinoic acid, there was an 
overall decrease in adhesion to this substrate. However, at the lower test 
concentrations (up to 5jig protein in 1.5ml PBS), it would appear that retinoic acid 
stimulates adhesion of melanoma cells to this substrate. At a concentration of 5pg 
protein in 1.5ml PBS approximately 24% of retinoic acid-pretreated cells adhered as 
compared to 9% of control cells. This was repeated three times and a similar result 
obtained each time. Although there was an overall decrease in adhesion to 
laminin/nidogen when the cells were pretreated with retinoic acid, this initial 
stimulation at low substrate concentrations is, perhaps, the more significant finding.
(c)Type IV Collagen.
B16F1M2 cells readily adhered to petri dishes coated with type IV 
collagen. After an incubation period of 60 min, half maximum adhesion was observed 
at a concentration of 1.8pg protein in 1.5ml PBS (fig.8 ). Once a concentration of 40pg 
type IV collagen in 1.5ml PBS had been reached, over 60% of control cells had
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Figure 6. B16F1M2 Adhesion to Fibronectin.
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Figure 7. B16F1M2 Adhesion to Laminin/Nidogen.
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Figure 8. B16F1M2 Adhesion to Type IV Collagen.
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adhered. Pretreatment of the cells with lCT^M retinoic acid resulted in a significant 
reduction in the number of adherent cells (p<0.01). Although at the lower substrate 
concentrations the number of adherent cells appeared to be slowly increasing, at 
substrate concentrations above 5 j i g  protein in 1.5ml PBS the number of cells attaching 
steadily decreased.
3.Time Dependence of B16F1M2 Cell Adhesion to Basement Membrane 
Components.
(a)Fibronectin.
B16F1M2 cells adhered very rapidly to dishes coated with 40pg 
fibronectin in 1.5ml PBS, with half maximum adhesion being reached by about 9 min 
in control cultures (fig.9). Pretreatment of the cells with 10'^M retinoic acid appeared 
to cause only a slight reduction in the rate of adhesion.
(b)Laminin/Nidogen.
B16F1M2 cells adhered at a much slower rate to laminin/nidogen than to 
type IV collagen or fibronectin (fig. 10). In control cultures, half maximum adhesion 
to this substrate was obtained after an incubation period of 30 min at which point 
approximately 18% of cells had adhered as opposed to 72% to fibronectin after the 
same incubation period. The adhesion to laminin/nidogen continued to increase until 
60 min incubation after which time it would appear that a plateau was reached. When 
the cells were exposed to 10'^M retinoic acid, there was a steady increase in the 
percentage of adherent cells with increasing incubation time and it is possible that, if 
the period of incubation had been extended, the number of adherent cells would 
continue to increase and a plateau achieved as for control cultures. However, it is 
unlikely that the number of adherent retinoic acid-treated cells would reach values 
similar to those obtained for the control cultures as initial experiments suggested that 
the number of cells which attach after a 90 min incubation are minimal.
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Figure 9. Time Dependent Adhesion
to Fibronectin.
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Figure 10. Time Dependent Adhesion of B16F1M2 
to Laminin/ Nidogen.
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(c)Type IV Collagen.
Half maximum adhesion by B16F1M2 control cells to dishes coated with 
type IV collagen occurred after an incubation period of 16 min (fig. 11). The control 
cells adhered readily to this substrate, with a plateau being reached after 60 min 
incubation after which the increase in the number of cells attaching was minimal. 
Pretreatment of these cells with 10“ retinoic acid had an effect on the rate of 
adhesion to this substrate. The incubation period required for half maximum 
attachment to occur increased to 26 min. As with control cultures, cells pretreated 
with retinoic acid showed a steady increase in adhesion over a 60 min period, after 
which time the increase in the number of adherent cells was minimal. Unlike control 
cells, the rate of initial attachment of retinoic acid-treated cells was much slower with 
very few cells attached at the first time point ( 1 0  min).
(d)Type I Collagen.
B16F1M2 cells adhered very slowly to type I collagen (fig. 12). Unlike 
type IV collagen, no plateau was reached at any point in the incubation profile, with 
the number of cells adhering still increasing at the final 90 min incubation time. 
Retinoic acid treatment again reduced the number of cells adhering to this substrate. 
As in the control cultures, the number of adhering cells appeared to be still increasing 
at the final incubation time point.
4. Time Dependence of B16F1M2 Cell Attachment to Dishes Coated With 
Laminin/Nidogen and Type IV Collagen.
Laminin/nidogen may mediate the adhesion of certain cell types to type 
IV collagen, thus dishes were treated with 40pg type IV collagen in 1.5ml PBS, 
unoccupied sites blocked with BSA, and the dishes then treated with 40pg 
laminin/nidogen in 1.5ml PBS. The adhesion profile of control and retinoic acid - 
treated cells is depicted in Figure 13. The control cells adhered very rapidly with 80% 
of the cells having attached after 60 min. After this time there was a slight decrease in 
the number of cells which adhered. When the cells were pretreated with 10‘^M 
retinoic acid there was a reduction in the number of cells which adhered to the
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Figure 11. Time Dependent Adhesion of B16F1 M2
to Type IV Collagen.
40
20
10 30 40 5020 60 70 80 90
Time (min)
Control Retinoic Acid
Figure 12. Time Dependent Adhesion of B16F1M2 
to Type I Collagen.
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substrate - after 60 min only 47% of retinoic acid-treated cells had adhered as 
compared to 80% of control cells. The initial rate of adhesion of the retinoic acid - 
treated cells was also much slower with a plateau reached after 40 min incubation.
When the rate of cell adhesion to the double substrate was compared to 
that of the individual substrates at the 60 min time point, the combined adhesion rate 
of the cells to laminin/nidogen and type IV collagen was higher than adhesion to the 
plates coated with both substrates. However, the number of cells which adhered to the 
dishes with both substrates was greater than to either of the individual substrates. 
Retinoic acid pretreatment of the cells had a similar effect, with the adhesion to dishes 
coated with both substrates being greater than adhesion to either of the individual 
substrates. Retinoic acid pretreatment of the cells had a similar effect with the 
adhesion to dishes coated with both substrates greater than the adhesion to either of 
the individual substrates.
5. Adhesion of B16F1M2 Cells to Bovine Serum Albumin.
As BSA was used to block any exposed adhesion sites on the petri dishes 
which were left untreated by the substrate under investigation, the adhesion of 
melanoma cells to dishes coated only with BSA was examined (fig. 14). Although the 
cells adhered very slowly, the number of cells attaching was still increasing at 90 min 
incubation. Unlike the other substrates, retinoic acid pretreatment of the cells slightly 
increased the rate of adhesion although, as in the control cells, adhesion was very 
slow and still increasing at the final time point. There was no difference in the initial 
rate of attachment of either control or retinoic acid-treated cells.
6 . Effect of Cell Density on Adhesion.
In all of the experiments the cells were seeded such that control and 
retinoic acid-treated cultures were of a similar density when harvested. To examine 
the possible effect of cell density on cell attachment, the adhesion of both low-density 
and subconfluent control cultures to fibronectin, laminin/nidogen and type IV 
collagen was investigated.
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Figure 13. Time Dependent Adhesion of B16F1M2 to 
Type IV Collagen-Laminin/Nidogen.
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Figure 14. Time Dependent Adhesion of B16F1M2 
to BSA.
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(a) Fibronectin.
Low-density control cells adhered much more slowly to fibronectin than 
did subconfluent control cells (fig. 15a). This was in contrast to retinoic acid 
pretreatment, which had no significant effect on the rate of adhesion to fibronectin. In 
this set of experiments the adhesion of the subconfluent control cells to fibronectin 
decreased at incubation times greater than 40 min. In previous studies, a plateau was 
achieved after 60 min with no significant change in the number of adherent cells. This 
may be due to slight differences in the prepared batches of fibronectin or, possibly, 
slight alterations in the adhesive properties in the cells themselves. It may also be due, 
in part, to partial degradation of the fibronectin which may have occurred while the 
substrate was stored prior to use.
b)Type IV Collagen.
The low-density cells exhibited a reduced adhesion to type IV collagen as 
compared to subconfluent cells, although by the 90 min time point, the number of 
cells attached were almost at the same levels as those of the subconfluent control cells 
(fig. 15b). The initial adhesion of the low-density cells to type IV collagen was much 
slower after 1 0  min than that of the subconfluent control cells.
(c)Laminin/Nidogen.
Again the low-density cells had a reduced adhesion to laminin/nidogen 
(fig. 15c). The profile of adhesion follows a very similar pattern to subconfluent 
control cells, but at a much reduced rate. In both cases a plateau is reached after 60 
min with no significant increase in adhesion after this time.
Cells seeded very thinly and incubated for 4 days were also examined for 
their adhesive properties to basement membrane components (VLD).
(d)Fibronectin.
Cells seeded at a very low-density (VLD cells) also exhibited a reduction 
in adhesion to fibronectin but this was not as pronounced as for the cells seeded at 
normal seeding density but incubated for 2 days (LD cells) (fig. 16a). Half maximum 
adhesion of VLD cells was observed at approximately 10 min. This was only slightly 
longer than the time required for control cells to reach this value.
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Figure 15. Effect of Cell Density on Adhesion. 
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Figure 16. Adhesion o f Very Low Density Cells. 
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(e)Type IV Collagen.
After an initial increase in adhesion over the first 30 min, VLD cells were 
slightly less adhesive to type IV collagen than subconfluent control cells (fig. 16b). 
After 40 min there was little or no increase in the number of VLD cells which adhered 
and unlike the LD cells, the number of VLD cells did not attain the same value as 
adherent subconfluent control cells. Half maximum adhesion of VLD cells occurred 
at about 14 min as compared to approximately 16 min for subconfluent control cells.
(f)Laminin/Nidogen.
There was very little difference in the adhesion profiles of VLD cells and 
subconfluent control cells to this substrate (fig. 16c). Over the first 20 min, 
approximately the same number of cells adhered in both sets of dishes. The half 
maximum adhesion of both occurred by about 9 min. This is a much reduced value for 
the control cells as in previous experiments, half maximum adhesion did not occur 
until 30 min. Also, in this experiment there was an increase in the percentage of cells 
which attached to laminin/nidogen. This may have been due, in part, to differences in 
the prepared batches of laminin/nidogen.
7. Reversibility of Retinoic Acid Treatment.
The reversibility of retinoic acid-induced inhibition of B16F1M2 
adhesion to laminin/nidogen and type IV collagen was examined over a period of 4 
days.
(a)Laminin/Nidogen.
Over the initial 2 days of the experiment, there was a marked reduction in 
the number of retinoic acid-exposed cells which adhered as compared to the 
attachment of control cells (fig. 17). There appeared to be no increase in retinoic 
acid-treated cells over this period. Once the retinoic acid was removed, there was an 
increase in adhesion from day 2 to day 3, however the increase from day 3 to day 4 
was more apparent. When retinoic acid was added to control cultures on day 2, there 
was a marked reduction in the number of adherent cells between day 2 and day 3 
which levelled out between day 3 and day 4.
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Figure 17. Reversibility of RA Treatment on 
B16F1M2 Adhesion to Laminin/Nidogen.
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Figure 18. Reversibility of RA Treatment on 
B16F1M2 Adhesion to Type IV Collagen.
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(b)Type IV Collagen.
During the initial 2 day control period, the number of cells which attached 
to type IV collagen-coated dishes remained constant. When retinoic acid was 
introduced into the system there was a steady decline in the number of attached cells 
(fig. 18). In the cultures seeded in the presence of retinoic acid, the number of attached 
cells decreased over the initial 2 day period. Once the retinoid was removed, there 
was a sharp increase in cell attachment on day 2 to day 3 and this increase levelled 
out between day 3 and day 4 (fig. 18).
8 . Adhesion to Subendothelial Extracellular Matrix.
The effect of retinoic acid pretreatment on the adhesion of B16F1M2 cells 
to intact subendothelial extracellular matrix (ECM) was examined (fig. 19). Control 
cells readily adhered to the ECM with half maximum adhesion occurring after 
approximately 6  min. This time was almost doubled for retinoic acid-treated cells. 
Between 20 and 40 min, the number of adherent control cells remained relatively 
constant. After this period, there was an increase in adhesion before a steady level 
was again achieved (fig. 19). With the retinoic acid-treated cells, adhesion appeared to 
be relatively constant between 20 and 30 min. After this period there was a slight, but 
steady, increase in the number of adherent cells but there was no real plateau attained 
following the increase.
In control cultures, the maximum number of adherent cells to ECM was 
greater than the observed maximum adhesion to any of the single substrates. Also, the 
initial rate of cell attachment to intact ECM was higher than for any of the single 
substrates - 62% of control cells had adhered to intact ECM after 10 min as compared 
to 44% to fibronectin, 2% to laminin/nidogen and 16% to type IV collagen. However, 
this initial rate of attachment was comparable to that observed with dishes coated with 
type IV collagen and laminin/nidogen (58% of cells had adhered after 10 min).
The effect of retinoic acid on B16F1M2 cell adhesion to intact ECM was 
to decrease it. Initial adhesion was reduced by about 18% when compared to control 
cultures (62% for control cells, 44% for retinoic acid-treated cells). As with control
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Figure 19. B16F1M2 Adhesion to Intact 
Extracellular Matrix.
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cultures, the maximum number of retinoic acid-treated cells which adhered to intact 
ECM was greater than for any of the single substrates with the exception of 
fibronectin to which the percentage of retinoic acid - treated cells which adhered was 
approaching the value obtained with ECM (72% for fibronectin and 74% for intact 
ECM). Again the initial rate of attachment by B16F1M2 cells pretreated with 1 0 "^M 
retinoic acid to ECM was much higher than for any single substrate, with the 
exception of fibronectin, or indeed for dishes coated with type IV collagen and 
laminin/nidogen - 44% to ECM, 41% to fibronectin, 2% to laminin/nidogen, 2.5% to 
type IV collagen and 7% to type IV collagen and laminin/nidogen.
9. Effect of Retinoic Acid on Cell Spreading.
Retinoic acid pretreatment of B16F1M2 cells would appear to inhibit their 
adhesion to laminin/nidogen and type IV collagen to varying degrees. It also has an 
effect on cell spreading. Both control and retinoic acid-treated cells spread well on 
fibronectin (fig.20 a & b), however spreading on laminin/nidogen and type IV 
collagen was inhibited by retinoic acid pretreatment (fig. 2 0  c & d, e & f), with the 
majority of adherent cells remaining rounded after an incubation period of 40 min. 
Cells which adhered to laminin/nidogen had more dendritic processes than did cells 
which adhered to the other substrates.
3:3. CELL-CELL ADHESION.
1. Homotypic Adhesion.
B16F1M2 cells adhered to attached monolayers of B16F1M2 cells with a 
half maximum adhesion time of approximately 18 min, and by about 30 min almost 
70% of the cells had attached (fig.21). Pretreatment of the cells with retinoic acid 
reduced the total number of cells which adhered, and the time taken for half 
maximum adhesion to occur increased to 28 min (fig.21). Initial attachment of 
retinoic acid-treated cells to the monolayer was slower than for control cells, but after 
60 min incubation the percentage of adherent cells was similar in both instances.
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Figure 20. Effect of Retinoic Acid on B16F1M2 Cell Spreading on Various 
Substrates.
B16F1M2 Control Cells (a) and Grown in The Presence of 10" 
Retinoic Acid (b) on Fibronectin.
B16F1M2 Control Cells (c) and Grown in The Presence of 10" 
Retinoic Acid (d) on Laminin/Nidogen.
B16F1M2 Control Cells (e) and Grown in The Presence of 10"^M 
Retinoic Acid (f) on Type IV Collagen.
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Figure 21. Homotypic Cell-Cell Adhesion.
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The adhesion of B16F1M2 cells to monolayers of B16F1M2 cells also 
treated with 10'^M retinoic acid was examined (fig.22). Half maximum adhesion of 
control cells occurred after approximately 15 min, but it took until 60 min for 70% of 
cells to adhere. Although the half maximum adhesion rate was slightly quicker than 
for untreated monolayers, fewer control cells adhered. Half maximum adhesion for 
the retinoic acid-treated cells occurred after 21 min. This is increased as compared to 
the control cell adhesion, but it is less than the value obtained for retinoic acid-treated 
cells adhering to untreated monolayers. However, fewer retinoic acid-treated cells 
adhered to treated monolayers than to untreated monolayers.
2. Heterotypic Adhesion.
CPAE cells were grown to confluence in 35mm petri dishes and the 
adhesion rate of B16F1M2 melanoma cells to the monolayer examined. Control cells 
adhered rapidly to the monolayer with over 70% of the cells attached following a 20 
min incubation, with half maximum adhesion achieved by about 16 min (fig.23). 
Retinoic acid-pretreated cells adhered more slowly with half maximum attachment 
occurring by about 21 min. It required an incubation time of 40 min for 70% of 
retinoid-treated cells to adhere to the monolayer.
Maximum adhesion to CPAE cells by control cells occurred after 90 min 
incubation, by which time 95% of cells had attached. This is a similar value to that 
obtained for homotypic adhesion to an untreated monolayer (93%) and to the intact 
ECM (92%). It is much higher than the maximum adhesion values obtained for type 
IV collagen (60%) or laminin/nidogen (36%), and although the value obtained for 
maximum control cell adhesion to fibronectin was higher than for the other two, it 
was also lower (80%). When the cells were treated with retinoic acid, maximum 
adhesion after 90 min incubation was 84%. This is slightly lower than for homotypic 
adhesion to untreated monolayers (90%) but is slightly higher than to intact ECM 
(74%). However, it is much higher than the values obtained for maximum adhesion to 
single substrates - type IV collagen 51%, laminin/nidogen 18% and fibronectin 72%.
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Figure 23. Heterotypic Cell-Cell Adhesion.
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Figure 24. Heterotypic Cell-Cell Adhesion.
B16F1M2 Control Cells (a) and those Grown in The Presence of 10" 
Retinoic Acid (b).
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The morphology of the B16F1M2 cells on the endothelial cell monolayer 
was also affected by treatment with retinoic acid (fig.24 a & b). Control cells 
appeared more flattened and spread out than those subjected to retinoic acid 
pretreatment which remained rounded even after 60 min incubation.
3. Cell-Cell Aggregation.
The ability of B16F1M2 cells to form cell-cell aggregates was 
investigated by seeding the cells onto an agar substrate. B16F1M2 cells do not adhere 
to agar, thus by seeding the cells onto this substrate the formation of cell-cell 
aggregates can be examined. After 4 days in culture, control cells formed compact 
cell-cell aggregates (fig.25). Pretreatment of cells with 10"^M retinoic acid resulted in 
the formation of smaller cell-cell aggregates. The cells also appeared to exhibit 
reduced cell-cell adhesion as fragmentation of the aggregates was achieved more 
easily than with control cell aggregates.
3:4. EFFECT OF RETINOIC ACID ON THE DEGRADATION OF THE 
EXTRACELLULAR MATRIX.
1. Degradation of ^ S-Labelled Extracellular Matrix.
B16F1M2 cells were treated with a concentration range of retinoic acid 
(1 0 - 1 0  _ io~5m), seeded onto intact subendothelial ECM radiolabelled with ^^S0 4 , 
and the release of radiolabelled degradation products monitored. As the major 
sulphated molecules in the ECM are the sulphated glycosaminoglycans, it was 
assumed that the degradation products labelled with ^ S 0 4  are breakdown products 
of these molecules. The results are shown in figure 26. Over the lower concentrations 
of retinoic acid there is a steady decline in the number of radioactive counts released 
into the medium. This continued until a concentration of 10'^M was reached. At 
concentrations higher than 10'^M, the number of counts in the medium increased 
slightly although the significance of this rise is doubtful as the standard errors 
obtained in this set of experiments were quite high. However, at 10'^M retinoic acid 
there is again a reduction in the amount of ^ S 0 4  detected in the medium. As
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Figure 25. Effect of Retinoic Acid on The Formation of Cell-Cell Aggregates 
B16F1M2 Control Cells (a) and Grown in The Presence of 10‘^Mv ' ij: , v
Retinoic Acid (b). ;
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Figure 26. Degradation of 35-S Radiolabelled 
Extracellular Matrix.
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Figure 27. Degradation of 3-H Proline Labelled 
Extracellular Matrix.
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previously stated, at 1 0 ‘^M ,retinoic acid is probably cytotoxic to the cells and as 
such the decrease at this concentration should probably be disregarded. Although the 
amount of ^ 3 0 4  detected in the medium increased at both 10‘^M and lO'^M 
retinoic acid, the values observed were still lower than control values. As stated 
earlier, the true significance of the results is unclear. However, it would appear that 
the general trend is that retinoic acid reduces the amount of breakdown products 
labelled with [^ S ] which are released into the medium.
2.Degradation of [^H] Proline-Labelled Extracellular Matrix.
Melanoma cells (B16F1M2) were treated with retinoic acid (10"^ - 
1 0 '^M) and then seeded onto intact subendothelial ECM labelled with [^H] proline. 
The major amino acid in the collagens is glycine, but there is also a high percentage 
of proline and hydroxyproline present in the collagens, and as this is almost exclusive 
to the collagens, it is assumed that most of the molecules in the matrix labelled with 
the radioactive proline will be collagens. The results are shown in figure 27. There 
appeared to be no general trend as the values obtained were inconsistent. The amount 
of radioactivity increased until a concentration of lO'^M was reached, then it 
appeared to decrease at lO'^M before increasing again at lO'^M and then dropping 
again at 10“^ M. The amount of %  detected at all of the tested concentrations was 
greater than the control value and as such it could be said that the amount of released 
[%]proline-labelled compounds was increased with retinoic acid treatment 
However, on closer examination it can be seen that the standard errors for each point 
in the experiment are quite large and as such the validity of the results may be 
questioned. Thus the real suggestion is that retinoic acid has little or no effect on the 
release of [^H]proline-labelled degradation products in this system.
3.Effect of Retinoic Acid on Glycosidase Production.
The degradation of glycosaminoglycans in the ECM is brought about, in 
part, by the action of glycosidase. To determine the effect of retinoic acid on the 
breakdown of GAGs, the effect of retinoid on the production of these enzymes was
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investigated. B16F1M2 cells were grown in the presence of retinoic acid (10"^ - 
10"^M) and the intracellular and extracellular levels of glycosidase determined. At all 
tested concentrations, retinoic acid reduced the amount of intracellular glycosidase 
activity detected in this assay (fig.28a). Between the control value and that obtained 
with 10'l^M retinoic acid there is a decrease of about 50%. This decrease continues 
until the highest test concentration (10'^M) is reached, and at which point the amount 
of enzyme activity is almost undetectable.
When the extracellular enzyme levels were examined, a different picture 
was observed (fig.28b). There was an immediate increase in the detected enzyme 
activity at the lowest test concentration (10* of about 400%. This value 
increased slightly but the value remained relatively constant until a concentration of 
10'^M when it dropped to just over double the control value. The activity detected at 
10"^M retinoic acid was very high and as such was disregarded.
Both sets of experiments were repeated three times with similar trends 
achieved on all three occasions. The intracellular results are in agreement with the 
earlier work on the release of ^ S 0 4  labelled degradation products from the ECM by 
cells treated with retinoic acid.
4.Effect of Retinoic Acid on Collagenase Production.
In an attempt to investigate the effect of retinoic acid on the degradation 
of collagens in the ECM, collagens type I and IV were isolated and radiolabelled with 
either or ^ C  and the ability of B16F1M2 cells treated with retinoic acid to 
degrade these substrates investigated. Using the assay systems outlined in the 
materials and methods, production of neither type I collagenase nor type IV 
collagenase could be detected. As such, the effect of retinoic acid on these enzymes 
could not be determined. Several attempts were made using each assay system and 
each time no activity was detected.
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Figure 28. Effect of Retinoic Acid on 
Glycosidase Activity, 
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5.Effect of Retinoic Acid on Plasminogen Activator Activity.
Plasminogen activators activate the conversion of plasminogen to plasmin 
which has a wide substrate specificity, and can directly degrade matrix proteins as 
well as activate the collagenases. The effects of retinoic acid on both intracellular and 
extracellular plasminogen activator activity of B16F1M2 cells are shown in Figure 
29. Intracellular plasminogen activator activity is increased at all tested 
concentrations of retinoic acid (1 0 '^  - 10"^M). There is a steady increase in detected 
activity until a concentration of 10'^M is achieved - the value at 10'^M is almost 
triple control levels. The amount of activity detected at 10'^M is reduced as compared 
to the 10'^M activity, but it is still well above control levels. The experiment was 
repeated on three separate occasions and each time a drop in activity at lCT^M was 
detected. At concentrations of 10'^M and 1 0 '^M retinoic acid , the detected 
plasminogen activator activity was increased, with the maximum effect being 
observed at 10"^M.
Extracellular plasminogen activator activity was also examined (fig.29). 
As with intracellular levels, extracellular plasminogen activator activity was increased 
at all tested concentrations of retinoic acid (10“^  - 10'^M). Again, there was a steady 
increase in detected activity until 10'^M retinoic acid - plasminogen activator activity 
detected after cells were pretreated with lO'^M retinoic acid was almost double that 
detected in control cells - with a decrease in detected activity at a retinoic acid 
concentration of lO'^M. The detected activity again increased, but at lO'^M this 
increase was only very slight and the size of the error bars at this point would suggest 
that the levels remained the same at both 10'^M and 10'^M whereas the increase at 
10'^M is very large. The dramatic increase at 10‘^M would perhaps suggest that the 
effect is due to the overall effect of retinoic acid at this concentration on the cells 
rather than its effects on the production of plasminogen activator activity. As with the 
measurements on intracellular levels of activity, the extracellular plasminogen 
activator activity would appear to increase on treatment of the cells with retinoic acid.
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Figure 29. Effect of Retinoic Acid on 
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Figure 30. Effect of Retinoic Acid on 
Collagen Gel Contraction.
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6 .Effect of Retinoic Acid on the Contraction of Collagen Lattices.
The effect of retinoic acid on the contraction of collagen lattices prepared 
using type I collagen and adult forearm fibroblasts was determined and the results 
shown in Figure 30. As can be seen, retinoic acid at a concentration of 10'^M had no 
effect on the contraction of collagen gels. Although the initial contraction of the gels 
may have been slightly slower in the presence of the retinoid, by the sixth day of the 
experiment both sets of gels were equally contracted.
7.Effect of B16F1M2 Serum-Free Conditioned-Medium on Fibroblast-Mediated 
Collagen Gel Contraction.
Serum-free conditioned medium from B16F1M2 cells grown in the 
presence and absence of 10"^M retinoic acid was tested for its ability to affect 
collagen gel contraction (fig.31). In the presence of 10% foetal calf serum, the lattices 
contracted rapidly between day 1 and 2 (fig.30), with further contraction, at a slower 
rate, over the remainder of the incubation period (5 days). If no serum was present, 
there was only minimal contraction between day 1 and day 2  after which there was no 
further contraction.
In the presence of B16F1M2 serum-free conditioned medium, the 
contraction of the lattices followed a similar pattern to that observed in the presence 
of serum, however, the rate of contraction was slower - in the presence of serum the 
lattices contracted 5mm between day 1 and day 2, but with the conditioned media the 
reduction was only 3.3mm. In the serum-containing gels, contraction was still 
observed on day 5, whereas in the presence of conditioned media, no contraction was 
measured after day 4.
When the medium was conditioned in the presence of retinoic acid, an 
inhibition of contraction was observed. Although the lattices contracted between day 
1 and day 2 (2.67mm), no further contraction was measured on subsequent days. This 
was similar to the observations with serum-free gels. When retinoic acid was added 
directly to serum-free medium, there was no noticable contraction of the lattices 
(results not shown).
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Figure 31. Effect of B16F1M2 Conditioned Medium 
+/- Retinoic Acid on Collagen Gel Contraction, 
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3:5. Glycosaminoglvcan Analysis.
1.Qualitative Analysis.
The glycosaminoglycan elution profiles from DEAE-cellulose columns 
of subconfluent control (^ C ) /retinoic acid (^H) and subconfluent control (^C)/low  
density control cultures (^H) of B16F1M2 are shown in Figure 32 a & b respectively. 
After separation by DEAE ion-exchange chromatography, the sulphated GAGs from 
subconfluent control/retinoic acid (CON/RA) cultures eluted at a salt concentration of 
about 0.30M following application of a NaCl gradient (0.05M-0.65M). However, 
under the same conditions, subconfluent control/low density control (CON/LD) 
sulphated GAGs eluted slightly earlier at about 0.28M.
There would appear to be no real difference in the elution profiles of 
control and retinoic acid-treated sulphated GAGs. In the trypsin-releasable and 
cell-associated fractions, there is a slight indication that the control sulphated GAGs 
may elute as two peaks, but the change in the profile is not distinct enough to confirm 
the suggestion. However, the profiles from CON/LD cultures suggest that there is a 
difference in the sulphated GAGs. Medium fractions from CON/LD cultures show 
that the control GAGs do elute as two distinct peaks, whereas those of the low-density 
control elute as only one peak. Additionally, the low-density GAGs elute at a lower 
salt concentration than do those of the control (0.48M) as compared to 0.53M for the 
control GAGs). Similarly, in the trypsin fraction control sulphated GAGs elute as two 
peaks, however, there is a slight suggestion that the low density sulphated GAGs may 
also elute as two peaks. Unlike those of the medium fraction, the trypsin-releasable 
GAGs elute at a similar salt concentration to those of control cells. The elution 
profiles from the cell-associated fractions are indistinct and as such revealed very 
little, although there would appear to be a difference in the salt concentration at which 
they elute.
The sulphated GAGs were pooled, digested enzymatically and 
rechromatographed as previously. The gel filtration profiles obtained after treatment 
with chondroitinase ABC are shown in Figure 33. The void volume peaks were 
pooled and treated with nitrous acid to demonstrate the presence of heparan sulphate
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Figure 33. Sulphated-GAGs G-50 Profiles.
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breakdown products in the samples. The profiles of the resulting heparan sulphate 
breakdown products are shown in Figure 34. In the CON/RA cultures, there would 
appear to be very little difference in the elution of the chondroitin sulphates. In the 
medium fraction chondroitin sulphates from both the controls and retinoic 
acid-pretreated cells eluted with a similar pattern, but the profiles suggest that those 
of the retinoic acid-pretreated cells may elute slightly later than those of the control. 
In contrast to this, elution of control and retinoic acid pretreated chondroitin sulphates 
from the trypsin-releasable fraction was identical. However, the profile of those from 
the cell-associated fraction presents a different picture. The control heparan sulphates 
elute as a broad peak with a small initial peak before the shoulder is reached. 
Pretreatment of cells with retinoic acid results in a change in profile, with small peaks 
present at each shoulder of the peak.
Eluted chondroitin sulphates from the medium fraction of control and 
low-density cells have very similar profiles. This was also the case for the 
trypsin-releasable fraction, however, cell associated chondroitin sulphates 
demonstrated a change in the elution profile. As with those found in the 
corresponding retinoic acid-treated fraction, the low-density chondroitin sulphates 
eluted as a broad peak with a smaller peak at either shoulder.
2.Quantitative Analysis.
A quantitative analysis of glycosaminoglycans labelled with 
[^HQglucosamine and ^SC>4 , from subconfluent control, retinoic acid-treated and 
low-density control cells was carried out. Isolation of the glycosaminoglycans by 
ion-exchange chromatography was undertaken and the elution profiles are shown in 
Figure 35. As can be seen, there is little difference in the elution profiles obtained by 
this separation. There is a slight indication that the sulphated GAGs from the 
subconfluent control cultures may elute slightly earlier than those of the retinoic 
acid-treated or low-density control cultures, but the difference is too small to be 
conclusive.
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Figure 35. DEAE Anion Exchange Profiles. 
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The sulphated GAGs were pooled, and then sequentially digested with 
chondroitinase ABC and nitrous acid. The distribution of the individual sulphated 
GAGs produced by subconfluent control, retinoic acid-treated and low-density control 
cells is shown in Figure 36. Treatment of cells with retinoic acid resulted in a 
decrease in the incorporation of ^ S 0 4  into the heparan sulphates. However, there 
was no difference in [^H] glucosamine incorporation (for all three control fractions, 
the incorporation of [^H]glucosamine was approximately 38% of that incorporated 
into all the GAGs, and this figure was the same after retinoic acid treatment). When 
low-density cell culture-derived heparan sulphates were examined, overall there was a 
slight increase in ^ S 0 4  incorporation when compared to subconfluent 
control-derived heparan sulphates but, again, the incorporation of [^H] glucosamine 
remained the same.
If the individual fractions of each set of results are examined, then a 
different picture is obtained. In the medium fractions, retinoic acid-treatment reduces 
the incorporation of both [% ] glucosamine and ^ S 0 4  into the heparan sulphates 
(36% and 61% respectively). This is again the case in the trypsin-releasable fractions, 
although the percentage reductions are smaller (23% for [^H] glucosamine and 43% 
for 3 5 sc>4 incorporation). However, in the cell-associated fractions, there is a marked 
increase in the incorporation of [^H] glucosamine into the heparan sulphates from 
retinoic acid-treated cells (35%), and this is accompanied by a small increase in 
3 5 S0 4  incorporation (2.3%). When the low-density cell culture heparan sulphate 
fractions were examined, it was found that in the medium fractions, there was an 
increase in [•%] glucosamine and ^ S 0 4  incorporation (28% and 40% respectively). 
A similar result was obtained with the heparan sulphates from the trypsin-releasable 
fraction. However, on examination of the cell-associated fractions, it was found that 
the incorporation of [^H] glucosamine was reduced by 81% whereas ^^S0 4  was 
increased by 6 6 %.
The incorporation of [%] glucosamine and ^ S 0 4  into the chondroitin 
sulphates was also considered. [^H] glucosamine incorporation was reduced slightly 
after retinoic acid treatment, but ^ S 0 4  incorporation was increased. Chondroitin
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Figure 36. Distribution of Sulphated GAGs. 
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Table 2. 3-H/35-S Ratios
Heparan Sulphate Chondroitin Sulphate
7.86 10.71
14.95 19.69
26.66 13.59
sulphates from low-density cell cultures exhibited a slight increase in incorporation of 
both isotopes. On examination of the individual fractions, [^H] glucosamine 
incorporation into the chondroitin sulphates in the medium fraction of retinoic 
acid-treated cells was similar to that of control chondroitin sulphates, however there 
was a slight increase in ^ S 0 4  incorporation (15%). There was little or no change in 
incorporation into the chondroitin sulphates of the trypsin-releasable fraction, but in 
the cell associated fraction, [^H] glucosamine incorporation was decreased by 69% 
and 3 5 S0 4  by 39%.
Examination of the chondroitin sulphates from low-density cells revealed 
that in the medium fraction, the incorporation of both isotopes was increased - [^H] 
glucosamine by 16% and ^ S 0 4  by 32%. This was also the case for the chondroitin 
sulphates in the trypsin-releasable fraction. However, in the cell-associated fraction, 
the incorporation of [^H] glucosamine was decreased by 83% whereas -^S0 4  
incorporation was increased by 37%.
The 3 H/3 5 S04  ratios were also determined and are shown in Table 2. 
Retinoic acid treatment increases the ^H:^^S0 4  ratio in the heparan sulphates but 
decreases it in the chondroitin sulphates. However, in the low-density cultures, the 
ratios are reduced for both sets of sulphated GAGs. The changes in ratios indicates a 
possible change in the degree of sulphation in the molecules and thus the charge 
densities may also be affected.
3.Effect of B16FlM2-Conditioned Medium on Fibroblast Glycosaminoglycan 
Production.
The ability of B16F1M2 melanoma cell-conditioned medium to alter the 
production of fibroblast glycosaminoglycans was examined. The DEAE ion-exchange 
profiles are shown in Figure 37. From these profiles it would appear that the 
tumour-conditioned medium has an effect on the production of the GAGs. The shape 
of the hyaluronate peak is also altered in as much as the presence of
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tumour-conditioned medium removes the shoulder from the peak. If the medium is 
conditioned in the presence of 10'^M retinoic acid GAG production is also affected 
but the shape of the hyaluronic acid peak is unaffected.
The distribution of radioactivity between the hyaluronate and the 
sulphated GAGs was also investigated (fig.38). As can be seen treatment of 
fibroblasts with tumour-conditioned medium increases the amount of hyaluronate 
present. Treatment of fibroblasts with melanoma cell-conditioned medium would 
appear to increase the amount of hyaluronate present by approximately 5 fold. When 
the sulphated glycosaminoglycans were examined it was found that 
B16FlM2-conditioned medium reduced the amount of S-GAGs in the cultures by 
approximately 3 fold. However, in the presence of tumour-conditioned medium 
prepared in the presence of lO'^M retinoic acid the sulphated glycosaminoglycans 
were found to be increased by 8  fold. To determine the composition of the sulphated 
GAG peak, the samples were treated with chondroitinase ABC, and the void volume 
peak obtained after gel chromatography treated with nitrous acid. The distribution of 
the heparan sulphates and chondroitin sulphates is shown in Figure 39.
As can be seen B16F1M2 tumour-conditioned medium reduces the 
amount of both heparan sulphate and chondroitin sulphate in the cultures. Treatment 
of the fibroblasts with control medium incubated in the presence of retinoic acid also 
induces reduction in both heparan and chondroitin sulphate. However, if the 
tumour-conditioned medium is prepared in the presence of retinoic acid there is an 
increase in the amount of heparan sulphate as compared to both controls - i.e 
fibroblasts treated with control medium and control medium incubated with 1 0 ‘^M 
retinoic acid. In the chondroitin sulphates, medium conditioned in the presence of 
B16F1M2 cells and retinoic acid caused a slight increase in the amount of chondroitin 
sulphate when compared to fibroblasts treated with control medium with retinoic acid, 
but not when compared to cells incubated only with control medium.
Figure 38. Distribution of Fibroblast Glycosaminoglycans.
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B16F1M2 cells do not synthesise hyaluronic acid as can be seen from the 
profiles shown for their glycosaminoglycan analysis. However, hyaluronic acid is 
thought to be important in the movement of cells in the metastatic process and as such 
the elicited increase by the B16F1M2 medium factors on fibroblast hyaluronate may 
be of importance.
DISCUSSION.
The metastatic process involves numerous complex steps, and the 
fact that retinoic acid has a wide variety of effects on tumour cells in culture would 
suggest that its inhibitory effects may be accomplished by several mechanisms. Using 
the murine metastatic melanoma cell line B16F1M2 cultured on plastic, retinoic acid 
has been shown to have an inhibitory effect on cell growth, with cell morphology also 
affected - cells pretreated with retinoic acid appear more elongated and their dendritic 
processes more complex and extensive. Under similar conditions these cells also 
exhibited an enhanced expression of melanogenesis and when injected into the tail 
veins of syngeneic mice, retinoic acid pretreatment brought about a decrease in the 
number of metastatic lung nodules formed.
The inhibitory effect of retinoic acid on cell growth has been shown to be 
accompanied by an increase in cAMP-dependent protein kinase activity (protein 
kinase A) (Ludwig et al, 1980). Another possible candidate for a role in the growth 
inhibitory effects of retinoic acid is protein kinase C, a phospholipid and 
Ca^+-dependent kinase which phosphorylates its substrate proteins on serine and 
threonine residues. It can be activated by several growth factors, hormones and 
neurotransmitters, and is the major receptor for the phorbol ester tumour promotors 
(Nishizuka, 1984; Nishizuka, 1986; Ashendel, 1984). Protein kinase C also 
phosphorylates the epidermal growth factor receptor, the insulin receptor and the 
protein product of the ras oncogene (Niles, 1987), which would suggest a role for this 
enzyme in the regulation of cell proliferation.
Niles and Loewy (1989) demonstrated that the growth inhibitory effects 
of retinoic acid on B16 melanoma cells are accompanied by a substantial increase in 
protein kinase C, and that it would appear that the enhancement was due to an 
increase in the number of protein kinase C molecules present within the cells. In the 
promyelocytic cell line HL-60, retinoic acid can induce differentiation which is 
accompanied by an increase in protein kinase C activity (Durham et al, 1985), and as 
such the increase is used as a marker of differentiation. However, in the system 
utilising melanoma cells, it is not clear whether the increase in protein kinase C is due
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to differentiation of the cells or to the inhibition of cell proliferation which 
accompanies the process. In B16 melanoma cells, retinoic acid specifically blocks the 
progression of the cells through the Gj phase of the cell cycle and inhibits their 
growth on soft agar (Ludwig et al, 1980). Melanocyte stimulating hormone (MSH) 
can also arrest B16 cells in the phase, however this is not accompanied by an 
increase in protein kinase C, thus in these cells the increase in protein kinase C is 
thought to be due to an increase in the number of enzyme molecules in the cell which 
would suggest that retinoic acid may act at the level of transcription (Niles, 1987). In 
the study reported here no attempt was made to measure protein kinase C or cAMP 
levels.
4:1. ADHESION TO BASEMENT MEMBRANE COMPONENTS.
When adhesion of B16F1M2 cells to basement membrane components 
was examined, it was found that adhesion and spreading of the cells on 
laminin/nidogen and type IV collagen was reduced by pretreatment of the cells with 
retinoic acid, while adhesion to fibronectin was virtually unaffected. Adhesion of the 
cells to intact subendothelial extracellular matrix was also reduced when the cells 
were pretreated with 1 0 ‘^M retinoic acid.
The interaction of cells with components of the extracellular matrix has 
been shown to play a critical role in the regulation of cell morphology, growth, 
differentiation and in the morphogenetic processes during development (Yamada, 
1983). Alterations in cell-matrix interactions have also been implicated in the 
pathogenesis of cancer (Poste & Fidler, 1980; Liotta, 1986; Nicolson, 1984), as 
interactions between normal cells and the matrix may be altered in neoplasia, and this 
may influence tumour proliferation and invasion (Liotta et al, 1983).
General and widespread changes occur in the distribution and quantity of 
the epithelial basement membrane during the transition from benign to 
undifferentiated invasive carcinomas (Barsky et al, 1983; Burtin et al, 1982). Benign 
pathological disorders with epithelial disorganisation or proliferation are usually
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characterised by a continuous basement membrane separating the epithelium from the 
stroma The basement membrane is also defective around tumour cells in lymph 
nodes and organ metastases (Burtin et al, 1982).
Both normal and neoplastic cells are capable of binding to laminin, either 
by specific high affinity cell surface receptors (Terranova et al, 1982; Rao et al, 1983; 
Rao et al, 1985), or with lower affinity by utilising membrane glycolipids. The sites of 
biological activity on the laminin molecule have been defined using sequence data for 
the B chains. Synthetic peptides prepared from these chains showed no activity in 
themselves, but antibodies against a specific sequence in domain HI of the Bj chain 
inhibited cell attachment. Additional peptides were prepared from neighbouring 
sequences and a nonapeptide Cys-Asp-Pro-Gly-Try-Ile-Gly-Ser-Arg (CDPGYIGSR) 
was found to support cell attachment, to be chemotactic and to interact with a variety 
of cells. From the nonapeptide the primary sequence of YIGSR has been defined as 
that responsible for binding (Graf et al, 1987).
Examination of sequences neighbouring YIGSR revealed a second site, 
Pro-Asp-Ser-Gly-Arg (PDSGR), which can also support cell attachment and it 
competes with the intact laminin molecule in this respect (Kleinman et al, 1989). The 
PDSGR sequence resembles the RGDS (Arg-Gly-Asp-Ser) cell attachment sequence 
found in fibronectin (McCarthy & Furcht, 1984), but shows no competition with 
fibronectin in either cell attachment or migration (Kleinman et al, 1989). 
Quantitatively, PDSGR was found to be less active than YIGSR in assays measuring 
cell adhesion and migration and in reducing experimental metastases in melanoma 
cells (Kleinman et al, 1989).
A third cell adhesion receptor has been identified on the laminin molecule 
(Chamois et al, 1988). A sequence designated peptide F-9 has been derived from the 
inner globular domain of the lateral short arm and has been demonstrated to have 
specific binding for heparin (Chamois et al, 1988). Although free heparin may not 
exist as a basement membrane component, there are many heparin-like domains 
present in the vicinity of laminin. These include the glycosaminoglycan chains of 
basement membrane proteoglycans (Fujiwara et al, 1984; Kleinman et al, 1982; Stow
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& Farquhar, 1987), and of cell surface-associated proteoglycans of various cell types 
associated with basement membranes (Gallagher et al, 1986; Lindahl & Hook, 1978; 
Stow & Farquhar, 1987). Recent work has shown that an endothelial cell-derived 
heparan sulphate proteoglycan may contain heparin-like stretches in regions of its side 
chains (Nader et al, 1987). Thus, heparin-binding sites on laminin may be important 
not only in the structural arrangement of the basement membrane, but also in the 
regulation of cell adhesion to laminin.
The positioning of this region on the laminin molecule is relatively close 
to the YIGSR cell-binding site (Graf et al, 1987), and may also be close to the binding 
sites for nidogen (Paulsson et al, 1987) and type IV collagen (Terranova et al, 1983). 
This close arrangement of interactive sites for basement membrane molecules and cell 
surface components may be important in the structural diversity of basement 
membranes (Chamois et al, 1986b).
Pretreatment with retinoic acid also had an effect on the adhesion of the 
melanoma cells to type IV collagen. Although it is generally thought that epithelial 
cells do not attach directly to type IV collagen but utilise laminin as an attachment 
factor, a native type IV collagen binding protein, colligin, has been isolated from the 
cell membranes of a variety of cell lines (Kurkinen et al, 1984). It has been identified 
as a glycoprotein which may either be involved in the assembly of type IV collagen 
into a network, or be an intercellular component involved in the biosynthetic pathway 
that reaches the cell surface as a result of fusion of secretory vesicles from the Golgi 
with the cell membrane. Some cells do attach readily and directly to type IV collagen, 
for example hepatocytes (Rubin et al, 1981) and metastatic melanoma cells (Dennis et 
al, 1982). Asparagine linked oligosaccharides on the cell surface have been 
implicated in this attachment (Dennis et al, 1984).
In this study it was found that the B16F1M2 cells adhered to type IV 
collagen, and that adhesion was reduced by pretreatment with retinoic acid. In cell 
systems in which laminin is known to mediate attachment to type IV collagen, factors 
that alter the expression or affinity of laminin receptors would be expected to affect 
cellular adhesion to both laminin and type IV collagen. This was found not to be the
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case, as the B16 melanoma cells adhered readily to type IV collagen when laminin 
was not present which would suggest a direct interaction with type IV collagen, 
probably due to specific receptors. Pretreatment of type IV collagen-coated dishes 
with laminin/nidogen did increase both the rate of cell adhesion and the number of 
adherent cells, suggesting a possible synergistic effect.
A study using the highly metastatic murine melanoma cell line K1735 M4 
indicated an active role for type IV collagen in promoting the adhesion, spreading and 
migration of malignant melanoma cells (Chelberg et al, 1989), thus supporting the 
findings reported here. They also demonstrated the involvement of multiple 
nonoverlapping domains of type IV collagen in promoting tumour cell adhesion, with 
de novo protein synthesis required for cell adhesion to the major noncollagenous 
domain of the molecule, while adhesion to the helical domain was less dependent on 
de novo protein synthesis. When they examined the RGD-related peptides, they found 
that the peptide GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro) had virtually no effect on 
melanoma cell adhesion to the substrate, but in contrast to this, when threonine was 
substituted for serine (GRGDTP), cell adhesion to type IV collagen was significantly 
reduced (Chelberg et al, 1989).
The effect of retinoic acid on the adhesion of B16F1M2 cells to 
fibronectin was also investigated, and it was found that retinoic acid pretreatment had 
little or no effect on cell attachment, spreading and migration of a variety of cell types 
including tumour cells (Ruoslahti, 1988b; Ruoslahti & Pierschbacker, 1987). 
Fibronectin is known to have two distinct cell binding domains - one located in the 
centre of the molecule and the other in the type m  connecting segment (IIICS) 
(Yamada, 1988). The central binding domain is recognised by a variety of cell types 
including fibroblasts, endothelial cells, myoblasts and tumour cells (Yamada, 1988). 
To date only cells derived from the embryonic neural crest - neural crest precursor 
cells, peripheral neurones, corneal fibroblasts and melanoma cells have been shown to 
recognise the IIICS binding domain (Humphries et al, 1989). The cell type specificity
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of this domain suggests that it may be involved in adhesive events during 
development and differentiation of the neural crest and its derivatives (Humphries et 
al, 1988).
The IIICS domain is located between the COOH-terminal heparin and 
fibrin binding domains, and its active sites have been identified using synthetic 
peptides. Two peptides, CS1 and CS5, have been found to promote melanoma cell 
adhesion directly, and to inhibit the adhesion of these cells to intact fibronectin 
(Humphries et al, 1986; Humphries et al, 1987). The active site within the CS5 
peptide has been identified as Arg-Glu-Asp-Val (REDV), a sequence which 
resembles the RGDS sequence of the central binding domain. Synthetic REDV was 
found to be inhibitory to melanoma cell adhesion to fibronectin, but had no effect on 
fibroblast adhesion (Humphries et al, 1986).
In the central binding domain of the molecule, one crucial attachment site 
has been localised to a specific tetrapeptide sequence Arg-Gly-Asp-Ser (RGDS) 
(Pierschbacker & Ruoslahti, 1984; Yamada, 1988). This sequence, on its own, can 
promote fibroblast adhesion and it can block the interaction of fibroblasts with intact 
fibronectin (Yamada & Kennedy, 1984). RGDS containing peptides can 
competitively inhibit the fibronectin receptor and other matrix-receptor interactions 
(Ruoslahti & Pierschbacker, 1986; Pytela et al, 1985; Yamada et al, 1985;).
The attachment of cells to fibronectin is, in part, mediated by the 
interaction of the RGDS sequence with a specific cell surface fibronectin receptor 
which is a member of the integrin family (Ruoslahti, 1988b). The integrins are a 
family of membrane glycoproteins which consist of two subunits, d .  and P  . Both 
subunits have a large extracellular domain, a transmembrane domain, and a short 
cytoplasmic domain (Buck & Horwitz, 1987; Hynes, 1987). The subunits are 
noncovalently bound to one another by an association promoted by divalent cations 
(Ginsberg et al, 1988). The integrin responsible for binding to the RGDS sequence of 
fibronectin has been identified as integrin0^  and it is commonly expressed by 
cultured cell lines (Ruoslahti, 1988). However, as previously outlined, for melanoma 
cells adhesion to fibronectin also occurs via a binding domain found in the EQCS
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region of the molecule. Recent work using the human metastatic melanoma cell line 
A375-M has identified an integrin receptor for this region - integrin (VLA-4) 
(Mould et al, 1990). However in these human melanoma cells, adhesion to fibronectin 
occurs via both binding domains. This is in contrast to the findings using B16 murine 
melanoma cells where attachment to fibronectin occurs almost exclusively via the 
IIICS binding domain (Humphries et al, 1989).
Cell adhesion to laminin and type IV collagen can also be mediated by 
integrins (Ramos et al, 1990; Kramer et al, 1989). Using the B16 mouse melanoma 
system Ramos and co-workers (Ramos et al, 1990) identified integrin-like complexes 
specific for laminin and type IV collagen. Neither receptor could be eluted with RGD 
peptides which would indicate that unlike, for example, the fibronectin receptor, the 
adhesion of these receptors to their substrates is not mediated through this sequence. 
Additionally YIGSR peptides were not effective at eluting the laminin-binding 
complex, which would suggest that the integrin receptor binds to a different site on 
the laminin molecule. Antibody work revealed that the laminin integrin receptor is 
composed of an and a subunit and is similar to the human laminin-binding 
integrin complex VLA-6 (Kramer et al, 1989b). A VLA-6 monoclonal antibody can 
substantially inhibit B16 adhesion to laminin, but inhibition is not always complete 
which would imply that other receptors are important in adhesion to laminin. In 
addition to the laminin-integrin complex and the receptor which recognises the 
YIGSR peptide, some work has indicated that B16 cells may express a surface 
galactosyltransferase capable of binding laminin oligosaccharides and promoting cell 
spreading, but not essential for the initial attachment of the cells (Runyan et al, 1988).
The type IV collagen receptor has been shown to be similar to the VLA-1 
receptor complex found in humans (Kramer & Marks, 1989) and has been identified 
as integrin Additional activity has also been demonstrated for integrin0^  ^ i
(VLA-2J in the human system (Kramer & Marks, 1989). The collagen binding 
sequence could not be eluted with RGDS-containing peptides which would suggest 
that other sequences are involved in the interaction (Ramos et al, 1990). The 
collagen-binding complex has been shown to bind preferentially to type IV collagen
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and only weakly to interstitial collagens suggesting a substrate specificity (Ramos et 
al, 1990). This collagen receptor has also been shown to bind to laminin immobilised 
on Sepharose columns, thus it has some affinity for the molecule, although it is 
thought that the collagen receptor is unable to initiate adhesion to laminin for which 
the presence of the0^  receptor is required (Ramos et al, 1990).
Working with three pairs of normal and transformed cells Plantefaber and 
Hynes (1989) have shown that transformed cells express different levels of P j 
integrins from their normal counterparts. Transformed cells were observed to express 
reduced levels of° 5  fibronectin receptor, but higher levels of the V i  integrin 
which can also mediate adhesion to fibronectin (Takada et al, 1988; Gehlsen et al, 
1989). Unlike ° ^ 5  P j, the ° ^ 3  integrin does not bind to intact fibronectin or its 
cell-adhesive fragment at physiological salt concentrations (Takada et al, 1988; 
Plantefaber & Hynes, 1989), but it does bind to fibronectin in radioreceptor assays 
(Gehlsen et al, 1989). Thus®^?} may have a lower affinity for fibronectin than0^ ^  
and thus may preclude its participation in matrix assembly without affecting its 
activity as an adhesion receptor.
Functional studies suggest that integrins are important in the metastatic 
process. Synthetic peptides containing the RGD sequence can inhibit the movement 
of human melanoma cells through an amniotic basement membrane (Gehlsen et al,
1988). These peptides are also able to reduce the number of lung colonies formed in 
mice after injection of B16F10 murine metastatic melanoma cells (Humphries et al, 
1986; Saiki et al, 1988; Humphries et al, 1988). Consistent with this is the observation 
that antibodies against the f  subfamily of integrins prevent the establishment of 
tumours when human melanoma cells are implanted into nude mice (Boukerche et al,
1989).
The deposition of matrix components other than fibronectin is also 
disrupted in malignant cells (Ruoslahti & Pierschbacher, 1987). As integrins can also 
serve as receptors for collagen and laminin (Takada et al, 1988; Gehlsen et al, 1989), 
it is possible that changes in integrin expression may, in part, be responsible for the 
defective matrix formation. Consistent with this suggestion is the observation that
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integrins other than °^5 i 1 are also expressed at reduced levels after transformation 
(Plantefaber & Hynes, 1989). These changes need not affect the ability of cells to 
attach to collagen or laminin, as the ^ 3 ^  integrin, which can serve as a collagen and 
laminin receptor, has been shown to increase in transformed cells (Takada et al, 1988; 
Gehlsen et al, 1989).
Modulation of the binding affinities of the integrins for their ligands may 
also play a part in defective matrix deposition by transformed cells. The affinity of 
integrins for their ligands can be modulated experimentally, by replacing Ca^+ and 
Mg2+ cations with Mn^+. This greatly enhances the affinity of several ligands 
including that of the fibronectin receptor (Ruoslahti & Pierschbacher, 1987). Also, the 
fact that the0* 2 ^ 1  integrin is a laminin and collagen receptor in some cells (Languino 
et al, 1989), whereas in other cells it is only a collagen receptor (Takada et al, 1988; 
Santoro et al, 1989) would indicate that integrin affinities are subject to regulation.
The results presented here indicate that although retinoic acid has an 
effect on cell adhesion, the process is not totally inhibited. As shown, retinoic acid 
pretreatment has no significant effect on B16F1M2 adhesion to fibronectin. This 
would suggest that only some of the mechanisms of adhesion are subject to alteration 
by retinoic acid treatment. Unlike other cell lines, the main binding domain for 
melanoma cells to fibronectin is located in the IIICS region of the molecule. It may be 
that retinoids act, in part, by altering the expression of integrin receptors for the main 
binding domain situated in the central region of the molecule. This could also 
account, in part, for the inhibition of adhesion to type IV collagen and laminin. The 
ability of retinoids to influence the adhesion of cells to basement membrane 
components is not surprising when the wide variety of effects these molecules can 
ellicit are considered. How exactly the retinoids induce their effects is, as yet, 
unknown. The ability of tumour cells to attach to laminin has been shown to affect a 
number of cellular processes including differentiation, invasion and metastasis (Liotta 
et al, 1986b; Barsky et al, 1984). The interaction of laminin with tumour cells is 
mediated by laminin cell surface receptors, and studies have shown that more laminin 
is associated with cells of a high metastatic potential than with those of lower
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metastatic potential, which would suggest a correlation between the number of cell 
surface laminin receptors and metastatic potential (Varani et al, 1983; Albini et al,
1989).
In this study, the adhesion of B16F1M2 melanoma cells to 
laminin/nidogen complex was inhibited by pretreatment with retinoic acid. As one of 
the possible effects of retinoic acid is to induce cell differentiation as demonstrated in 
HL-60 promyelocytic cells (Durham et al, 1985), it is possible that the observed 
reduction in cell adhesion may be related to a lowering of the metastatic potential and 
as such, possibly making the cells more "normal". In partial support of this is the fact 
that the study also demonstrated that on laminin/nidogen, the cells exhibited a 
morphology more consistent with normal melanocytes ie. the cells spread out more 
and had an increased number of dendritic processes. Also, retinoic acid pretreatment 
of the cells reduced the number of lung metastases formed after tail vein injection into 
mice and, in vitro, retinoic acid modulates melanogenesis. Melanogenesis is a marker 
of differentiation and enhancement of its expression would suggest a move towards a 
more "normal" cell type. However, in contrast to this, there have been reports that in a 
variety of melanoma cells of human origin, retinoic acid can increase the number of 
cells that express the laminin receptor (Hendrix et al, 1990). This would suggest that 
the role of the laminin receptor does not correlate with cell attachment and invasion in 
the human system.
Work on the effect of retinoic acid on fibroblasts demonstrated an 
increase in cell adhesion to laminin following retinoic acid pretreatment, with the 
suggestion that the effect was due to an increase in the number of laminin receptors 
(Kato & DeLuca, 1987). It is possible that this is further evidence of the bifunctional 
activity of retinoic acid. However, another study on cells derived from a murine 
adenocarcinoma demonstrated no correlation between the ability of cells to invade a 
reconstituted basement membrane and the presence of laminin and laminin-binding 
proteins (Penno et al, 1989), with another cell surface glycoprotein implicated in 
invasion.
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The adhesion of B16F1M2 cells to basement membrane components 
laminin/nidogen and type IV collagen were, in this study, considered important in the 
process of metastasis. The reduction in this adhesion elicited by retinoic acid was 
thought to be associated with the observed reduction in lung colony formation by the 
cells. However, the evidence on the role of laminin in the process of invasion must 
also be considered. No attempt was made to measure the expression of laminin 
receptors by the cells nor was the effect of retinoic acid on the expression quantitated. 
It is possible that inhibition of attachment was achieved by modulation of some 
binding mechanisms other than the integrins.
The finding that adhesion of retinoic acid pretreated cells to 
laminin/nidogen and type IV collagen had not reached a maximum after an incubation 
period of 90 min would suggest that adhesion required the synthesis of new cell 
surface molecules and that retinoic acid may inhibit this synthesis. This would again 
suggest that retinoic acid may act at the level of transcription. Various cell surface 
molecules have been identified as possible receptors for basement membrane 
components, and there have been reports of retinoids exerting effects on some of 
these. One such family of molecules are the cell surface proteoglycans.
Several extracellular matrix molecules and growth factor peptides have 
been demonstrated to bind to heparin (Ofosu et al, 1989). Although heparin is found 
extracellularly when mast cells and basophils degranulate, the binding, in vitro, is 
thought to represent the in vivo interactions of the heparin-like glycosaminoglycan 
heparan sulphate (Bemfield & Sanderson, 1990). Heparan sulphate proteoglycan is a 
ubiquitous component of the surfaces of all adherent vertebrate cells. It predominantly 
contains a core protein which spans the cell membrane, however, peripheral cell 
surface components exist as do heparan sulphate proteoglycans that can be released 
from the cell surface by phosphatidyl inositol-specific phospholipase C, for example 
glypicans (Carey & Evans, 1989). One of the most widely studied cell surface 
proteoglycans is syndecan, which contains both heparan sulphate and chondroitin 
sulphate chains (Rapraeger et al, 1985). It binds to several extracellular matrix
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components via its heparan sulphate chains - it binds with high affinity and specificity 
to the interstitial collagens (Koda et al, 1985), to fibronectin (Saunders & Bemfield, 
1988) and to thrombospondin (Sun et al, 1989).
Although syndecan can bind cells to a variety of components of the 
extracellular matrix, there is insufficient evidence to categorise it as a physiologically 
relevant matrix receptor. However, syndecan does show several biological properties 
that are consistent with its possible role as a matrix receptor, with most of this 
evidence coming from work carried out on cultured mammary epithelial (NMUMG) 
cells. Before these cells reach confluence, they are surrounded by syndecan and its 
ectodomain is shed as a non-lipophilic proteoglycan into the culture medium 
(Jalkanen et al, 1987). Once the cells reach confluence, the shedding of syndecan 
decreases rapidly and it becomes localised at the basolateral cell surfaces. In vivo, 
simple epithelial cells also show this localisation of syndecan at their basolateral 
surfaces (Hayashi et al, 1987). This localisation would be an appropriate site for a 
matrix receptor. Studies on a variety of cell types have indicated that the level of cell 
surface syndecan correlates with cell type (Hinkes et al, 1988), but at a molecular 
level the variation in expression is not always accompanied by a concurrent variation 
in the amount of syndecan mRNA, which would suggest there is substantial post 
transcriptional regulation of syndecan expression (Bemfield & Sanderson, 1990).
Retinoids have been shown to induce changes in cell surface glycoconjugates 
which include glycosaminoglycans such as heparan sulphate (Lotan et al, 1983). 
Indeed, changes in the synthesis and charge density of B16 glycosaminoglycans after 
pretreatment with retinoic acid have been reported (Edward & MacKie, 1989). This 
evidence would suggest that these macromolecules may possibly have a role in the 
retinoic acid-induced changes in cell adhesion.
When B16F1M2 cells were pretreated with retinoic acid, their adhesion to 
intact subendothelial extracellular matrix was also reduced. Presumably the 
mechanisms involved in the inhibition were similar to those involved for the 
individual components. No analysis of the matrix was carried out, but it was assumed
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to be composed mainly of laminin/nidogen and collagen, with the amount of type IV 
collagen present being increased by feeding the endothelial cells with ascorbate prior 
to isolation of the substratum.
4:2. CELL-CELL ADHESION: HOMOTYPIC AND HETEROTYPIC.
The inhibition of cell-cell adhesion, both homotypic and heterotypic, was 
also observed after B16F1M2 cells were pretreated with retinoic acid. In metastasis, 
both types of adhesion are thought to be important in determining the success of the 
process at several steps (Nicolson, 1982; Nicolson & Poste, 1983). Studies with 
homotypically aggregated B16F1 cells have shown that the frequency of lung 
colonies per cell number, after intravenous injection of tumour cells, was significantly 
higher than with a single cell suspension inoculum of B16F1 cells (Fidler, 1973b). 
Also, several B16 sublines have been selected, both in vivo and in vitro, for various 
properties and they show correlations between homotypic or heterotypic adhesiveness 
and experimental metastatic potential (Lotan & Raz, 1983; Nicolson & Winkelhake, 
1975). The selection of a subline of B16F1 with a reduced homotypic aggregation 
resulted in a lower lung colonizing potential than that observed with the parental line 
(Lotan & Raz, 1983).
Of importance in cell-cell interactions are the cell adhesion molecules 
(CAMs). Down regulation of N-CAM in migrating cells led to the suggestion that 
CAM expression might be altered in transformed cells (Brackenbury et al, 1984). In 
order to test this hypothesis, neural retinal cells were transformed with 
temperature-sensitive mutants of Rous sarcoma virus. These cells normally express 
N-CAM and aggregate by an N-CAM-dependent mechanism. After transformation, 
the cells behaved in this way at the non-permissive temperature for the virus, 
however, at the permissive temperature, the cells failed to aggregate to the same 
extent, and decreased amounts of N-CAM RNA and cell surface N-CAM were 
observed, with the change being reversible on return to the non-permissive
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temperature. From this it was suggested that CAM expression might be inversely 
correlated with the transformed state of certain cells and possibly with their metastatic 
potential (Brackenbury et al, 1984).
Similarly, work on MDCK cells transformed with either Harvey or 
Moloney sarcoma virus has demonstrated that the calcium-dependent CAM 
uvomorulin (E-cadherin) can be affected by transformation (Beherens et al, 1989). 
MDCK is an epithelial cell which normally expresses uvomorulin at high levels. 
Transformed cells were selected on the basis that they either retained both their 
epithelial character and high levels of surface uvomorulin, or that they had lost both 
of these characteristics. The ability of the cells to invade collagen gels was examined, 
and this was found to correlate with the expression of uvomorulin ie. cells which 
expressed uvomorulin were non-invasive (Behrens et al, 1989). '
The loss of CAM expression in cell lines can be correlated with decreased 
aggregation, increased motility and increased invasiveness. However, this may not 
always be the case as observations have indicated that different CAMs are expressed 
differently in a variety of tumours (Behrens et al, 1989).
As retinoids are thought to act at the level of transcription, mediation of 
the observed effects on cell-cell adhesion may, in part, be due to altered expression of 
CAMs. Loss of aggregation in the spheroid model is thought to be an indication of a 
decrease in the potential of a tumour to invade, and this may correlate with a decrease 
in the expression of some CAMs, or an increase in the expression of others such as 
uvomorulin.
One of the factors that can influence aggregation is the presence of serum 
in the culture system. When the ability of B16F1M2 cells to adhere to monolayers of 
the same cells was examined, both cell populations were washed extensively to 
remove as much of the residual serum as possible before initiation of the experiment 
However, when cell-cell aggregation was examined by culturing the cells on soft 
agar, the cells were continually in the presence of serum. In both cases, retinoic acid 
had an inhibitory effect on cell-cell adhesion, although this could not be compared 
quantitatively as the effect on cell-cell aggregation was not measured only observed.
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There have been reports that the presence of serum can stabilise cell aggregates, with 
the effect being greatest in sublines of B16 melanoma which have the highest 
proteolytic activities, suggesting that serum proteinase inhibitors may act in the 
process (Updyke & Nicolson, 1986).
The ability of tumour cells to form cell-cell aggregates is important in the 
metastatic process for a number of reasons. Firstly, the formation of aggregates may 
give the cells some protection against the defence mechanisms of the host. Cells at the 
centre of aggregates may be protected from the action of, for example, NK cells or 
from the actions of various antitumour substances such as retinoic acid. In this study, 
the effects of retinoic acid were only examined in the context of aggregate formation 
and not on preformed aggregates. Thus any protective effects aggregation may have 
against retinoic acid treatment were not determined in the course of the study.
Aggregation is just one of the methods by which tumour cells protect 
themselves in the circulation. One of the other important factors in this survival is the 
mechanical properties of the cells themselves. Tumour cells which survive in the 
microvasculature must be resistant to the shear stresses arising in the vascular bed 
(Brooks, 1984), the frictional forces arising between their peripheries and the vessel 
walls (Weiss & Dimitrov, 1984), and be able to traverse capillaries which generally 
are rigid and smaller in diameter than the tumour cells (Sato & Suzuki, 1976; Weiss 
& Dimitrov, 1984). Depending on the type of tumour, the deformability of tumour 
cells may play an important role in their ability to form neoplastic foci. Using the B16 
mouse melanoma, work has been undertaken to determine if there is a correlation 
between deformability and metastatic potential (Ochalek et al, 1988). Cell 
deformability was measured as the percentage of cells crossing a 10pm Nucleopore 
filter membrane at a constant pressure as a function of time. They found that cells 
with the lowest metastatic potential required the most time to cross the membrane, 
while those with the highest metastatic rate required the least time (Ochalek et al,
1988). Physiochemical factors, such as changes in the cytoskeleton, may play an 
important role in metastasis.
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The heterotypic adhesion of tumour cells to host cells, such as those of the 
endothelium, is also important in metastasis. Adhesion of circulating tumour cells to 
specific organ microvessel endothelial cells is probably one of the most important 
events in determining organ-specific metastasis (Alby & Auerbach, 1986; Auerbach 
et al, 1987; Nicolson, 1988). An example of this is the finding that brain-colonizing 
B16 melanoma cells will adhere to brain-derived endothelial cells at a higher rate than 
lung colonizing B16 cells (Tohgo et al, 1986). Also, it has been demonstrated that the 
adhesive interactions of malignant cells with organ-derived microvessel, but not large 
vessel, endothelial cells correlated with their origin, metastatic properties and the 
preferential organ of metastasis (Alby & Auerbach, 1986; Auerbach et al, 1987).
In the system reported here, the endothelial cells were derived from 
bovine pulmonary artery. However, the purpose of the study was not to look at organ 
specificity, but to look at cell-cell interactions of these cells and B16F1M2 melanoma 
cells, and the effect of retinoic acid on these interactions. In addition, it may be that 
adhesion of malignant cells to endothelium is only important in as much as it is the 
initial step in the attachment of the metastasising cells to the underlying extracellular 
matrix.
Heterotypic cell-cell adhesion may be mediated, in part, through cell 
adhesion molecules. Monoclonal antibodies have been used to identify and 
characterise three cytokine-inducible endothelial cell adhesion molecules - 
intercellular adhesion molecule 1 (ICAM-1), endothelial leukocyte adhesion molecule 
1 (ELAM-1), and vascular cell adhesion molecule 1 (VCAM-1) (Bevilacqua et al, 
1989; Rothlein et al, 1986; Osbom et al, 1989). As well as playing an important role 
in leukocyte-vascular endothelial cell adhesion (Bevilacqua et al, 1989; Osbom et al, 
1989; Dustin & Springer, 1988), recent studies have demonstrated that activation of 
large-vessel endothelial cells by cytokines can alter the adhesion of human melanoma 
cells and carcinoma cells in vitro (Dejana et al, 1988; Rice et al, 1988; Rice & 
Bevilacqua, 1989). The expression of ELAM-1 and a protein which is closely related
to VCAM-1, inducible cell adhesion molecule 110 (INCAM-110) on large-vessel 
endothelium appears to correlate with the ability of specific tumour cells to adhere to 
human umbilical vein endothelial cells (Rice & Bevilacqua, 1989).
Another study examined the mechanisms by which human melanoma 
cells attached to microvascular endothelial cells derived from human dermis (Lee et 
al, 1992). They found that cytokine or protein kinase C agonist stimulation of the 
dermal endothelial cells increased human melanocyte cell binding in vitro. Some of 
the effects appear to be specific for microvascular endothelial cells, and they suggest 
that it is extremely unlikely that the increases in binding can be completely explained 
by pathways involving ICAM-1, VCAM-1 or ELAM-1. This suggests that melanoma 
cell adhesion to these endothelial cells may be mediated by novel microvascular 
endothelial-specific adherence molecules (Lee et al, 1992). The inhibitory effects of 
retinoic acid on cell-cell adhesion could be mediated through several systems. In the 
formation of aggregates, retinoic acid may act upon the proteolytic enzyme/proteinase 
inhibitor system. Support for this comes from the observation that, in the spheroid 
model system, cells in the middle of the spheroid tend to be necrotic. The enzymes 
produced in this state would be capable of preventing aggregation, however spheroids 
can grow to a reasonable size before they fall apart, usually due to lack of nutrients 
and oxygen reaching the centre. An alternative to this is the possibility that retinoic 
acid acts directly on the binding site(s), altering their expression and either blocking 
them or, as is more likely, inducing changes. As retinoic acid is thought to act at the 
level of transcription, it is possible that it alters the expression of cell adhesion 
molecules at this level.
The cell morphology of retinoic acid-treated cells was also affected, with 
retinoic acid-pretreated B16F1M2 cells remaining rounded on CPAE monolayers. It is 
possible that the retinoid treatment has affected the cytoskeleton of the cell and thus 
the deformability making them less invasive. The adherence of the B16F1M2 cells to 
endothelial cells is important, as retraction of the endothelial cells allows access to the
underlying extracellular matrix. It may be that the observed inhibition of cell 
spreading may reduce the endothelial cell retraction, thus preventing exposure of the 
extracellular matrix.
In the homotypic cell-cell adhesion system retinoic acid had an inhibitory 
effect. When retinoic acid was added to both populations of cells as opposed to only 
the seeding cell suspension, there was little difference in the reduction of adhesion. 
Possibly once the cells have been attached for a period of time (the monolayers were 
incubated for 4 days prior to use), they are capable of synthesising new proteins that 
can counteract the effect of the retinoid. Alternatively, it may be that retinoic acid 
affects only some of the cell-cell adhesion mechanisms, thus allowing some cell-cell 
interaction. No attempt was made to determine how strong the cell-cell interactions 
were as the strength of such interactions may be important in the process.
The effect of seeding density on the adhesion of B16F1M2 cells was also 
examined. Cells seeded at the routine seeding densities and incubated for 2 days 
exhibited a decreased adhesion to all tested substrates - fibronectin, type IV collagen 
and laminin/nidogen. If the melanoma cells were seeded at very low numbers and this 
adhesion examined there was also a reduction in adhesion. However, this was not as 
pronounced as that obtained for the cells incubated for 2 days. This would perhaps 
suggest that the microenvironment of the cells has an effect on their ability to adhere 
to the substrates. The cells which were seeded very thinly and incubated for 4 days 
produced a number of small colonies containing a reasonable number of cells and the 
cells within these colonies may have produced a microenvironment similar to that 
found in confluent control cultures. However, in the cultures seeded at the standard 
seeding densities and incubated for 2 days, the cells were thinly spread over the 
surface of the dish and as such did not form concentrated colonies, thus having a 
different microenvironment.
In summary, retinoic acid pretreatment of B16F1M2 melanoma cells was 
shown to inhibit their attachment to laminin/nidogen, type IV collagen and to an 
intact subendothelial extracellular matrix. Retinoic acid pretreatment also had an 
inhibitory effect on cell-cell adhesion, - both homotypic and heterotypic. Adhesion to
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fibronectin remained unaffected, with the melanoma cells adhering readily to this 
substrate both in the presence and absence of the retinoid. Cell morphology was also 
affected by retinoic acid treatment, with the cells becoming more elongated and 
having more dendritic processes when grown on plastic, and this was accompanied by 
an enhancement of melanogenesis. On laminin/nidogen, type IV collagen, the intact 
matrix and on the monolayer of endothelial cells, retinoic acid pretreated B16F1M2 
cells remained rounded, suggesting that retinoic acid also had an inhibitory effect on 
cell spreading.
4:3. DEGRADATION OF THE EXTRACELLULAR MATRIX.
The ability of invading tumour cells to degrade the underlying 
extracellular matrix is a crucial step in the process of metastasis. The invasive step is 
mediated, at least in part, by the production of certain degradative enzymes. The 
second part of the study reported here examined the effect of retinoic acid on the 
production of these enzymes.
The first set of results relate to the ability of B16F1M2 cells to degrade 
the sulphated components of the extracellular matrix. As proteoglycans, and in 
particular heparan sulphate, are the most highly sulphated components of the matrix, 
it was assumed that the majority of the ^^S0 4  was incorporated into these molecules 
(Robinson & Gospodarowicz, 1983). The results indicate that, in general, retinoic 
acid-pretreatment of the cells reduced their ability to degrade the sulphated 
components of the matrix.
Melanoma cells, and in particular the murine B16 melanoma cell’s ability 
to degrade the heparan sulphate components of extracellular matrix is well 
documented (Nakajima et al, 1983; Nakajima et al, 1984; Kramer & Vogel, 1984). 
The enzyme produced by these cells has been identified as an endo-f-glucuronidase 
(heparanase), which is capable of cleaving heparan sulphate at specific intrachain 
sites (Nakajima et al, 1984). The production of this enzyme has been correlated to
metastatic potential, with highly metastatic cells being capable of solubilizing the 
extracellular matrix heparan sulphate proteoglycans at a higher rate than cells of low 
metastatic potential (Nakajima et al, 1983).
Another set of enzymes thought to be involved in the degradation of the 
extracellular matrix are the glycosidases which can mediate the hydrolysis of 
proteoglycans. Glycosidases, particularly hexosaminidases, have been identified at 
elevated levels in a variety of solid tumours and/or their interstitial fluid (Bosmann, 
1969; Whitehead et al, 1979; Whitehurst et al, 1982). Studies using ovarian tumour 
cells have demonstrated a relationship between extracellular 
-N-acetylglucosaminidase activity and the ability of these cells to morphologically 
and biochemically degrade the extracellular matrix (Niedbala et al, 1987). 
Additionally, the rate of enzyme accumulation by the tumour cells was progressive 
with time, and closely paralleled tumour cell-mediated release of 
[^Hj-N-acetylglucosamine-containing fragments from the extracellular matrix 
(Niedbala et al, 1987).
In the study reported here, the ability of B16F1M2 cells to produce 
N-acetyl-glucosaminidase was investigated. Intracellular levels of the enzyme 
decreased as the retinoic acid concentration increased. Examination of intracellular 
enzyme levels revealed an increase in activity at all tested concentrations. The results 
may at first seem contradictory, however it may be that although the retinoic acid has 
decreased the amount of intracellular enzyme, perhaps at the level of transcription, the 
expression of extracellular enzyme may require a longer period of treatment before 
being inhibited. However, that does not explain the extracellular enzyme levels. It is 
possible that elevated extracellular levels are required to release factors held in the 
matrix which, in turn, inhibit the extracellular production ie. a feedback loop system. 
The results reported were obtained with B16F1M2 cells grown on plastic, cells grown 
on extracellular matrix may produce different results.
The other major components of the extracellular matrix examined were 
the collagens, and degradation of these molecules was monitored by the release of 
[^H] from the matrices labelled with [^H]-proline. At all tested concentrations of
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retinoic acid, there was an increase in the release of [^H] from the extracellular 
matrix. However, the curve produced from the results is somewhat erratic with some 
points having large standard errors, and as such the results may not be totally reliable. 
There have, however, been reports that when added to an intact subendothelial 
extracellular matrix, B16 melanoma cells are not able to solubilize [^H]-proline 
labelled material (Kramer & Vogel, 1984). This is an unexpected finding as the 
ability of highly metastatic cells to produce collagenase is well documented (Salo et 
al, 1982; Eisenbach et al, 1985; Starkey et al, 1984). Indeed, as with the action of 
heparanase, type IV collagenase activity in the cell culture media of B16 melanoma 
cells has been shown to correlate with metastatic potential (Poste & Fidler, 1980).
It is possible that the proteins found in the subendothelial extracellular 
matrix are resistant to proteinase digestion because they are arranged in a complex 
structure in which many molecular interactions exist. Laminin is known to bind 
tightly to both type IV collagen (Kleinman et al, 1981) and heparan sulphate 
(Sakashita et al, 1980), and these interactions could result in the masking or protecting 
of specific macromolecules from digestion by degradative enzymes. Also, it may be 
that the presence of glycoproteins delay the digestion of elastin and collagen by 
tumour cells (Jones & deClerck, 1980), and work with isolated collagens has 
demonstrated that the presence of contaminating proteoglycans can protect the 
collagen from enzymatic degradation (Etherington, 1977).
The susceptibility of collagens to enzymatic action can be modified in the 
presence of inter molecular cross-links which can stabilise the collagen fibres, thus 
inhibiting degradation (Fessler & Fessler, 1982; Etherington, 1977). It is possible that 
if such a network of cross-linked proteins was present in the CPAE extracellular 
matrix, then insoluble homopolymers and heteropolymers may form, which could 
provide some resistance to degradation. Alternatively, the effect of the retinoids on 
the action of the enzymes may be hampered by the orientation of the enzymes in such 
structures. Although the enzymes may be able to cause some breakdown, the 
fragments produced may be immobilised on the matrix superstructure by cross-links 
or noncovalent interactions. Any degradation deeper in the structure might then be
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hindered by inaccessibility. Another consideration may be the presence of 
endogenous proteinase inhibitors, either in the matrix itself or synthesised by the cells 
seeded onto it. Retinoic acid may be able to reduce the synthesis or secretion of these 
inhibitors as well as the collagenases, thus any inhibitory effects on degradation may 
be countered by the effects on the inhibitors.
An attempt was made to investigate the ability if B16F1M2 cells to 
degrade purified collagen substrates - type I and type IV - but no activity was 
detected. This may be due to a variety of reasons. It is possible that collagenases were 
produced, but in a latent form. Experimental conditions may not have been 
appropriate for activation to occur. Another possibility is that impurities in the 
substrate are required for the release of collagen breakdown products by enzymatic 
degradation.
In contrast to the work presented here, a study utilising human melanoma 
cell lines has demonstrated anti-invasive effects for retinoic acid (Hendrix et al, 1990; 
Wood et al, 1990). Similar results have also been obtained using rat mammary 
adenocarcinoma cells (Nakajima et al, 1989). Using a reconstructed basement 
membrane gel (Matrigel), retinoic acid treatment of cells was found to inhibit 
invasion in a dose and time-dependent manner (Hendrix et al, 1990). Further 
investigation revealed that retinoic acid-treated cells secreted lower levels of 
collagenolytic enzymes, which was measured by the degradation of 
[^H]-proline-labelled type IV collagen substrate and by the reduction in the activity of 
the secreted type IV collagenolytic enzymes. The cells also expressed lower levels of 
human type IV collagenase mRNA and exhibited decreased amounts of tissue-type 
plasminogen activator activity. A decreased adhesion to Matrigel was also observed, 
and this was related to an increase in the high affinity metastasis-associated cell 
surface laminin receptor, and a decrease in the expression of a cell surface receptor 
for motility factor (Hendrix et al, 1990). From these studies they concluded that 
retinoic acid inhibited tumour cell invasion through a reconstituted basement
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membrane by inhibiting matrix degradation by suppression of type IV collagenolytic 
activity and plasminogen activator activity, and by alteration of cell surface receptors 
(Hendrix et al, 1990; Woods et al, 1990).
Other workers have examined the effects of retinoids on type IV 
collagenolytic activity produced by human melanoma cell lines using type IV 
collagen substrate labelled with [^H]-proline (Oikarinen & Salo, 1986). They found 
that retinoids, at concentrations of up to 10"^M, did not significantly affect type IV 
collagenolytic activity. It is possible, therefore, that the effects of retinoids on tumour 
cell production of type IV collagenolytic activity may be inconsistent, or may be 
dependent upon the type of cell line being studied.
The ability of retinoic acid to influence the production of proteinase 
inhibitors is also a consideration. There have been reports that in normal skin 
fibroblasts, retinoids can increase the production of TIMP. Clark and co-workers 
(Clark et al, 1987) found that in monolayer cultures, retinoid treatment could increase 
the production of TIMP by 2-3 fold and this was accompanied by a simultaneous 
decrease in collagenase activity. The effects were reversible on the removal of the 
retinoid, and the effect was found to be mediated by an increase in the biosynthesis of 
new inhibitor protein. Increased levels of TIMP mRNA were accompanied by a 
decrease in the amount of collagenase mRNA, which would suggest that the retinoid 
acts on transcriptional control. From this they concluded that the retinoid co-regulated 
the expression of collagenase and TIMP in an inverse manner (Clark et al, 1987). It is 
possible that the effect arises due to the action of another factor stimulated by retinoid 
treatment. In some cells, such as cultured keratinocytes, retinoic acid induces TGF-£ 
Modulation of TGF-^ activity can inhibit the expression of various proteinases 
including collagenases, while stimulating the synthesis of various proteinase 
inhibitors. This would also explain the observations made with the fibroblast system. 
In the study reported here, the effect of retinoic acid on the production of proteinase 
inhibitors was not examined. The method of investigation used was to seed a cell 
suspension onto a substrate, thus a monolayer was not formed. It is possible that 
reports implicating the production of TIMP and the inhibition of invasion by retinoic
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acid were performed in such a way that the conditions were conducive to the 
production of inhibitors, thus retinoids would then be able to activate the required 
biosynthetic pathways. Alternatively, it may be a feature of the particular cell line 
being studied.
The fact that malignant tumour tissues usually contain high proteinase 
activities does not prove decisively that the enzymes are of tumour cell origin. It 
should be remembered that tumour tissue usually contains host tissue cells such as 
fibroblasts, macrophages and monocytes in addition to the tumour cells, and that all 
the host cell types are reported to be able to secrete a variety of proteinases including 
collagenases (Tryggvason et al, 1987). Therefore, it may be that, in some cases, the 
host cells play a role in the degradation of the extracellular matrix during invasion. 
Human basal cell carcinoma extracts have been shown to contain greater levels of 
immunoactive interstitial collagenase than normal skin extracts, and immunostaining 
has shown that the enzyme is present only around the stromal elements surrounding 
the tumour islands (Bauer et al, 1979). The implication from this is that host cells may 
have been stimulated to increase the secretion of collagenase. It is unlikely that the 
B16F1M2 cells used in this study would not produce sufficient collagenase to allow 
invasion to occur, and indeed the production of type IV collagenase by these cells has 
been correlated to their metastatic potential (Liotta et al, 1980).
One of the other important enzymes associated with the metastatic 
phenotype is plasminogen activator, a serine proteinase capable of activating 
plasminogen by converting it to plasmin which can, in turn, degrade fibrin and 
laminin (Quigley et al, 1986; Liotta et al, 1981; Saksela & Rifkin, 1988). It has been 
suggested that the breakdown of extracellular matrix components may occur by 
plasminogen activator activation, with the plasmin formed activating procollagenases 
(Tryggvason et al, 1987; Saksela & Rifkin, 1988; Reich et al, 1988). Additionally, a 
role for the plasminogen activator-plasmin-collagenase activation pathway has been 
demonstrated in an invasive model for B16 melanoma cells utilising human amniotic 
basement membrane (Mignatti et al, 1986).
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Immobilisation of plasminogen activators on the surface of proteolytically 
active cells may direct proteolysis to specific sites of activity, and in mobile cells such 
as macrophages, fibroblasts and several types of malignant cells which express u-PA 
receptors, the bound enzyme may be localised to sites where the activity is required 
(Saksela & Rifkin, 1988). Immunofluorescence and immunoelectron microscopy have 
demonstrated a co-localization of u-PA with vinculin, but not with extracellular 
matrix components such as fibronectin (Pollanen et al, 1988; Herbert & Baker, 1988).
When the effect of retinoic acid on the activation of urokinase 
plasminogen activator was examined, it was found that treatment of the cells 
increased plasminogen activator activity both intracellularly and extracellularly. This 
is in direct contrast to work carried out using human melanoma cell lines in which 
retinoic acid treatment produced a reduction in plasminogen activator activity. 
However, in that study the plasminogen activator activity assayed was primarily that 
of tPA (Wood et al, 1990), whereas in the study reported here u-PA activity was 
assayed.
In other systems it has been demonstrated that low concentrations of 
retinoic acid can stimulate plasminogen activator activity. In chick embryo fibroblasts 
and chick embryo muscle cells both the induction of the enzyme and its reduction by 
the removal of retinoic acid required mRNA synthesis (Wilson & Reich, 1978; 
Miskin et al, 1978). However, the effect of retinoids on plasminogen activator activity 
has been examined in a variety of human cultured cells lines of both neoplastic and 
normal origin (Wilson & Dowdle, 1980), and in murine tumour cells (Lotan et al, 
1983). Results from these studies conclusively show that retinoids have no consistent 
effects on plasminogen activator activity.
Although correlations between plasminogen activator secretion and the 
metastatic potential of tumour cells have been made, they are not as consistent as the 
relationship of type IV collagenase to metastatic potential (Quigley et al, 1986; 
Saksela & Rifkin, 1988; Reich et al, 1988; Mignatti et al, 1986). Migration of tumour 
cells through the basement membrane has been shown to be dependent on a 
proteolytic cascade in which collagenase is activated by plasminogen-activated
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plasmin (Saksela & Rifkin, 1988; Reich et al, 1988; Mignatti et al, 1986; Yagel et al, 
1989). In support of this, direct genetic evidence for a causal role of plasminogen 
activators in invasion and metastasis has been produced by transfecting 
H-ras-transformed NIH 3T3 cells with human plasminogen activator cDNA of both 
types. The cells were then monitored for their ability to invade a basement membrane 
and to form experimental lung metastases, both of which were increased (Axelrod et 
al, 1989).
The formation of plasmin can be controlled by either inhibition of plasmin 
or plasminogen activator activities by proteinase activities. Proteinase inhibitors such 
as ^ -macroglobulin, o(-proteinase inhibitor and antithrombin HI may inhibit a wide 
range of proteinases, whereas some may act against only one. Proteinase inhibitors 
have an important function in the control of excessive proteolytic reactions in blood 
coagulation, fibrinolysis, tissue remodelling and inflammatory processes. 
Plasminogen activator inhibitors belong to the serpin family of inhibitors and are 
classified as arginine-serpins according to the location of arginine at the reactive 
centre (Carrell & Travis, 1985; Hill & Hastie, 1987). Enzyme activity is inhibited by 
the formation of 1:1 covalent complexes between the enzyme and the inhibitor. Three 
different effective and functionally rapid plasminogen activator inhibitors have been 
characterised - PAI-1, PAI-2 and the protease nexins. PAI-1 and PAI-2 have a more 
limited target specificity than the protease nexins, which primarily inhibit the action 
of thrombin, but also that of both types of plasminogen activator and trypsin (Knauer 
& Cunningham, 1984).
Some hormones and hormone-like substances have been implicated in the 
regulation of the proteolytic activity of cultured cells. The enhancement of 
plasminogen activator activity by such factors has, in some cases, been connected 
with the malignant behaviour of these cells, but enhanced plasminogen activator 
activity also seems to be required for several developmental and reparative processes 
(Dano et al, 1985; Saksela, 1985). Growth factors which affect various growth 
parameters of cells may also mediate plasminogen activator activity, but the effects 
may vary depending upon the cell line under investigation, with different cells
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responding by either a stimulation or inhibition of the secretion of plasminogen 
activator. It may be that if bound plasminogen activator is present at the surface of the 
melanoma cells, the extracellular levels of enzyme activity are increased by the 
release of the binding complex. This would, however, have little effect on 
intracellular levels unless cell attachment required a u-PA receptor-bound complex at 
the surface, and continuing amounts of plasminogen activator were produced in order 
to fulfill this requirement Alternatively, a growth factor could regulate the expression 
of plasminogen activators or their inhibitors.
The stimulation of plasminogen activator activity by retinoic acid may be 
brought about either by de novo synthesis of the enzyme, or by the inhibition of 
plasminogen activator inhibitors. It is also possible that retinoic acid may act in a 
similar manner to the growth factors, with responses depending on the cell line under 
investigation. Further work is required to investigate the mode of action in the system 
reported here.
In summary, retinoic acid appears to have very little effect on the 
extracellular matrix degradative processes relating to the B16F1M2 melanoma cell 
line. Although the results observed for type IV collagenolytic activity and 
plasminogen activator activity are in contrast to recent reports (Hendrix et al, 1990; 
Wood et al, 1990), this could be due to the different assay systems used or to 
differences between the murine and human melanoma systems. Previous work has 
shown no consistent effect of retinoids on plasminogen activator synthesis by various 
tumour cell lines (Lotan et al, 1982). Similarly, there have been conflicting reports on 
the effects of retinoids on type IV collagenolytic activity, again suggesting a 
dependency on the assay system used and the cell line under investigation.
4:4. EFFECT OF RETINOIC ACID ON THE ACTION OF TUMOUR 
CELL-DERIVED FACTORS.
If fibroblasts are suspended in type I collagen gels in the presence of 
serum and the gels allowed to set, contraction of the gel occurs over a few days. If 
serum is omitted from the system, there is no contraction. In the presence of serum
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retinoic acid had no effect on gel contraction. There have been reports that tumour 
cells can alter the production of various macromolecules by fibroblasts - fibronectin 
and collagen (Noel et al, 1992), hyaluronate (Knudson et al, 1984) and 
glycosaminoglycans (Merrilees & Finlay, 1985). When serum-free 
B16FlM2-conditioned medium was tested, gel contraction occurred at a rate similar 
to that obtained with serum. If the conditioned medium was prepared in the presence 
of retinoic acid, the rate of contraction was reduced. This would suggest that a factor 
or factors produced by the B16F1M2 cells were capable of stimulating the fibroblasts 
to reorganise the gel, and mediate contraction. Retinoic acid would appear to be able 
to partially inhibit either the production of these factors or affect their mode of action. 
To ensure that the observed effects were due to the action of retinoic acid on the 
melanoma cells as opposed to on the fibroblasts, the conditioned media were 
U.V.-irradiated to destroy any residual retinoic acid before being introduced into the 
system.
Tumour-conditioned medium can alter fibroblast glycosaminoglycan 
synthesis. Thus the effect of B16FlM2-conditioned medium on fibroblast 
glycosaminoglycan production was examined, with the fibroblasts grown on plastic. 
The presence of conditioned medium would appear to increase the production of 
hyaluronate by the fibroblasts even in the presence of retinoic acid. The sulphated 
glycosaminoglycans were also affected by the presence of the conditioned media - the 
second sulphated GAG peak is composed of two distinct peaks in control 
experiments, but becomes one solid peak after exposure to B16FlM2-conditioned 
medium. Medium conditioned in the presence of retinoic acid caused this second peak 
to become more like that observed in control cultures.
The effect of tumour-conditioned medium on the sulphated 
glycosaminoglycans was to ellicit a decrease in their overall production. The reverse 
of this was found to be the case if the medium was prepared in the presence of 
retinoic acid. When the individual sulphated glycosaminoglycans were examined it 
was found that both heparan sulphate and chondroitin sulphate were reduced by the 
conditioned medium, with the decrease in chondroitin sulphate the more dramatic.
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However, tumour-conditioned medium prepared in the presence of 10'^M retinoic 
acid produced an increase in the amount of heparan sulphate detected but a decrease 
in the amount of chondroitin sulphate. This is the opposite to the effect of retinoic 
acid on sulphated GAG production in B16F1M2 melanoma cells - retinoic acid 
increases the chondroitin sulphates by a small amount while eliciting a decrease in the 
heparan sulphates. This may be a cell line-specific response or, alternatively, it may 
reflect the different responses induced by retinoic acid in normal and malignant cells.
The increase in the hyaluronate produced by the fibroblasts is, perhaps, 
the more important effect caused by the conditioned medium. Recent evidence has 
suggested a direct role for cell surface hyaluronic acid in the regulation of cell 
migration. Hyaluronic acid-binding protein has been demonstrated to concentrate in 
the ruffling lamellae of actively locomoting cells (Turley & Auersperg, 1989). If 
hyaluronic acid and hyaluronic acid-binding protein are added to fibroblasts cell 
movement is stimulated (Turley et al, 1985). A 70kDa factor associated with foetal 
fibroblasts and fibroblasts derived from cancer patients has been shown to stimulate 
confluent cells to penetrate collagen gels by a mechanism which is dependent on 
hyaluronic acid. This effect can be inhibited if the cells are treated with a hyaluronic 
acid-specific hyaluronidase (Schor et al, 1989).
A cell surface proteoglycan, CD44, which is involved in lymphocyte 
activation and adhesion, and homing of circulating lymphocytes has also been 
identified as a hyaluronic acid receptor (Toole, 1990). CD44 has been demonstrated 
in a number of tumour cell lines including human melanoma cell lines (Birch et al, 
1991). Work on human melanoma cells has suggested a relationship between the 
expression of CD44 and the metastatic potential of the cell line (Birch et al, 1991). 
Thus it may be that in vivo, melanoma cells produce factor(s) which induce host 
fibroblasts to produce more hyaluronic acid, allowing migration of these cells along 
the hyaluronate tracks. In the glycosaminoglycan analysis of the conditioned 
medium-treated fibroblasts, retinoic acid pretreatment appeared to have little effect on 
this increase in hyaluronate which would suggest that it has limited effects on cell
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locomotion by this method. Interestingly, a glycosaminoglycan analysis of B16F1M2 
cells revealed that they did not express hyaluronic acid, a fact which will be discussed 
later.
4:5. ANALYSIS OF CELL-SURFACE GLYCOSAMINOGLYCANS.
Proteoglycans are intrinsic constituents of the cell surface, extracellular 
matrix and basement membrane, three logistically and functionally important 
structures involved in most cellular interactions. They can influence the behaviour of 
normal and malignant cells by virtue of their expanded configuration, polyanionic 
nature and their ability to interact with a variety of cellular products. Thus they have 
been implicated in a number of biological processes including proliferation, 
recognition, adhesion and migration. They can serve as links between the 
extracellular and intracellular environment thus transducing key biological signals. In 
addition to this, they can act as receptors for matrix proteins thereby contributing to 
the organisation of the pericellular matrix. During neoplastic development, there is a 
profound structural arrangement of these macromolecules at both the plasma 
membrane and the pericellular level. Qualitative and quantitative abnormalities in 
proteoglycan metabolism may contribute to some aspects of neoplasia such as lack of 
cohesiveness, abnormal assembly of the extracellular matrix, abnormal growth and 
invasion.
Both proteoglycans and their carbohydrate side chains, the 
glycosaminoglycans, have been implicated in the regulation of cell division, with 
indirect evidence for this concept coming from studies of glycosaminoglycans in 
neoplastic tissues (Dietrich et al, 1977; Chiarugi et al, 1978; Iozzo et al, 1981). High 
amounts of chondroitin sulphates were detected in a variety of mesenchymal and 
epithelial neoplasms as compared to their normal counterparts. A positive role in 
tumour cell proliferation has been demonstrated for chondroitin sulphates on 
mammary carcinoma cells in vitro (Ozzello et al, 1960), and Ehrlich ascites tumour in
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vivo (Takeuchi, 1972a). Furthermore, enzymes capable of degrading chondroitin 
sulphates can inhibit or retard the growth of Ehrlich ascites tumour cells (Takeuchi, 
1972b).
In contrast to this, heparan sulphates have been implicated in the negative 
control of cell proliferation (Kraemer, 1971; Kraemer & Smith, 1974). Cell surface 
heparan sulphate is released during premitosis and the cyclic exposure of this 
glycosaminoglycan to the cell surface has been proposed to negatively affect the 
transport of nutrients and ions across the plasma membrane, resulting in a negative 
effect on cell growth (Kraemer & Tobey, 1972; Chiarugi & Vannucchi, 1976). 
Heparan sulphate may exert its effects either locally or distally following its release 
from the cell surface. It has been demonstrated that glutaraldehyde-fixed confluent 
cultures of fibroblasts, which are enriched in cell surface heparan sulphate 
proteoglycan, inhibit the growth of freshly seeded cells, and this effect can be 
abolished by pretreating the fibroblasts with heparitinase (Culp et al, 1978). Heparan 
sulphate isolated from liver cells or from their plasma membrane inhibits the growth 
of hepatoma cells in vitro (Ohnishi et al, 1975; Kawakami & Terayama, 1981). Also, 
it has been shown that endothelial cells release a heparin-like molecule, or a highly 
sulphated heparan sulphate proteoglycan which can inhibit the growth of smooth 
muscle cells in vitro (Castellot et al, 1981), with the active molecules apparently 
released from the cell surface by a platelet endoglycosidase found in serum (Castellot 
et al, 1982).
There have been several reports describing profound changes in the 
amounts and types of glycosaminoglycans and proteoglycans associated with 
neoplasms. One of the first demonstrations of this was the elevated levels of 
hyaluronic acid detected in the pleural effusion of mesotheliomas. However, in tissue 
extracts from mesotheliomas, elevated amounts of chondroitin sulphate have been 
detected and this suggests the existence of biochemical variants in this neoplasm 
(Iozzo et al, 1981).
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Alterations in heparan sulphate proteoglycan have been linked to the 
neoplastic phenotype. One of the most consistent qualitative abnormalities in the 
structure of the macromolecule that has been proposed to be directly related to the 
transformed phenotype is a reduced degree of sulphation in the heparan sulphate 
glycosaminoglycan side chains. SV40-transformed 3T3 cells have been demonstrated 
to synthesise undersulphated heparan sulphate chains (Underhill & Keller, 1975). 
This has also been shown to be the case for human hepatoma (Nakamura & Kojima,
1981), ascites hepatoma (Hurst et al, 1981) and myeloma (Stamatoglou & Keller,
1983). Also, spontaneously transformed mouse mammary cells synthesise 
undersulphated basement membrane heparan sulphate proteoglycan (David & Van 
Den Berghe, 1983).
There are several possible mechanisms and resulting functional 
consequences for the observed changes. It is possible that transformation has an effect 
on the enzyme required in the modification reactions of the molecules. The major 
difference between normal and transformed 3T3 cells has been shown to be the 
degree of O-sulphation (Keller et al, 1980), whereas in hepatoma cells the difference 
occurs primarily at the level of N-sulphation of the glucosamine residues caused by a 
defect in the deacetylase (Robinson et al, 1984), which is the key enzyme involved in 
the modification of the unsulphated heparan, and the extent of the initial deacetylation 
appears to regulate the subsequent polymer modification reactions (Riensenfeld et al,
1982). It is also possible that transformation may generate some inhibitor of 
sulphotransferase, or it may directly alter the levels of the major sulphate donor, 
3’-phosphoadenosine-5’-phosphosulphate (PAPS). The availability of the sulphate 
donor plays a fundamental role in the sulphation of glycosaminoglycans (Sugahara & 
Schwartz, 1979).
The undersulphation of glycosaminoglycans could exert a multiplicity of 
effects. It is possible that undersulphation could lower the affinity of the molecules 
for laminin, collagen and fibronectin, all of which can contribute to the abnormal 
assembly of the extracellular matrix and a decrease in adhesiveness, two properties of 
malignant cells (Iozzo, 1988). In myeloma and hepatoma cells, undersulphation of
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heparan sulphate has been detected, and both of these lack a detectable pericellular 
matrix and show little or no affinity for fibronectin (Stamatoglou & Keller, 1983; 
Robinson et al, 1984). This is in contrast to the B16F1M2 murine melanoma cell line 
which has been shown to adhere readily to fibronectin (Edward et al, 1989). Another 
possible consequence of undersulphation would be a decrease in overall cell surface 
charge, which could favour the entrance of cells into the mitotic cycle (Chiarugi & 
Vannucchi, 1976). Also, this structural change may significantly influence the 
molecular interactions which normally occur during the assembly of the basement 
membrane, and this may be directly involved in the abnormal or lack of basement 
formation by neoplastic cells (David & Van Den Berghe, 1983).
The changes observed in heparan sulphate after transformation have been 
associated with their abnormal self affinity (Fransson et al, 1981). When 
SV40-transformed cells were examined, it was found that their heparan sulphates had 
no affinity for agarose-substituted heparan sulphate species (Fransson et al, 1981). 
The alterations in the structure of the macromolecules may contribute to the abnormal 
behaviour of the tumour cells by inhibiting self-association and adhesion, 
alternatively they may interfere with the recognition of a suitable substrata. It may be 
that the presence of a certain type of microenvironment around the tumour cells is 
essential for the full expression of the neoplastic phenotype (Gallagher et al, 1986).
Over production of heparan sulphate can also be identified in neoplasia as 
demonstrated in patients with multiple myeloma who have high levels of circulating 
heparan sulphate which has anticoagulant activity (Khoory et al, 1980; Palmer et al,
1984). A similar finding has been reported in some cases of acute monoblastic 
leukaemia (Russell et al, 1984). It is possible that the neoplastic cells produce and 
release the molecule in large quantities or, alternatively, the circulating proteoglycan 
may be derived from endothelial cells which have been damaged by chemotherapy. 
Another possibility is that it may be produced by tumour cells to induce an 
immunological response towards endothelial cells or platelets. However, it has been 
shown that cloned endothelial cells synthesise anticoagulant heparan sulphate
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proteoglycan (Marcum et al, 1986), and that some patients with heparin-associated 
thrombocytopenia contain antibodies that react against heparan sulphate synthesised 
by endothelial cells (Cines et al, 1987).
The changes in cell surface glycosaminoglycans after transformation have 
been linked to the metastatic potential of the cells. The glycosaminoglycan synthesis 
of B16 metastatic melanoma variants, both in vivo and in vitro, have been examined. 
Turley and Tretiak (1985) found both an increase in the deposition of hyaluronic acid 
around the tumours during the early stages of invasion in vivo, and an increase in the 
release of hyaluronic acid and heparan sulphate in vitro by the cell lines, and this 
correlated with enhanced metastatic capabilities. In the study reported here, it was 
found that B16F1M2 cells did not synthesise hyaluronic acid in vitro. However, it has 
been shown that B16FlM2-conditioned medium can stimulate hyaluronic acid 
synthesis by fibroblasts, which in turn could be responsible for the increased amounts 
of hyaluronic acid detected around tumours in vivo.
The presence of hyaluronic acid, either within a capsule or distributed 
throughout the tumour tissue adjacent to the stromal-tumour interface has been widely 
reported (Nigam & Cantero, 1972). It has been demonstrated that the largest amount 
of hyaluronic acid surrounding each tumour variant coincided with the onset of 
observable metastasis, suggesting an instructive role for hyaluronic acid during early 
tumour invasion (Turley & Tretiak, 1985). It was noted that the absolute levels of 
hyaluronic acid were lower for the highly invasive variants, and it may be that this is 
related to the increased degradative abilities of these invasive cells (Nicolson, 1982). 
Although the highly metastatic cells were shown to secrete more hyaluronic acid than 
the less metastatic cells, the reduction in deposition of the glycosaminoglycan around 
the tumour in vivo may be related to a higher turnover of the molecule or the absence 
of an extracellular matrix, and as such other molecules to bind to it (Turley & Tretiak, 
1985). In the capsule surrounding the tumour produced by the least metastatic variant 
B16F1, the presence of hyaluronic acid was shown to have an inhibitory effect on the 
invasion of cells into the surrounding muscle tissue (Turley & Tretiak, 1985), with 
invasion occurring only after extensive breakdown of the capsule. The presence of
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stromal capsules and basement membranes around other tumours has led to the 
suggestion that part of their function may be to act as physical barriers restricting 
extravasation and intravasation (Ingber et al, 1981; Gusterson et al, 1982).
A variety of epithelial and mesenchymal tumours have been shown to 
express abnormal levels of chondroitin sulphate, and there have been attempts to 
correlate the production of this glycosaminoglycan with the properties of the tumour 
cells (Iozzo, 1985b). Chondroitin sulphate is found in only small amounts in most 
adult noncartilaginous tissue, but is present in raised concentrations in foetal and 
neoplastic tissue (Chiarugi et al, 1978; Dietrich et al, 1977), with raised amounts 
being reported in breast (Takeuchi et al, 1982), lung (Horai et al, 1981), liver (Kojima 
et al, 1975), colon (Iozzo et al, 1982; Iozzo & Wight, 1982) and prostate (DeKlerk et 
al, 1984) carcinomas. In melanomas, chondroitin sulphate is' a major cell surface 
component which can be identified in cell lines (Bumol et al, 1984) and in biopsy 
specimens (Harper et al, 1984). Chondroitin sulphate has been shown to stimulate the 
growth of Ehrlich ascites tumours in vivo (Takeuchi, 1972a) and conversely, enzymes 
capable of degrading chondroitin sulphate can inhibit the growth of these cells 
(Takeuchi, 1972b).
Heparan sulphate is the major proteoglycan associated with the basement 
membrane. Using monoclonal antibodies directed against the glycosaminoglycan side 
chains, heparan sulphate glycosaminoglycan expression on the surface of B16 murine 
melanoma cells has been studied (Kure et al, 1987). Sublines of B16 which expressed 
low amounts of cell surface heparan sulphate were highly metastatic and the parental 
variant, which was only weakly metastatic, expressed the highest amounts of the 
glycosaminoglycan. If cells were prepared from the metastatic lung colonies found in 
mice injected with the parental B16F1 cell line, examination of the expressed heparan 
sulphate revealed lower levels than seen in the original cells, which suggests that cells 
with reduced amounts of heparan sulphate are selected in the process of lung 
colonization. In agreement with this is the finding that in vitro selection of B16 cells 
with low surface heparan sulphate resulted in the selection of cells with high 
metastatic potential. The correlation between the expression of cell surface heparan
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sulphate and metastatic potential is not linear, thus it is possible that the expression of 
low levels of this cell surface glycosaminoglycan is either one of many phenotypes 
which contribute to the metastatic potential of the cells, or a change which is 
somehow associated with a potentiating phenotype (Kure et al, 1987).
. In contrast to this, work on other cell lines such as the Lewis lung 
carcinoma, has indicated that highly metastatic cells contain a relatively higher 
amount of heparan sulphate than do cells of lower metastatic potential (Timar et al, 
1987). Using xenografts of human melanomas, similar results have been obtained 
(Timar et al, 1989). The differences in the patterns obtained may be due to the 
experimental conditions used. Another possibility is that the variations are due to 
differences in the cell type being studied, as it may be that heparan sulphate 
expression in the murine system differs from that of the human system. This would 
seem unlikely as there have been reports describing glycosaminoglycan production in 
B16 cells, and it has been shown that the more invasive and highly metastatic variants 
produce higher amounts of heparan sulphate in vitro than did cells which were less 
invasive and poorly metastatic (Turley & Tretiak, 1985).
The results presented here suggest that retinoic acid has an effect on the 
production of glycosaminoglycans by B16F1M2 cells. A quantitative analysis of 
glycosaminoglycan synthesis revealed that incorporation of [^H] glucosamine and 
35s o 4 into the heparan sulphates, in the medium fraction, was reduced by 33% and 
63% respectively. Thus it would appear that heparan sulphate production in this 
fraction is reduced, with an accompanying reduction in the degree of sulphation. In 
the low density medium fraction, incorporation of the radiolabel into the heparan 
sulphates showed a different pattern, with a large increase in [^H] glucosamine 
incorporation (30%) and for ^ S 0 4 , a 35% increase which indicates an overall 
increase in the synthesis of this glycosaminoglycan and an increase in the degree of 
sulphation. This would suggest that the density of the cells can have an effect on the 
production of this macromolecule. The chondroitin sulphates of retinoic acid-treated 
cells were also altered, with incorporation of [^H] glucosamine reduced by 9%, while 
35sC>4 incorporation remained essentially unaffected, suggesting a slight decrease in
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chondroitin sulphate synthesis accompanied by a small increase in the degree of 
sulphation. The low density cultures exhibited an increase in chondroitin sulphate and 
an increase in the degree of sulphation. This finding is obviously related to cell 
density.
These results are in partial agreement with a previous study using 
B16BL6 melanoma cells treated with retinoic acid, which showed that there was an 
overall decrease in glycosaminoglycan synthesis, but an increase in the degree of 
sulphation of heparan sulphate (Edward & MacKie, 1989). Although they reported a 
decrease in the amount of chondroitin sulphate, the sulphation was hardly affected 
which agrees with the findings reported here. The results are, however, in total 
contrast to other work carried out on the B16F10 murine melanoma treated with 
retinoic acid which demonstrated an increase in glycosaminoglycan synthesis 
(Maniglia & Sartorelli, 1981). It is possible that the differences are due to the 
different methods employed to estimate glycosaminoglycan production or 
alternatively, it may be that although all three cell lines were derived from the same 
parental line (B16 melanoma) each may have a different response to retinoic acid 
treatment. Indeed, this has been shown to be the case with variants of B16 treated 
with retinoic acid and the melanotic expression estimated (Edward et al, 1988).
Qualitatively, retinoic acid would appear to have little effect on the 
heparan sulphates or the chondroitin sulphates, although in the initial isolation of the 
glycosaminoglycans, the sulphated molecules eluted as two peaks as opposed to one 
peak for the controls. Ion-exchange chromatography revealed elution profiles for 
retinoic acid-treated cells which were very similar to those of control cells, indicating 
little or no change in the charge density of the eluted glycosaminoglycans. This is 
perhaps unexpected as a change in the sulphation of the molecules may have been 
expected to elicit a change in the overall charge of the structure. The results are in 
contrast to the B16BL6 melanoma study in which the heparan sulphates of the 
retinoic acid-treated cells eluted at a lower salt concentration than control cells
143
suggesting that they have a lower charge density. Similarly, the chondroitin sulphates 
exhibited a lower charge density after retinoic acid treatment (Edward & MacKie,
1989).
The changes elicited in the synthesis of glycosaminoglycans by retinoic 
acid can have an effect on a variety of cellular processes. The positioning of 
glycosaminoglycans on the cell surface make them ideal candidates for receptors, and 
indeed they have been identified as receptors for matrix components such as 
fibronectin and laminin. Any change in the structure of these molecules, heparan 
sulphate in particular, could affect the receptor properties and as such the adhesive 
capabilities of the cells. Undersulphation of heparan sulphate in myeloma and 
hepatoma cells has been associated with the lack of affinity these cells have for 
fibronectin (Stamatoglou & Keller, 1983; Robinson et al, 1984). In this study, a 
reduction in the sulphation of heparan sulphate was detected, but both control and 
retinoic acid-treated cells adhered readily to fibronectin. This would suggest that, at 
least in B16F1M2 melanoma cells, changes in the sulphation and the amount of 
heparan sulphate have no direct affect on fibronectin binding.
In this system, it is possible that retinoic acid may be important in 
receptor-mediated interactions. Heparin and heparan sulphates can bind fibroblast 
growth factors (FGFs), giving them some protection from degradation. This may be 
one method of holding a reservoir of the growth factor, with changes in the 
proteoglycans, either by chemical modification or enzymatic degradation, releasing 
the active growth factor. TGF-f has been shown to stimulate decorin synthesis, thus 
decorin may act to effect a negative feedback system. Again it is possible that 
formation of the decorin-TGF complex holds a reservoir of TGF-^ in the matrix. 
Retinoids may modulate the activities of these growth factors by altering the 
properties of the proteoglycan - changes in sulphation or synthesis may affect the 
binding properties of the molecules. The reported effects of retinoic acid on the 
production of enzymes involved in the degradation of the matrix may also modify the 
action of the growth factors and as such the properties of the metastasizing cell.
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Heparan sulphate proteoglycans have self affinity properties, and as such 
may be involved in the process of cell-cell adhesion. Changes in the structure or 
sulphation of the molecules may have profound effects on this process. Exactly how 
this may come about is unknown but it is possible that cell adhesion molecules, some 
of which have been shown to have proteoglycan structures in their binding regions, 
may be of importance.
The effects of retinoic acid on glycosaminoglycan synthesis have, in some 
instances, been shown to be reversible. In a study using HL-60 leukaemia cells, 
retinoic acid was shown to inhibit the production of chondroitin sulphate, the major 
glycosaminoglycan produced by these cells. When retinoic acid was removed from 
the system, production of chondroitin sulphate returned to control levels (Reiss et al,
1985). The study also revealed the presence of a second class of molecules believed to 
be keratan sulphate, which also exhibited a reduction in production and was 
undersulphated. Removal of retinoic acid had no effect on the production of this 
molecule demonstrating the diverse effects retinoids can elicit within one cell type.
As part of the study reported here, the reversibility of retinoic acid on 
adhesion to basement membrane components was examined. Adhesive properties 
were reinstated on the removal of retinoic acid from the culture system. It would seem 
likely, therefore, that if the synthesis of glycosaminoglycans was investigated after 
removal of retinoic acid from the system, the pattern observed would be similar to 
that of controls. This would suggest that one of the possible modes of action for 
retinoic acid would be in blocking some particular stage in the synthetic process or in 
the inhibition of the synthesis of some proteins or enzymes required for the process.
Some of the evidence for the mode of action of retinoids suggests that 
they may act at the level of transcription. The presence of specific retinoic acid 
receptors within both the cytoplasm and nucleus of the cell would perhaps agree with 
this suggestion. The cellular retinoic acid binding proteins (CRABPs) are found in the 
cytoplasm and appear to transport their non-covalently bound ligands, either
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extracellularly or intracellularly, to sites of action or metabolism, with the ability of 
these proteins to bind their ligand being associated with biological activity (Jetten & 
Jetten, 1979).
Binding of retinoic acid to specific nuclear chromatin acceptor sites can 
be demonstrated by incubating isolated nuclei with preformed RA-CRABP 
complexes (Barkai & Sherman, 1987; Takase et al, 1986). Two theories for the role of 
CRABPs have been proposed. The "shuttle theory" suggests that CRABP is involved 
in the transport of retinoic acid from the cytosol to nuclear receptors causing 
enhancement of retinoid action (Mehta et al, 1982; Takase et al, 1986; Wang & 
Gudas, 1984). The second theory is the "sequestration theory" which suggests that 
CRABP functions to limit the interaction of retinoic acid with its nuclear receptors 
(Maden et al, 1988; Boylan & Gudas, 1991).
Two families of nuclear retinoid receptors have been identified - retinoic 
acid receptors (RARs) and retinoid X receptors (RXRs) (Petkovich et al, 1987; 
Giguere et al, 1988; Mangelsdorf et al, 1990). RARs and RXRs both have three 
receptor types - c(, p , and X  - and are thought to transcriptionally activate target genes 
by binding to specific DNA sequences termed retinoic acid response elements 
(RAREs), which are generally located upstream from the sites of transcriptional 
initiation (Glass et al, 1991; Leid et al, 1992). RARs bind with high affinity to both 
all-trans retinoic acid and a stereoisomer of it, 9-cis retinoic acid, while RXRs only 
bind to the 9-cis form with high affinity (Allenby et al, 1993).
Recent data has indicated that RXRs form heterodimers with RARs and 
other receptors in the steroid/thyroid superfamily, and that RXRs coregulate the 
activity of RARs on their response elements (Leid et al, 1992). It is possible that the 
formation of RAR-RXR heterodimers may be responsible for the diversity in the 
transcriptional response to retinoic acid. Heterodimers may generate diversity at two 
levels in the retinoid signalling system - at the level of the RAREs or at the level of 
the trans-activational process (Leid et al, 1992). Such diversity may explain, in part, 
the mechanisms of retinoic acid action within the cell.
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4:6. SUMMARY OF RESULTS.
In the study reported here, no attempt was made to determine if CRABPs 
were present in B16F1M2 cells or to assay any changes induced by the presence of 
retinoic acid. Similarly, it was outwith the scope of the study to investigate the 
expression of the nuclear retinoic acid receptors.
One of the first steps in the formation of metastatic deposits is the 
adhesion of cells from the primary tumour mass to the extracellular matrix. In the 
instance of tumours such as melanoma, the extracellular matrix in question is the 
basement membrane. The ability of retinoids to modify this adhesion may lead to a 
further understanding of this step in the metastatic cascade.
When the effect of retinoic acid-pretreatment on B16F1M2 melanoma 
cells was examined with respect to adhesion to individual components of the 
extracellular matrix, it was found that adhesion to type IV collagen and 
laminin/nidogen was inhibited, but the ability of the cells to adhere to fibronectin 
remained essentially unaffected. The inhibition was dependent on both time and 
retinoic acid concentration. Adhesion to type I collagen was also examined and was 
found to be relatively unaffected by retinoic acid pretreatment.
Most treatments utilizing the inhibitory effects of retinoids on the 
metastatic process require a regular supply of the compound. Thus the effect of 
treating the cells for two days with retinoic acid, then removing it from the system 
was investigated as a function of adhesion to either type IV collagen or 
laminin/nidogen. It was found that removal of the retinoid resulted in an increase in 
cell adhesion to both substrates to levels approaching those of the control. If the cells 
were grown for two days then had retinoic acid added, adhesion to the substrates was 
reduced.
Examination of the effect of retinoic acid pretreatment on murine 
melanoma cell adhesion to individual components of the extracellular matrix provided 
a limited amount of information. In vivo the individual components of the 
extracellular matrix interact with each other to form the intact structure, thus the next 
step in the investigation was to consider the effect of retinoic acid pretreatment on
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the adhesion of B16F1M2 cells to an intact extracellular matrix. It was not possible to 
synthesize a basement membrane in vitro, thus the extracellular matrix used was that 
deposited by endothelial cells. Pretreatment of the murine melanoma cells with 
retinoic acid resulted in an inhibition of cell adhesion. The composition of the 
deposited matrix was not determined, however, if the main components are type IV 
collagen and laminin/nidogen, then the results generated from the studies involving 
the intact extracellular matrix concur with those obtained with both type IV collagen 
and laminin/nidogen. When dishes were coated with both type IV collagen and 
laminin/nidogen, cell adhesion was again inhibited by the pretreatment of B16F1M2 
cells with retinoic acid. This again supports the findings using the intact matrix.
Treatment of B16F1M2 cells with retinoic acid at a concentration of 
10“ results in a decrease in the growth rate of the cells and a reduction in cell 
numbers. Thus it is possible that the results obtained are due to a cell density effect 
rather than to retinoic acid pretreatment of the cells. Cell seeding densities were 
adjusted such that, when harvested, the number of cells in the retinoic acid-treated 
cultures was the same as for those from control cultures. To double check the density 
effect, a series of experiments were carried out to determine the effect of density on 
cell adhesion. Cells seeded at the normal seeding density but cultured for 2 days, 
rather than 4 days, were found to adhere much more slowly and at a reduced rate to 
fibronectin, type IV collagen and laminin/nidogen.
Cells were also seeded at a much lower density than normal and cultured 
for 4 days. Their adhesion to the three substrates fibronectin, type IV collagen and 
laminin/nidogen followed a pattern very similar to that obtained for control cultures. 
This may be a function of the B16F1M2 growth pattern in addition to a density 
effect.
Tumour cells not only interact with the basement membrane, they also 
make contact with other cells - both homotypic and heterotypic in origin. Such 
cell-cell interactions are important in the formation of cell aggregates and may afford 
the metastatic cells some protection against the host defence mechanisms. Retinoic 
acid pretreatment of B16F1M2 cells was found to inhibit their adhesion to
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monolayers of B16F1M2 cells (homotypic cell-cell adhesion) and endothelial cells 
(heterotypic cell-cell adhesion). If the B16F1M2 monolayers were also pretreated 
with 10"^M retinoic acid, there was no significant change in the pattern of inhibition.
The formation of homotypic cell-cell aggregates was also investigated. 
Pretreatment of B16F1M2 cells with retinoic acid decreased the size of the aggregates 
and the cell clumps were more easily disrupted by mechanical means. This would 
suggest that retinoic acid has an effect on cell-cell adhesion processes with, perhaps, 
some modulation of cell adhesion molecules. The effect of retinoic acid on 
heterotypic adhesion is also of interest as tumour cells are thought to interact with and 
modulate host cells. This may involve an initial adhesion event which, in turn, may 
stimulate or inhibit the production of various compounds by the host cells.
The positioning of the glycosaminoglycan side chains of proteoglycans on 
the surface of the cell make them possible candidates for a role in the cell adhesion 
processes. In fact, the hyaluronate receptor, CD44, is a proteoglycan with chondroitin 
sulphate chains. It is possible that modulation of cell adhesion by retinoic acid may, in 
part, occur by altering the expression of the cell surface glycosaminoglycans. 
Examination of cell surface glycosaminoglycans of retinoic acid-pretreated B16F1M2 
cells did reveal changes in expression. A change in the degree of sulphation of the 
molecules was detected as was a change in the chondroitin sulphaterheparan sulphate 
ratios. However, it is unlikely that this correlates to the results obtained for cell 
adhesion. An attempt was made to determine whether or not the isolated 
glycosaminoglycans would bind to affinity columns prepared with either fibronectin 
or laminin/nidogen, but this proved unsuccessful and no further correlation was 
attempted.
Once the tumour cells adhere to the basement membrane, they must 
traverse it. This involves the dissolution of the matrix by the production of 
degradative enzymes. The ability of B16F1M2 melanoma cells to produce the 
degradative enzymes collagenases types I & IV, plasminogen activators and 
glycosidase was determined. The enzymes were selected for the following reasons. 
The collagens are the structural components of the extracellular matrix and as such
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breakdown of these would undermine the integrity of the structure. Glycosidases act 
on the glycosaminoglycans which are thought to function, in part, as reservoirs for 
growth factors and small peptides in the matrix. Any alteration in their structure may 
bring about the release of these factors which would, perhaps, be of use to the 
metastasising cell. Plasminogen activators are serine-proteinases which can act on 
various substrates. Their role may be to cause partial degradation of the matrix 
allowing easier access for the more specific enzymes.
To determine if B16F1M2 cells were capable of degrading the matrix, 
intact extracellular matrix was radiolabelled with (glycosaminoglycans) or 
[^HJ-proline (collagens). Breakdown products labelled with -^S  were released by the 
cells, but this was inhibited by pretreatment of the cells with retinoic acid in a 
concentration-dependent manner. However, although ^H-labelled compounds were 
released, the degradation of the matrix was essentially unaffected by retinoic acid 
pretreatment. This is in contrast to other findings and as such requires further 
investigation.
When specific substrates were used to determine the production of 
individual degradative enzymes, similar results were obtained. Intracellular 
glycosidase activity was inhibited by retinoic acid and this was 
concentration-dependent. Conversely, extracellular glycosidase activity was slightly 
increased in the presence of retinoic acid up to a concentration of 10‘^M, but was 
reduced to approximately base levels at 10‘^M. An attempt was made to examine 
type I and type IV collagenase production, but this proved unsuccessful. No activity 
could be detected for either enzyme.
Plasminogen activator activity was found to increase if the cells were 
pretreated with retinoic acid. This was the case for both intracellular and extracellular 
levels. Why this should occur is unclear.
The effect of tumour cells on the host cells may be of importance in the 
metastatic process. For example, B16F1M2 melanoma cells were found not to 
produce hyaluronate, one of the requirements for cell migration. These cells may 
stimulate the surrounding host cells to produce tracts of hyaluronate to allow
150
migration. Fibroblasts, when suspended in a type I collagen gel solution and in the 
presence of serum, will ellicit gel contraction by reorganising the collagen to form 
fibrils, and this can be used as a model dermal equivalent. The effect of B16F1M2 
serum-free conditioned-medium on the process of contraction was observed. 
Serum-free tumour cell-conditioned medium brought about gel contraction in a 
similar manner to control gels containing serum. This contraction was inhibited if the 
medium was conditioned in the presence of 10‘^M retinoic acid. This would suggest 
that retinoic acid can alter fibroblast function in such a way as to prohibit their ability 
to reorganize the collagen. The ability of tumour-conditioned medium prepared in the 
presence or absence of 10'^M retinoic acid to modulate fibroblast glycosaminoglycan 
expression was also examined.
B16F1M2 cell-conditioned medium was found to greatly increase the 
amount of hyaluronate produced by the fibroblasts. This was slightly decreased by the 
presence of 10"^M retinoic acid, but this level was still above that from control 
cultures. This would suggest that B16F1M2 cells are indeed capable of stimulating 
host fibroblasts to produce hyaluronate and that retinoic acid has little or no effect on 
this stimulation. The sulphated glycosaminoglycans expressed by the fibroblasts were 
decreased in the presence of tumour cell-conditioned medium, but the decrease was 
slightly reduced if the medium was conditioned in the presence of retinoic acid. It is 
unclear if this is related to the observed inhibition of collagen gel contraction. 
However, it would suggest that B16F1M2 cells produce factor(s) which have a similar 
effect to those found in serum. How, exactly, retinoic acid acts on the production and 
function of the factor(s) is unclear.
4:7. POSSIBLE FUTURE WORK.
1. The work presented here was carried out on one melanoma cell line and used only 
one retinoid. Thus further investigation is required using other melanoma cell lines 
and other forms of retinoid. This would allow comparisons to be made on both the 
effectiveness of retinoids as possible compounds for use in the inhibition of metastisis 
and on their usefulness within different cell lines.
2. The production of collagenases by B16F1M2 melanoma cells requires further 
investigation. The results presented in this thesis are in contrast to other reports found 
in the literature and the reason(s) for the differences is of importance in the metastatic 
cascade.
3. The observed increase in plasminogen activator activity after retinoic 
acid-pretreatment is of interest. Further investigation may reveal whether the increase 
is due to an increase in enzyme production or to a decrease in enzyme inhibition. This 
may also incorporate the role of plasminogen activator inhibitors in the process.
4. The mechanisms of cell adhesion to the extracellular matrix provides another 
possible project. The expression of the various cell adhesion molecules and how their 
expression is affected by retinoic acid is an area of importance. Any alteration in the 
expression of these molecules may be associated with the metastatic process of the 
melanoma cells, and possibly give an indication as to the mode of action of retinoic 
acid within this particular system.
5. Also in relation to adhesion, the role of cell surface proteoglycans requires further 
investigation. Affinity work was attempted during the course of the project, but 
proved to be unsuccessful. Further isolation of the surface proteoglycans using 
different methods may allow identification of potential adhesion substrates recognised 
by these molecules.
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6. No attempt was made to investigate the expression of either the nuclear retinoid 
receptors or the cellular retinoic acid binding proteins by B16F1M2 melanoma cells. 
The effect of retinoic acid pretreatment on the expression of these receptors and 
binding proteins may provide useful information in the elucidation of the mechanisms 
involved in the metastatic cascade.
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